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ABSTRACT 
Zachary G. Robbins: Biomarkers of oligomeric 1,6-hexamethylene diisocyanate exposure in the 
automotive refinishing industry  
(Under the direction of Leena Nylander-French) 
 
Spray-painters in automotive refinishing industries are exposed to the oligomeric trimer 
of 1,6-hexamethylene diisocyanate (HDI) monomer, HDI isocyanurate, a sensitizing agent that 
poses a significant risk for acute and chronic health effects. Biomonitoring of HDI exposures has 
been mostly limited to quantification of 1,6-diaminohexane (HDA), the hydrolysis product of 
HDI monomer, in urine or plasma. Because biomarkers of HDI monomer exposure are not 
appropriate biomarkers of oligomeric HDI exposures, the magnitude and distinct characteristics 
of HDI monomer and oligomer exposures and their relationships to their biomarkers need to be 
determined in exposed workers. We hypothesized that trisaminohexyl isocyanurate (TAHI), a 
hydrolysis product of HDI isocyanurate, is quantifiable in urine or plasma and is associated with 
HDI isocyanurate exposures. Towards this goal, sample extraction and analytical methods were 
developed and optimized to measure TAHI levels in urine and plasma of 47 spray-painters 
whose HDI monomer and HDI isocyanurate inhalation and skin exposures and urine and plasma 
HDA levels were previously characterized. Urine and plasma samples were acid hydrolyzed, 




TAHI biomarker levels were significantly associated with HDI isocyanurate inhalation 
exposure levels and the duration of spray-painting task in both linear regression and linear mixed 
model analyses. Painting in downdraft booths significantly reduced exposure to HDI 
isocyanurate and urine TAHI levels. TAHI biomarker levels were also significantly correlated 
with HDI monomer exposures. As expected, HDA levels in urine or plasma were observed to be 
unsuitable biomarkers of HDI isocyanurate exposure. Based on the observations in this study, 
painting in downdraft booths, wearing nitrile or neoprene gloves, and wearing full-face air 
purifying, PAPR, or supplied-air respirators offers the greatest combination of respiratory and 
skin protection to reduce hazardous HDI exposures and biomarkers of exposure in automotive 
spray-painters. In summary, the developed method for quantification of HDI isocyanurate 
biomarker, TAHI, in urine and plasma is a significant advancement for HDI exposure assessment 
and will advance future investigations to oligomeric isocyanate exposures and biomarkers as 
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 1
CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
 
1.1. Overview of isocyanates 
Isocyanate is the general terminology for a family of semi-volatile organic compounds 
that include one or more isocyanate functional groups (–N=C=O). Isocyanate functional groups 
are electrophilic and favorably react with compounds containing nucleophilic functional groups 
such as: hydroxyl (–OH); carboxyl (–COOH); amino (–NH2); and sulfhydryl (–SH) groups 
(Randall and Lee, 2002, Bello et al., 2004, Thomas, 2015, Covestro, 2017). The isocyanate 
reaction with a hydroxyl group is of considerable importance for manufacturing and construction 
worldwide. Polyols (an alcohol with two or more hydroxyl groups) react with isocyanates to 
form a urethane linkage, an essential component of the class of chemicals and products we know 
as polyurethane (Figure 1.1) (Randall and Lee, 2002, Bello et al., 2004, Lockey et al., 2015, 
Thomas, 2015). Isocyanates are used to produce a wide variety of polyurethane-based products 
(Randall and Lee, 2002, Bello et al., 2004, Bayer MaterialScience, 2005, Dow Chemical 
Company, 2010, Thomas, 2015, Covestro, 2017, Covestro, 2018a) that include: 
 flexible foams used in furniture, bedding, carpeting, and packaging, or rigid foams for 
building insulation and refrigeration 
 epoxies, adhesives, sealants, and wood binders 
 waterproof coatings and paints for automobiles, aircraft, watercraft, bridges, parking 
decks, roofing, floors, and heavy equipment vehicles 
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Figure 1.1.  Representative chemical reaction of a diisocyanate and a polyol to form a 
urethane linkage in a polyurethane compound. 
 
An estimated 4.4 million metric tons of isocyanates were produced globally in 2000, and the 
demand has risen in the last two decades (Randall and Lee, 2002). The most recognized class of 
isocyanates are diisocyanate monomers (containing two NCO groups) (Randall and Lee, 2002, 
Bello et al., 2004, Bayer MaterialScience, 2005). Common diisocyanate monomers include: 2,4- 
and 2,6-toluene diisocyanate isomers (TDI), 2,4’- and 4,4’-methylenediphenyl diisocyanate 
isomers (MDI), 1,6-hexamethylene diisocyanate (HDI), and isophorone diisocyanate (IPDI) 
(Figure 1.2) (Randall and Lee, 2002, Bello et al., 2004, NIOSH, 2004, Bayer MaterialScience, 
2005, Lockey et al., 2015). Isocyanates are further classified as either aromatic (NCO group 
directly attached to an aromatic ring) or saturated (aliphatic and cycloaliphatic) (Bello et al., 
2004, Thomas, 2015, Covestro, 2017). Saturated isocyanates are more commonly known as 
aliphatic isocyanates which are further classified as linear and cycloaliphatic (also known as 
alicyclic) structures (Thomas, 2015, Covestro, 2017). Additionally, isocyanates with NCO 





Figure 1.2.  Structures and molar masses of 2,4-toluene diisocyanate (2,4-TDI), 1,6-
hexamethylene diisocyanate (HDI), 4,4’-methylenediphenyl diisocyanate (4,4’-
MDI), and isophorone diisocyanate (IPDI). 
 
Aromatic isocyanates MDI and TDI and aliphatic isocyanates HDI and IPDI accounted 
for approximately >95% and <5% of the global market in 2000, respectively (Randall and Lee, 
2002). Aromatic isocyanates are more reactive than aliphatic isocyanates and are susceptible to 
degradation by UV radiation (Randall and Lee, 2002, Bello et al., 2004). Cured aromatic 
isocyanates will rapidly yellow from UV exposure and may structurally degrade over time. 
Aromatic isocyanates are primarily found in applications with little to no UV exposure or are 
pigmented to disguise color change (Bayer MaterialScience, 2005). By contrast, aliphatic 
isocyanates are highly resistant to UV radiation and are preferred for exterior coatings/paints due 
to their long-term resistance to weather corrosion and UV radiation (Randall and Lee, 2002, 
Bello et al., 2004, Thomas, 2015, Covestro, 2018b). The lower reactivity of aliphatic isocyanates 
is also desirable for slow-curing applications (Randall and Lee, 2002, Bello et al., 2004). 
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Although isocyanates are classified by the naming conventions of the diisocyanate 
monomers, the actual use of diisocyanate monomers is limited in most industrial applications due 
to their volatility, reactivity, and health concerns (Bello et al., 2004, NIOSH, 2004). The 
majority of isocyanates used in manufacturing and construction industries are oligomers of the 
diisocyanate monomers (Bello et al., 2004, NIOSH, 2004). In the literature, oligomers may also 
be denoted as polyisocyanates, pre-polymers, or polymeric isocyanates (Bello et al., 2004, 
NIOSH, 2004). Oligomer and oligomeric will be used in this dissertation to classify these 
chemicals. Oligomeric isocyanate structures may consist of repeated chains of monomers, central 
aliphatic moieties that link monomers and side chains, or complex adducts of monomers and 
oligomers (Bello et al., 2004, Bayer MaterialScience, 2005). Figure 1.3 displays some common 
oligomeric isocyanates originating from the diisocyanate monomers of MDI, TDI, HDI, and 




Figure 1.3.  Structures and molar masses of polymeric MDI, TDI isocyanurate, IPDI 
isocyanurate, and isocyanurate copolymer of TDI and HDI. 
 
1.2. Health effects associated with isocyanate exposures 
Isocyanate exposures are associated with acute and chronic adverse health effects of the 
respiratory tract and of the skin (NIOSH, 1978, Bernstein, 1996, NIOSH, 1996, Liu and 
Wisnewski, 2003, Bello et al., 2004, NIOSH, 2004, Bello et al., 2007a, Lockey et al., 2015, 
Covestro, 2017, California OEHHA, 2019). Acute health effects may include shortness of breath, 
rhinitis, pulmonary edema, asthma induction, irritation of the eyes, irritation of the respiratory 
tract, or irritant contact dermatitis (NIOSH, 1978, NIOSH, 1996, Bello et al., 2004, Bello et al., 
2007a, Lockey et al., 2015, Covestro, 2017, California OEHHA, 2019). Chronic health effects 
associated with sensitization from respiratory and skin exposures to isocyanates may include 
occupational asthma, allergic contact dermatitis, or hypersensitivity pneumonitis (NIOSH, 1978, 
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Malo et al., 1983, Wilkinson et al., 1991, Vandenplas et al., 1992, Vandenplas et al., 1993a, 
Vandenplas et al., 1993b, Vandenplas et al., 1993c, Chan-Yeung and Malo, 1995, Bernstein, 
1996, NIOSH, 1996, Piirila et al., 2000, Goossens et al., 2002, Frick et al., 2003a, Frick et al., 
2003b, Liu and Wisnewski, 2003, Bello et al., 2004, Bello et al., 2007a, Liippo and 
Lammintausta, 2008, Aalto-Korte et al., 2010, Aalto-Korte et al., 2012, Kiec-Swierczynska et 
al., 2014, Lockey et al., 2015, Covestro, 2017, California OEHHA, 2019).  
Exposure to isocyanates is considered a leading cause of occupational asthma worldwide 
(Bernstein, 1996, Lockey et al., 2015). It has been estimated that <1 – 30% of workers in 
production facilities and end-user applications develop isocyanate-induced asthma (Bernstein, 
1996, Bello et al., 2004, NIOSH, 2004, Bello et al., 2007a, Lockey et al., 2015). After 
sensitization, levels of isocyanates below occupational exposure limits can induce an asthmatic 
response (NIOSH, 1996, NIOSH, 2004, Bello et al., 2007a). Inhalation exposure was previously 
considered the dominant pathway for sensitization and development of asthma, however, animal 
studies have shown that skin exposure is an important route of isocyanate sensitization (Karol et 
al., 1981, Rattray et al., 1994, Zissu et al., 1998, Herrick et al., 2002, Bello et al., 2004, Bello et 
al., 2007a). Skin exposure may also induce respiratory sensitization and/or a respiratory response 
without concomitant inhalation exposure (Rattray et al., 1994, Petsonk et al., 2000, Redlich and 
Karol, 2002, Bello et al., 2004, Bello et al., 2007a, Redlich, 2010, Wisnewski et al., 2011, 
Henriks-Eckerman et al., 2015). In addition to sensitization linked to the development of asthma, 
sensitization from skin exposure may also lead to the development of allergic contact dermatitis 
(Goossens et al., 2002, Frick et al., 2003a, Frick et al., 2003b, Bello et al., 2007a, Liippo and 
Lammintausta, 2008, Aalto-Korte et al., 2010, Aalto-Korte et al., 2012, Kiec-Swierczynska et 
al., 2014).   
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1.3. Oligomeric isocyanate exposures 
 As mentioned in Section 1.1, oligomeric isocyanates are prevalent in formulations for 
end-user industrial applications of isocyanates. The higher volatility and reactivity of 
diisocyanate monomers is undesirable for coatings/paints, additionally, pressurized applications 
of liquid formulations combined with potential higher work environment temperatures may lead 
to substantial vapor hazards (Bello et al., 2004, NIOSH, 2004). By contrast, the lower volatility 
and reactivity of oligomers compared to their diisocyanate monomer counterparts makes them 
easier to work with in occupational settings (Bello et al., 2004, NIOSH, 2004). Notwithstanding 
the practical advantages of applying formulations with high concentrations of oligomeric 
isocyanates, these chemicals still contain two or more reactive isocyanate functional groups that 
present considerable exposure hazards (Bello et al., 2004, Bayer MaterialScience, 2005). 
Exposures to oligomeric isocyanates can lead to acute and chronic adverse health effects 
historically associated with diisocyanate monomer exposures (Vandenplas et al., 1993a, Bello et 
al., 2004, Bello et al., 2007a, Aalto-Korte et al., 2010, California OEHHA, 2019). Inhalation was 
considered the primary route of exposure leading to respiratory sensitization and development of 
isocyanate-induced asthma. Less data are available for health hazards associated with oligomeric 
isocyanate exposures because their prevalence in industrial products is a recent development 
over the last few decades (Bello et al., 2004). Thus, vapor exposures of semi-volatile and volatile 
diisocyanate monomers were considered the major source of respiratory adverse health effects 
while exposures to aerosols that contain high levels of semi-volatile and/or non-volatile 
oligomers were largely ignored. However, exposures to aerosols containing oligomeric 
isocyanates may also cause adverse respiratory health effects and furthermore present a more 
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significant skin exposure hazard than diisocyanate monomers (Bello et al., 2004, Bello et al., 
2007a).  
Aromatic isocyanate formulations have similar concentrations of oligomers and 
diisocyanate monomers in mixtures. TDI exposure assessment has been primarily limited to 
measuring 2,4- and 2,6-TDI monomers while levels of TDI oligomers and adducts are largely 
unreported in surveillance of occupational settings (Maitre et al., 1993, Lind et al., 1996, Lind et 
al., 1997, Tinnerberg et al., 1997, Kaaria et al., 2001, Jarand et al., 2002, Yeh et al., 2002, 
Austin, 2007, De Palma et al., 2012, Geens et al., 2012, Gui et al., 2014, Tinnerberg et al., 2014, 
Brzeznicki and Bonczarowska, 2015, Swierczynska-Machura et al., 2015). Polymeric MDI 
exposure concentrations have been recently reported in an occupational setting (Bello et al., 
2019). However, polymeric MDI exposures during MDI applications are not typically measured 
or are included with MDI monomers in the total NCO concentration (Skarping et al., 1996, 
Crespo and Galan, 1999, Karoly et al., 2004, Lesage et al., 2007, Booth et al., 2009, Liljelind et 
al., 2010, Tinnerberg et al., 2014, Jones et al., 2017). Although formulations of aromatic 
isocyanates contain significant levels of oligomers, the lack of exposure monitoring for aromatic 
oligomers limits further investigation of associated health effects and biomarkers.  
Low volatility and reactivity are highly desirable characteristics for exterior coating/paint 
applications; thus, formulations are comprised of high concentrations of oligomeric aliphatic 
isocyanates. Polyurethane-based coatings/paints are applied to vehicle, bridge, and building 
surfaces to prevent weather corrosion and degradation by UV radiation contain monomers and 
oligomers of HDI and/or IPDI (Randall and Lee, 2002, Bello et al., 2004, Bayer 
MaterialScience, 2005, Dow Chemical Company, 2010, California OEHHA, 2019). The U.S. 
Bureau of Labor Statistics estimates that approximately 58,000 painters were employed in motor 
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vehicle manufacturing and refinishing industries (U.S. Bureau of Labor Statistics, 2019b), and 
approximately 382,000 painters were employed in construction and maintenance in 2016 (U.S. 
Bureau of Labor Statistics, 2019a). Despite the prevalence of polyurethane-based coating/paint 
applications across vehicle and construction industries, exposures to aliphatic isocyanates have 
mostly been assessed in the automotive refinishing industry (Janko et al., 1992, Maitre et al., 
1996, Woskie et al., 2004, Pronk et al., 2006a, Pronk et al., 2006b, Fent et al., 2008, Fent et al., 
2009a, Fent et al., 2009b, Reeb-Whitaker et al., 2012, Reeb-Whitaker and Schoonover, 2016), 
and to a lesser extent in the aircraft refinishing industry (Carlton and England, 2000, Ceballos et 
al., 2017, Bennett et al., 2018). The established research of exposures in the automotive 
refinishing industry affords further investigation of oligomeric aliphatic isocyanate exposures 
when exposure monitoring of oligomers in aromatic isocyanate applications is lacking.  
1.4. HDI exposures in the automotive refinishing industry 
In 2016, the U.S. automotive refinishing industry employed an estimated 20,000 – 25,000 
painters and >227,000 workers in >33,900 auto body shops, with a projected job growth of 7% 
for painters from 2016 to 2026 (U.S. Census Bureau, 2018, U.S. Bureau of Labor Statistics, 
2019b). Workers in the automotive refinishing industry are potentially exposed to HDI monomer 
and its oligomers: the dimer HDI uretdione, and the trimers HDI biuret and HDI isocyanurate 
(Figure 1.4). Isocyanates in formulations for clearcoat paint applications are comprised of small 
amounts of HDI monomer (<1%), small amounts of HDI uretdione and HDI biuret (<1-10%), 
and much higher amounts of HDI isocyanurate (>80%) (Janko et al., 1992, Bello et al., 2004, 
Woskie et al., 2004, Pronk et al., 2006a, Pronk et al., 2006b, Bello et al., 2007a, Fent et al., 
2008, Fent et al., 2009a, Fent et al., 2009b, Reeb-Whitaker et al., 2012). The highest exposures 
to HDI monomer and HDI oligomers occur during a paint task when vapors and aerosols are 
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generated by a spray gun (Fent et al., 2009a, Fent et al., 2009b). Paint tasks normally occur in 
partially or fully enclosed ventilated booths (e.g., crossdraft, semi-downdraft, or downdraft) 
(Fent et al., 2009a, Fent et al., 2009b). However, >200,000 technicians and office workers may 
also be exposed to HDI vapors and aerosols (Woskie et al., 2004, Boutin et al., 2006, Pronk et 
al., 2006a, Pronk et al., 2006b).  
 
Figure 1.4.  Structures and molar masses of HDI monomer and its oligomers HDI uretdione, 
HDI biuret, and HDI isocyanurate. 
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1.4.1. Inhalation exposures to HDI 
Inhalation exposures to HDI monomer and oligomers are monitored by area sampling or 
personal breathing-zone (PBZ) sampling (Janko et al., 1992, Rudzinski et al., 1995, Sparer et al., 
2004, Woskie et al., 2004, Pronk et al., 2006a, Pronk et al., 2006b, Henneken et al., 2007, Fent 
et al., 2008, Fent et al., 2009a, Reeb-Whitaker et al., 2012). However, measurements of PBZ 
concentrations are potentially confounded by respiratory protection. To account for respirator 
use, the Occupational Safety and Health Administration (OSHA) established assigned protection 
factors (APF) for respirator type [1 = no respirator; 10 = half-face negative-pressure air purifying 
respirator; 50 = full-face negative-pressure air purifying respirator; 1000 = powered-air purifying 
respirator (PAPR) or continuous flow supplied-air respirator] to adjust personal exposure 
concentrations for workers who use respirators (OSHA, 2009). Adjustment with APF may be 
confounded by improper fit, poor respirator maintenance, or facial hair that prevents a tight seal 
for half- and full-face negative-pressure air purifying respirators (Liu et al., 2006, Fent et al., 
2008, OSHA, 2009, Floyd et al., 2018). Liu et al. monitored 22 workers wearing half-face air 
purifying respirators during spray-painting and priming and calculated respirator protection 
factors of 17 and 388 for HDI monomer and HDI oligomers, respectively, which were both 
higher than the OSHA APF of 10 for this respirator type (Liu et al., 2006). However, 20% of 142 
spray-painters failed the first respirator fit factor test due to loose fitting respirators, wrong sizes, 
and facial hair, and 8% failed the second fit test after respirator use training (Liu et al., 2006). 
Floyd et al. demonstrated a significant reduction in the respirator fit factor in 19 subjects with 
beard lengths equal to or greater than 0.25 in (Floyd et al., 2018). Additionally, Bello et al. 
measured HDI monomer and HDI oligomers in 30% and 80% of face skin samples, respectively, 
collected by SWYPE™ sampling surfaces occluded by half-face air purifying respirators for 20 
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workers (Bello et al., 2008). Furthermore, Reeb-Whitaker et al. determined that in order to 
reduce HDI monomer and HDI oligomer exposures below occupational exposure limits, 
automotive spray-painters would need to wear a respirator with a minimum APF value of 25 
(Reeb-Whitaker et al., 2012). These studies indicate that respiratory protection, most notably 
half-face air purifying respirators, may not sufficiently reduce inhalation exposures to HDI in the 
automotive refinishing industry.  
1.4.2. Skin exposures to HDI 
Isocyanate aerosols generated by spray-painting present significant skin exposure hazards 
in the automotive refinishing industry (Pronk et al., 2006b, Bello et al., 2007a, Liu et al., 2007, 
Bello et al., 2008, Fent et al., 2008, Fent et al., 2009b, Fletcher, 2015). Workers may wear 
protective clothing (e.g., coveralls, hat) and/or gloves to minimize exposures during painting, 
however, their use is less prevalent than respirators amongst automotive spray-painters (Bello et 
al., 2007a, Fent et al., 2008, Fent et al., 2009b, Ceballos et al., 2011, Ceballos et al., 2014a). 
Additionally, contact exposure with unreacted HDI species on surfaces may occur after painting 
or during tasks unrelated to painting (e.g., sanding, buffing, taping and untaping, mechanical 
work, detailing, compounding) (Liu et al., 2000, Pronk et al., 2006b, Bello et al., 2007b, Liu et 
al., 2007, Bello et al., 2008). In a recent study, skin exposure from surface contact appeared to be 
minimal for 18 automotive spray-painters in 5 auto body shops (De Vries et al., 2012). However, 
more research is warranted to assess whether unreacted isocyanates present a significant 
exposure hazard when PPE is not worn during tasks unrelated to painting. 
1.4.3. Challenges for monitoring skin exposures 
Exposure assessment in the automotive refinishing industry has focused on inhalation 
exposures, therefore, skin exposure assessment and associated adverse health effects are not well 
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understood. Skin exposures have been primarily monitored with removal techniques that 
collected unreacted HDI species on the skin after a paint task has ended. Qualitative and 
quantitative SWYPE™ sampling have been used to collect unreacted HDI species on skin 
surfaces post-exposure (Liu et al., 2000, Bello et al., 2007a, Liu et al., 2007, Bello et al., 2008). 
Tape-stripping is an alternative removal technique that was developed to monitor skin exposure 
and penetration after painting (Fent et al., 2006). Unlike SWYPE™ sampling, multiple tape-
strips applied to the same skin site collects unreacted HDI species in the outermost layers of the 
stratum corneum, thereby providing an estimate of percutaneous absorption (Fent et al., 2006). 
This method has been utilized in two independent exposure assessment studies of automotive 
spray-painters (Fent et al., 2008, Fent et al., 2009b, Fletcher, 2015). However, neither of these 
techniques measure skin exposure during a spray-painting task and thus may underestimate 
exposure due to evaporation, physical removal, chemical removal, or skin absorption of the 
isocyanates (Bello et al., 2007a, Bello et al., 2008, Thomasen et al., 2011, Thomasen and 
Nylander-French, 2012).  
HDI species on skin surfaces, particularly the more volatile HDI monomer, may 
evaporate quickly from the skin post-exposure. Additionally, isocyanates may be physically 
removed from the skin by surface contact, glove contact and removal, or coverall removal to 
expose skin for sampling. There may be chemical removal of isocyanates due to reactions with 
curing agents in the paint, or with water and proteins on or in the skin. Chemical removal will 
reduce quantitative measurements because SWYPE™ and tape-strip sampling rely on piperazine 
derivatization of unreacted isocyanates (Fent et al., 2006, Bello et al., 2007a, Bello et al., 2008, 
Fent et al., 2008, Fent et al., 2009b). Lastly, significant levels of HDI monomer and HDI 
oligomers may be absorbed based on two studies of excised skin dosed with HDI. Bello et al. 
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dosed excised guinea pig skin with HDI-containing Desmodur® products diluted with ethyl 
acetate and observed that approximately 10% of HDI oligomers were absorbed in the skin after 5 
min and approximately 20% were absorbed after 2 h with minimal evaporation of the unreacted 
oligomers (Bello et al., 2006). Thomasen et al. performed a similar experiment dosing excised 
human skin with slow- and fast-drying clearcoat containing HDI monomer and HDI oligomers 
(Thomasen and Nylander-French, 2012). Approximately 20% of HDI monomer and 15 – 25% of 
HDI isocyanurate were absorbed in the skin after a 10-min exposure. Similar absorption levels 
were observed in the 30- and 60-min exposures, however, the recovery of isocyanates in the 
occlusion material dropped from 70 – 80% in the 10- and 30-min exposures to 55 – 60% in the 
60-min exposure. Absorption and reactions with water or proteins in the skin may have led to 
low recovery of dosed HDI monomer and HDI isocyanurate after 60 min (Thomasen and 
Nylander-French, 2012). These permeation studies suggest that a longer task would lead to more 
absorption of HDI monomer and HDI isocyanurate. However, the conditions of both studies did 
not allow for investigation of the porosity of living human skin in an occupational environment 
where heat stress, physical stress, PPE use and contact, and perspiration may enhance skin 
porosity and absorption of isocyanates (Bello et al., 2006, Thomasen and Nylander-French, 
2012). 
Interception techniques have been developed to capture skin isocyanate exposure during 
painting. Thomsen et al. developed an impregnated felt patch to be worn around the forearms of 
a painter (Thomasen et al., 2011). This method measured much higher skin exposures to HDI 
monomer and HDI isocyanurate than tape-strip sampling for 25 automotive spray-painters in 
Washington State (Fletcher, 2015). Two other promising methods have been developed to 
capture breakthrough exposure through coveralls or gloves. Blake et al. impregnated arm-length 
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cotton sleeves to measure monomeric and polymeric MDI and methylene bis(4-cyclohexyl 
isocyanate) (H2MDI) exposures (Blake et al., 2012), and Harari et al. impregnated cotton gloves 
to measure monomeric and polymeric MDI exposures (Harari et al., 2016). The combination of 
these two methods may provide the best estimate of skin exposure during a paint task; however, 
neither method has been utilized to measure HDI exposures in occupational settings. 
Impregnated felt patches have been field tested and producing patches and sample extraction is 
both less laborious and requires less disposables and solvents than similar procedures for 
producing impregnated cotton gloves or sleeves and extracting derivatized isocyanates from 
these materials (Thomasen et al., 2011, Blake et al., 2012, Harari et al., 2016). These recently 
developed sampling techniques may soon supplant removal techniques for measuring isocyanate 
skin exposures in the workplace if they are proven reliable and reproducible during multiple 
exposure assessment studies. 
1.4.4. HDI monomer and HDI oligomer inhalation exposures in the literature 
Exposure assessment studies conducted in the automotive refinishing industry have 
reported HDI oligomer exposures as a sum of HDI uretdione, HDI biuret, and HDI isocyanurate 
concentrations (Janko et al., 1992, Maitre et al., 1996, Liu et al., 2006, Pronk et al., 2006a, 
Pronk et al., 2006b, Bello et al., 2008). Alternatively, the combined concentrations of HDI 
monomer and HDI oligomers have been reported as a total NCO concentration, also known as 
total reactive isocyanate groups (TRIG) in the literature (Sparer et al., 2004, Woskie et al., 2004, 
Creely et al., 2006, Liu et al., 2006, Pronk et al., 2006a, Pronk et al., 2006b, Bello et al., 2008, 
Fent et al., 2008, De Vries et al., 2012, Reeb-Whitaker et al., 2012, Jones et al., 2017). The 
analysis of combined HDI oligomer concentration or total NCO concentration offers simplicity 
and uniformity of measurement across multiple studies in compliance with current occupational 
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exposure limits (see Section 1.6). However, these measurements treat HDI species 
homogeneously and may be inadequate for investigating the contributions of individual HDI 
oligomer exposures to biomarker levels and development of adverse health outcomes (Bello et 
al., 2004, Bello et al., 2007a, Fent et al., 2008). Combined measurements would be appropriate if 
the physical and chemical properties of each isocyanate were the same. However, the reactivity 
of the NCO groups may vary due to stereochemical configuration and size of the isocyanate, and 
electronegativity of attached moieties (Bello et al., 2004, Thomas, 2015). Additionally, the 
properties of the moieties may affect hydrophilicity and lipophilicity of the chemical altering 
pulmonary and skin absorption rates and toxicokinetics between HDI species (Bello et al., 2004, 
Bello et al., 2007a). Recent exposure assessment studies have reported concentrations of 
individual HDI oligomer exposures in the automotive refinishing industry to aid investigation of 
adverse health effects and biomarkers of exposures that may not be strongly associated with 
combined measurements of HDI species (Pronk et al., 2006a, Pronk et al., 2006b, Fent et al., 
2008, Fent et al., 2009a, Fent et al., 2009b, Reeb-Whitaker et al., 2012, Reeb-Whitaker and 
Schoonover, 2016).  
1.5. Concerns for exposures to HDI isocyanurate 
Although HDI monomer is more reactive and volatile than HDI isocyanurate (Pauluhn, 
2015), animal and human studies have shown HDI isocyanurate exposures lead to acute and 
chronic adverse health effects without concomitant exposure to HDI monomer (Vandenplas et 
al., 1993a, Zissu et al., 1998, Bello et al., 2004, Bello et al., 2007a, Aalto-Korte et al., 2010, 
California OEHHA, 2019). Murine studies have shown that HDI isocyanurate is an acute 
respiratory irritant (Ferguson et al., 1987, Pauluhn, 2000, Pauluhn and Mohr, 2001, Pauluhn, 
2004, Ma-Hock et al., 2007). Decreased lung function has also been observed in workers after 
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short-term and long-term exposures to HDI oligomers (Alexandersson et al., 1987, Dahlqvist et 
al., 1995, Randolph et al., 1997, Glindmeyer et al., 2004, Pourabedian et al., 2010, California 
OEHHA, 2019). In a controlled inhalation study, 4 volunteers had asthmatic reactions after HDI 
oligomer exposure (with unspecified concentrations of HDI biuret and HDI isocyanurate) but not 
after HDI monomer exposure (Vandenplas et al., 1993a). In the same study, HDI oligomer-
specific immunoglobulin E (IgE) and immunoglobulin G (IgG) in human serum were 
significantly correlated with HDI oligomer exposures (Vandenplas et al., 1993a). Additionally, 
HDI isocyanurate-specific IgE and IgG in human serum have been identified in occupationally 
exposed populations, however, these markers were not validated as biomarkers of HDI 
isocyanurate exposures (Campo et al., 2007, Pronk et al., 2007). HDI isocyanurate also exhibits 
skin sensitizing capacity without inhalation exposure and without concomitant exposure to HDI 
monomer or HDI biuret in guinea pigs and humans (Zissu et al., 1998, Pauluhn et al., 2002, 
Aalto-Korte et al., 2010). Lastly, HDI oligomers are known causes of allergic contact dermatitis 
in humans (Aalto-Korte et al., 2010). Because HDI isocyanurate is the predominant HDI 
exposure in the automotive refinishing industry, it is important to identify and investigate HDI 
isocyanurate inhalation and skin exposures during spray-painting.  
1.6. Exposure limits to HDI monomer, HDI oligomers, and total NCO 
Although adverse health outcomes are associated with both HDI monomer and HDI 
oligomer exposures, OSHA has not established permissible exposure limits (PEL) or short-term 
exposure limits (STEL) for HDI monomer or HDI oligomers (Bello et al., 2004, OSHA, 2018, 
OSHA, 2019b, OSHA, 2019a). Other governmental agencies and recommendatory bodies in the 
U.S. and abroad have established exposures limits for HDI monomer, HDI oligomers, or total 
NCO content (Table 1.1). In the U.S., the National Institute for Occupational Safety and Health 
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(NIOSH) and the American Conference of Governmental Industrial Hygienists (ACGIH) 
established 10-h and 8-h recommended exposure limits (REL), respectively, for HDI monomer 
(Bello et al., 2004, OSHA, 2018, ACGIH, 2019). NIOSH also established a 10-min ceiling 
STEL for HDI monomer (Bello et al., 2004, OSHA, 2018). Neither NIOSH nor ACGIH have 
established exposure limits for HDI oligomers (Bello et al., 2004, ACGIH, 2019, OSHA, 2019b, 
OSHA, 2019a). Oregon OSHA is the only governmental agency in the U.S. with established PEL 
and STEL for HDI oligomers (sum of HDI biuret and HDI isocyanurate) (Oregon OSHA, 2017). 
These limits were adopted in 1986 from the Bayer Corporation and were primarily based on one 
animal pulmonary irritation study to HDI biuret (Weyel et al., 1982, Janko et al., 1992, Bello et 
al., 2004, Oregon OSHA, 2017). 
Globally, the United Kingdom Health and Safety Executive (UK HSE) and the Swedish 
Work Environment Authority (WEA) have established short-term and full-shift exposure limits 
for total NCO content (Bello et al., 2004, UK HSE, 2005a). The total NCO content may be 
converted to equivalent concentrations of HDI monomer, HDI biuret, or HDI isocyanurate, but 
the limits are based on total NCO content of all isocyanates measured (Bello et al., 2004). In 
Table 1.1, the UK HSE and Swedish WEA exposure limits for total NCO content are shown as 
the equivalent concentrations of HDI isocyanurate. Using the conversion factor of 4.64 for HDI 
isocyanurate (Bello et al., 2004), the total NCO content equivalent exposure limits are lower than 
the current exposure limits established by Oregon OSHA (Oregon OSHA, 2017). In 2017, the 
California Office of Environmental Health Hazard Assessment (OEHHA) within the California 
Environmental Protection Agency proposed reference exposure levels for HDI monomer and 
HDI oligomers with the goal of protecting human health in occupational and residential settings 
(California OEHHA, 2019). Although the proposed reference exposure levels are not explicitly 
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intended for occupational settings, they are derived from animal and human exposure studies that 
have been conducted since the establishment of Oregon OSHA exposure limits for HDI 
oligomers. The 1-h limit (0.3 µg/m3) and 8-h limit (0.06 µg/m3) for HDI monomer, and 1-h limit 
(4.5 µg/m3) and 8-h limit (0.8 µg/m3) for HDI oligomers are considerably lower than the current 
exposure limits established by the Oregon OSHA, UK HSE, and Swedish WEA (Bello et al., 
2004, Oregon OSHA, 2017, California OEHHA, 2019). 
Table 1.1.  Occupational and recommended exposure limits (µg/m3) publicized by 
governmental agencies and recommendatory bodies for HDI monomer, HDI 
oligomers, and total NCO content. 
 HDI monomer  HDI oligomers  Total NCO 
Agency TWA STEL  TWA STEL  TWA STEL 
OSHA ** **  ** **  ** ** 
NIOSH 35 140  ** **  17.5a 70a 
ACGIH 34 **  ** **  17a ** 
Oregon OSHA ** **  500 1000  107.8a 215.5a 
UK HSE 40b 140b  92.8b 324.8b  20 70 
Swedish WEA 40b 88b  92.8b 204.2b  20 44 
California OEHHA 0.06 0.3  0.8 4.5  0.2c 1.0c 
TWA = full-shift time-weighted average concentration (µg/m3); STEL = short-term time-weighted 
average concentration (µg/m3); ** = Agency does not have occupational exposure limit for this chemical. 
TWA values represent an 8-hour full-shift limit for ACGIH, Oregon OSHA, UK HSE, Swedish WEA, 
and California OEHHA, and a 10-hour full-shift limit for NIOSH (Bello et al., 2004, UK HSE, 2005a, 
Oregon OSHA, 2017, OSHA, 2018, ACGIH, 2019, California OEHHA, 2019, OSHA, 2019a, OSHA, 
2019b). 
STEL values represent a 5-min short-term limit for Swedish WEA, a 10-min ceiling limit for NIOSH and 
UK HSE, a 15-min short-term limit for Oregon OSHA, and a 1-hour short-term limit for California 
OEHHA (Bello et al., 2004, UK HSE, 2005a, Oregon OSHA, 2017, OSHA, 2018, ACGIH, 2019, 
California OEHHA, 2019, OSHA, 2019a, OSHA, 2019b).  
aTotal NCO equivalent concentration (µg NCO/m3) of HDI monomer or HDI oligomer exposure limit, 
calculated by dividing the exposure limit by the conversion factor (HDI monomer = 2.00; HDI 
isocyanurate = 4.64) (Bello et al., 2004). 
bHDI monomer or HDI isocyanurate equivalent concentration (µg/m3) of total NCO exposure limit, 
calculated by multiplying the exposure limit by the conversion factor (HDI monomer = 2.00; HDI 
isocyanurate = 4.64) (Bello et al., 2004). 
cTotal NCO equivalent concentration (µg NCO/m3) of HDI oligomer exposure limit, calculated by 
multiplying the exposure limit by the conversion factor (HDI isocyanurate = 4.64) (Bello et al., 2004). 
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1.7. Biomonitoring metabolites of HDI exposures in urine and blood 
 Exposure assessment of HDI is complicated by time and effort associated with workplace 
surveillance and variability of sampling methods for monitoring multiple exposure routes. 
Additionally, inter-individual physical characteristics, varying PPE use, and workplace exposure 
controls can modify exposures. Thus, traditional sampling methods may not provide accurate 
exposure measurements and furthermore, are unable to predict past exposures. Biomonitoring 
complements exposure assessment by integrating multiple exposure routes into one measurement 
and may shed light on modification of exposures. Monitoring inhalation, ingestion, or skin 
exposure routes will not provide information on the absorption, distribution, metabolism, and 
excretion (ADME) of the chemical/s of interest. Levels of metabolites measured in urine or 
blood may provide an estimate of rapid ADME from recent exposure or may also indicate 
favored metabolic pathways by measurement of long-lived macromolecule conjugates. 
1.7.1. Urine HDA levels in controlled laboratory exposure settings 
Biomonitoring to estimate rapid systemic availability and blood circulation of HDI 
monomer exposures largely relies on measuring unbound 1,6-diaminohexane (HDA), the 
hydrolysis product of HDI monomer, in urine (Rosenberg and Savolainen, 1986, Brorson et al., 
1990a, Tinnerberg et al., 1995, Maitre et al., 1996, Williams et al., 1999, Liu et al., 2004, Creely 
et al., 2006, Pronk et al., 2006b, Flack et al., 2010a, Flack et al., 2010b, Gaines et al., 2010a, 
Budnik et al., 2011, Jones et al., 2013, Hu et al., 2017, Jones et al., 2017). HDA has been 
measured in urine shortly after controlled exposure challenges or occupational exposures to HDI 
monomer and/or HDI oligomers. Rosenberg et al. were the first to quantify HDA in urine by 
exposing 5 volunteers to HDI monomer and HDI oligomers in an exposure chamber (Rosenberg 
and Savolainen, 1986). Brorson et al. validated urinary HDA as a biomarker of short-term HDI 
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monomer exposure by exposing 5 volunteers to HDI monomer in an exposure chamber and 
calculated a urinary HDA excretion half-life of 1.2 h (Brorson et al., 1990a). Tinnerberg et al. 
calculated a longer urinary HDA excretion half-life of 2.5 h after exposing 3 volunteers to HDI 
monomer in an exposure chamber (Tinnerberg et al., 1995). More recently, Liu et al. and Budnik 
et al. corroborated the longer urinary HDA excretion half-life calculated by Tinnerberg et al. 
(Tinnerberg et al., 1995, Liu et al., 2004, Budnik et al., 2011). Liu et al. exposed 23 volunteers 
to HDI biuret aerosols [geometric mean (GM) = 98.7 µg/m3] containing HDI monomer (GM = 
53.8 µg/m3) and trace levels of HDI uretdione (included in HDI biuret concentration) with a 
closed-circuit breathing apparatus, and calculated a urinary HDA excretion half-life of 2.8 h (Liu 
et al., 2004). Budnik et al. exposed 55 volunteers to HDI monomer in an exposure chamber or 
with a closed-circuit breathing apparatus, and calculated a urinary HDA excretion half-life of 2.5 
h (Budnik et al., 2011). A closed-circuit breathing apparatus has an inherent advantage over an 
exposure chamber for an inhalation challenge because it removes the possible contribution of 
HDI monomer skin exposure to metabolism and excretion of HDA in urine. Budnik et al. did not 
specify how many volunteers each were exposed to HDI monomer in a closed-circuit breathing 
apparatus or in an exposure chamber (Budnik et al., 2011). Thus, the 2.8 h half-life calculated by 
Liu et al. after inhalation exposure to HDI biuret aerosols with low levels of HDI monomer may 
be the best estimate of excretion half-life after inhalation exposure to complex mixtures of HDI 
monomer and HDI oligomers in occupational settings (Liu et al., 2004).  
1.7.2. Urine HDA levels in occupationally exposed populations 
HDA has also been measured in urine collected from workers exposed to HDI monomer 
and/or HDI oligomers. Maitre et al. observed that post-shift urine HDA levels were significantly 
correlated with HDI monomer inhalation exposures monitored during 8-h work-shifts in HDI 
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production and manufacturing facilities (Maitre et al., 1996). Pronk et al. collected urine for 24 h 
from employees in automotive refinishing shops and industrial painting companies potentially 
exposed to HDI and detected HDA in urine collected from spray-painters, technicians, and office 
workers (Pronk et al., 2006b). The odds ratios for occurrence of HDA in urine samples collected 
from all automotive spray-painters were approximately 1.1 for samples collected between 08:00 
– 15:00, and >2.0 for samples collected between 15:00 until 08:00 the next morning (Pronk et 
al., 2006b). Gaines et al. observed that both HDI monomer breathing-zone and skin exposures 
were significantly associated with unadjusted and creatinine-adjusted urine HDA levels in 
automotive spray-painters (Gaines et al., 2010a, Gaines et al., 2011). Other studies have also 
measured HDA in urine samples collected from workers in vehicle manufacturing and 
refinishing industries but associations with HDI monomer, HDI oligomers, and/or total NCO 
concentrations were not reported (Rosenberg and Savolainen, 1986, Williams et al., 1999, Creely 
et al., 2006, Jones et al., 2013, Ceballos et al., 2017, Jones et al., 2017). 
1.7.3. Plasma HDA levels in populations exposed to HDI 
HDI monomer-specific IgE and IgG have been identified in serum of workers exposed to 
HDI. An isocyanate-specific IgE is strongly predictive of isocyanate-induced asthma, while 
isocyanate-specific IgG is not predictive of adverse health effects but is frequently identified in 
workers exposed to isocyanates (Wisnewski, 2007, Wisnewski et al., 2012). HDI monomer-
specific IgG is readily detected in serum of workers and has been significantly associated with 
exposures to HDI (Wisnewski et al., 2004, Pronk et al., 2007, Wisnewski et al., 2012). Analysis 
of HDA in blood as a biomarker of short-term HDI monomer exposure is less common. Flack et 
al. measured HDA in plasma of automotive spray-painters and observed significant associations 
with both short-term and past HDI monomer exposures (Flack et al., 2010b). In a follow up 
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study, Flack et al. quantified HDA-hemoglobin adducts and found stronger associations with 
past HDI monomer exposures compared to short-term exposures (Flack et al., 2011). Although 
research on biomarkers of HDI monomer exposures in blood is less common than in urine, these 
studies show metabolites in blood are significantly associated with short-term and past HDI 
monomer exposures and may also be indicative of sensitization and isocyanate-induced asthma. 
1.7.4. Quantification of hydrolyzed HDA 
Sample treatment steps to extract HDA from urine and plasma normally involve 
hydrolysis, liquid extraction, and derivatization prior to quantitative analysis (Flack et al., 
2010a). Strong acids such as HCl and H2SO4 are routinely used to hydrolyze biological samples 
to release conjugated HDI monomer and HDA from conjugates prior to extraction (Rosenberg 
and Savolainen, 1986, Brorson et al., 1990a, Dalene et al., 1990, Tinnerberg et al., 1995, Maitre 
et al., 1996, Williams et al., 1999, Rosenberg et al., 2002, Liu et al., 2004, Creely et al., 2006, 
Pronk et al., 2006b, Flack et al., 2010b, Gaines et al., 2010a, Jones et al., 2013, Hu et al., 2017, 
Jones et al., 2017). The HDA level measured in acid-hydrolyzed samples represents a 
combination of free HDA, HDI monomer or HDA conjugated with macromolecules, and 
partially or fully acetylated HDA and conjugates (Flack et al., 2010a). This hydrolysis method is 
used for non-specific quantification of total HDA to yield the highest measurable concentrations 
in biological samples and will mask different biomarkers resulting from multiple exposure routes 
and rapid or slow metabolism and excretion (Flack et al., 2010a). Base hydrolysis with NaOH 
has also been used to measure free and acetylated HDA in biological samples (Skarping et al., 
1994b, Tinnerberg et al., 1995, Flack et al., 2010a). Base hydrolysis will release HDA 
conjugated with macromolecules by amide linkages but will not convert other conjugates to the 
amine form, thus the yield of HDA species will be lower than with acidic hydrolysis (Flack et 
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al., 2010a). However, the levels of free and acetylated HDA in base-hydrolyzed samples 
compared to acid-hydrolyzed total HDA may provide insight on the N-acetyltransferase (NAT) 
enzyme status of each individual (Flack et al., 2010a). NAT acetylates amino groups of the 
toxicant promoting rapid excretion in urine (Flack et al., 2010a). Studies have shown that 
polymorphisms to the slow acetylator NAT1 and NAT2 genotypes are associated with an 
increased risk of isocyanate-induced asthma (Wikman et al., 2002, Yucesoy et al., 2015). 
Alternatively, low concentrations of acetylated HDA may indicate the majority of biologically 
available HDI monomer and HDA are conjugated with macromolecules. 
Liquid-liquid extraction (LLE) with nonpolar organic solvents is the standard method for 
extracting liberated HDA from hydrolyzed biological samples (Flack et al., 2010a). Toluene is 
the most commonly used extraction solvent (Rosenberg and Savolainen, 1986, Brorson et al., 
1990a, Dalene et al., 1990, Tinnerberg et al., 1995, Maitre et al., 1996, Rosenberg et al., 2002, 
Liu et al., 2004, Pronk et al., 2006b, Flack et al., 2010b, Gaines et al., 2010a, Hu et al., 2017), 
although dichloromethane (Flack et al., 2010a) and diethyl ether have also been used for 
extraction (Williams et al., 1999, Creely et al., 2006, Jones et al., 2013, Jones et al., 2017). 
Extracted amines are typically derivatized with polyfluorinated acid anhydrides such as 
heptafluorobutyric anhydride (HFBA) or pentafluoropropionic anhydride (PFPA) for quantitative 
analysis by gas chromatography-mass spectrometry (GC-MS) with negative chemical ionization 
(NCI) (Rosenberg and Savolainen, 1986, Brorson et al., 1990a, Dalene et al., 1990, Maitre et al., 
1996, Williams et al., 1999, Rosenberg et al., 2002, Liu et al., 2004, Creely et al., 2006, Pronk et 
al., 2006b, Jones et al., 2013). GC-MS analysis of HDA-HFBA or HDA-PFPA derivatives is 
specific and sensitive with limits of detection (LOD) commonly below 0.1 µg/L (Tinnerberg et 
al., 1995, Flack et al., 2010a, Flack et al., 2010b, Gaines et al., 2010a). However, GC-MS 
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analysis is hindered by its inability to monitor large molecular weight semi-volatile or non-
volatile compounds including amines and polyfluorinated derivatives of HDI oligomers. Liquid 
chromatography-mass spectrometry (LC-MS) and liquid chromatography-tandem mass 
spectrometry (LC-MS/MS) have been sparingly used to quantify HDA in hydrolyzed biological 
samples (Skarping et al., 1994b, Marand et al., 2004a, Hu et al., 2017). Because LC-MS with 
electrospray ionization (ESI) induces multiple charge states, it extends the detectible mass range 
for analytes, and possesses the ability to quantify derivatized biomarkers of oligomeric 
isocyanates or macromolecule conjugates of monomeric isocyanates and amines. 
1.7.5. Urine HDA biomarker limits 
Recommended biomarker limits for hydrolyzed HDA levels in post-shift urine samples 
have been established by the ACGIH and the UK HSE. The ACGIH Biological Exposure Index 
(BEI) recommends a maximum HDA concentration of 15 µg/g creatinine in a post-shift urine 
sample (ACGIH, 2015). This BEI corresponds to the absorbed and excreted dose of HDI 
monomer after a full-shift exposure to the recommended 8-h TWA of 34 µg/m3 (ACGIH, 2015). 
The UK HSE established a Biological Monitoring Guidance Value (BMGV) for post-shift urine 
HDA of 1 µmol/mol creatinine (approximately 1.03 µg/g creatinine) (UK HSE, 2005b). The 
HDA BMGV is determined as the 90th percentile of the measured HDA levels in workers 
exposed to HDI monomer in UK workplaces (Cocker et al., 2007). An HDA concentration 
exceeding the BMGV does not necessarily mean adverse health outcomes will occur, but it does 
indicate exposures may need to be reduced (UK HSE, 2005b). There are no established limits for 
biomarkers of oligomeric isocyanates because these biomarkers have not previously been 
measured in human urine. 
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1.7.6. Biomonitoring of oligomeric isocyanate exposures 
Biomonitoring of HDI oligomer exposures and other oligomeric isocyanate exposures has 
been primarily limited to measurement of corresponding amines of the monomers. Liu et al. 
measured HDA in urine of exposed volunteers as a biomarker of short-term exposure to inhaled 
aerosols of HDI biuret containing HDI monomer and trace levels of HDI uretdione (included in 
HDI biuret concentration) (Liu et al., 2004). Urine HDA levels were significantly correlated with 
HDI monomer inhalation exposures, however, urine HDA levels were not significantly 
correlated with either HDI biuret or total NCO inhalation exposures (Liu et al., 2004). This 
controlled exposure study demonstrates that urinary HDA is not a suitable biomarker of HDI 
oligomer inhalation exposures. In other studies where HDA was measured in urine or plasma as 
a biomarker of HDI monomer exposure in occupational settings, associations with concomitantly 
monitored HDI oligomers were not reported (Pronk et al., 2006b, Flack et al., 2010a, Flack et 
al., 2010b, Gaines et al., 2010a, Gaines et al., 2011).  
 Studies identifying biomarkers of oligomeric isocyanate exposures are lacking. To our 
knowledge, biomarkers of oligomeric IPDI or TDI have not been identified. Biomarkers of short-
term inhalation and skin exposures to polymeric 3-core MDI have been quantified in rats 
(Pauluhn, 2002a, Pauluhn and Lewalter, 2002). Low levels of 3-core methylenedianiline (3-core 
MDA) were measured in rat urine collected in both studies, however, hemoglobin adducts with 
3-core MDA were not detected (Pauluhn, 2002a, Pauluhn and Lewalter, 2002). HDI biuret- and 
HDI isocyanurate-specific IgE and IgG in human serum have been identified in epidemiologic 
studies of workers exposed to HDI (Campo et al., 2007, Pronk et al., 2007). These biomarkers of 
HDI biuret and HDI isocyanurate exposures were primarily used to associate exposures with 
respiratory symptoms and isocyanate-induced asthma. Pronk et al. observed that HDI biuret-
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specific IgE was significantly associated with estimated HDI biuret exposures, however, HDI 
isocyanurate-specific IgE or IgG were not significantly associated with estimated HDI 
isocyanurate exposures (Pronk et al., 2007). 
1.8. Automotive spray-painters in North Carolina and Washington State 
 An exposure assessment of 48 automotive spray-painters employed in auto body shops 
located in North Carolina and Washington State was conducted during 2005 – 2007 (NIOSH 
R01-OH007598). Inhalation exposures were monitored by PBZ sampling and skin exposures 
were monitored by tape-strip sampling for 47 spray-painters during 115 sampling visits (Fent et 
al., 2009a, Fent et al., 2009b). Hydrolyzed HDA levels were monitored in the urine of 48 spray-
painters during 120 sampling visits (Gaines et al., 2010a) and in the plasma of 46 spray-painters 
during 112 sampling visits (Flack et al., 2010b). 
A summary of HDI monomer and HDI isocyanurate exposures measured in this worker 
population is shown in Table 1.2 (Fent et al., 2009a, Fent et al., 2009b). Spray-painters had 
higher inhalation and skin exposures to HDI isocyanurate compared to other HDI species during 
each task and during the full work-shift. HDI monomer and HDI isocyanurate PBZs were 
measured above the LOD in 279 (91%) and in 303 (99%) of 307 total tasks, respectively (Fent et 
al., 2009a). However, PBZs and PBZ-APFs for HDI isocyanurate were significantly higher for 
task and visit measurements than HDI monomer (Fent et al., 2009a). HDI monomer and HDI 
isocyanurate PBZs for tasks and visits frequently exceeded occupational exposure limits (Table 
1.3). After APF adjustment, HDI isocyanurate PBZ-APF exceeded the STELs for Oregon 
OSHA, UK HSE, Swedish WEA, and California OEHHA during 8 (3%), 42 (14%), 108 (35%), 
and 172 (56%) tasks, respectively. HDI isocyanurate PBZ-APF exceeded the California OEHHA 
full-shift exposure limit during 79 of 115 (69%) visits. By contrast, the HDI monomer PBZ-APF 
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did not exceed the UK HSE or Swedish WEA exposure limits during any task, and only 
exceeded the California OEHHA exposure limits during 29 of 307 (9%) tasks and during 19 of 
115 (17%) visits. 
The tape-stripping method developed by Fent et al. was utilized in this study to measure 
skin exposures to HDI monomer and HDI oligomers (Fent et al., 2006, Fent et al., 2009b). HDI 
isocyanurate skin exposures were significantly higher than HDI monomer skin exposures. HDI 
monomer was only measured above the LOD in 101 of 276 (37%) tasks and in 61 of 115 (53%) 
visits, while HDI isocyanurate was measured above the LOD in 262 of 276 (95%) tasks and in 
113 of 115 (98%) visits. The oligomers HDI uretdione and HDI biuret were also monitored in 
this study cohort by PBZ and tape-strip sampling (data not shown), however, HDI isocyanurate 
was the predominant HDI oligomer exposure in this worker population (Fent et al., 2009a, Fent 
et al., 2009b). 
Hydrolyzed HDA was previously quantified in urine and plasma samples collected from 
this worker population by GC-MS with method detection limits (MDL) of 0.04 µg/L for urine 
and 0.02 µg/L for plasma (Flack et al., 2010b, Gaines et al., 2010a). Hydrolyzed HDA was 
detected in 259 of 417 (62%) urine samples in 47 of 48 (98%) workers and had an arithmetic 
mean (AM) ± arithmetic standard deviation (SD) of 0.53 ± 3.32 µg/L (Gaines et al., 2010a). 
Hydrolyzed HDA was detected in 82 of 112 (73%) plasma samples in 45 of 46 (98%) workers 
and had an AM ± SD of 0.10 ± 0.14 µg/L (Flack et al., 2010b). Flack et al. observed that plasma 
HDA levels were significantly correlated with both HDI monomer inhalation and skin exposures, 
and were also significantly correlated with HDI monomer skin exposures when inhalation 
exposure levels were below the LOD (Flack et al., 2010b). HDI monomer PBZ with APF 
adjustment and HDI monomer skin exposure were both significantly associated with unadjusted 
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and creatinine-adjusted urine HDA levels by multiple linear regression analyses (Gaines et al., 
2010a, Gaines et al., 2011). Additionally, painting in downdraft booths or wearing coveralls 
were both significantly associated with lower urine and plasma HDA levels in this study cohort 
(Flack et al., 2010b, Gaines et al., 2011). 
For the purpose of this dissertation research, urine and plasma samples collected from the 
48 automotive spray-painters were available for further analysis. The inhalation and skin 
exposures to HDI monomer and HDI isocyanurate and HDA levels in urine and plasma were 
previously characterized (Fent et al., 2009a, Fent et al., 2009b, Flack et al., 2010b, Gaines et al., 
2010a). Because HDI isocyanurate was the predominant inhalation and skin exposure in this 
worker population and HDA was readily measured despite low HDI monomer exposures, 
biomarkers of HDI isocyanurate exposures were anticipated to be identifiable and quantifiable in 





Table 1.2.  Summary statistics by task and visit of personal breathing-zone, inhalation, and skin exposures to HDI monomer and 
HDI isocyanurate for 47 automotive spray-painters in North Carolina (n = 15) and Washington State (n = 32). 
 Summary Statistics by Task  Summary Statistics by Visit 
 Range Mean SD GM GSD  Range Mean SD GM GSD 
HDI monomer            
PBZ (µg/m3) <LOD – 178.6 10.9 16.6 3.3 12.0  <LOD – 178.6 13.2 22.8 5.8 5.1 
PBZ-APF (µg/m3) <LOD – 53.0 1.0 3.4 0.08 21.8  <LOD – 53.0 1.5 5.4 0.2 11.4 
INH (µg) <LOD – 31.5 1.9 3.1 0.5 14.8  <LOD – 59.7 5.2 8.5 1.9 6.0 
INH-APF (µg) <LOD – 3.2 0.1 0.3 0.01 24.2  <LOD – 6.0 0.4 0.8 0.06 11.4 
Skin (µg) <LOD – 211.9 1.5 13.8 0.001 199.1  <LOD – 211.9 3.7 21.3 0.005 331.2 
HDI isocyanurate            
PBZ (µg/m3) <LOD – 20313.9 3035.5 3355.4 1543.2 5.6  14.6 – 14565.7 3052.8 2949.7 1979.4 2.9 
PBZ-APF (µg/m3) <LOD – 13951.1 268.3 856.2 39.2 13.7  0.3 – 13951.1 352.6 1313.6 65.7 9.2 
INH (µg) <LOD – 12094.5 567.2 1056.5 215.2 6.7  3.2 – 18284.7 1512.6 2664.5 658.5 3.9 
INH-APF (µg) <LOD – 1209.4 43.0 108.2 5.5 14.4  0.1 – 1828.5 114.7 262.5 21.9 9.5 
Skin (µg) <LOD – 17979.4 495.0 1475.1 46.8 32.5  <LOD – 17979.4 1187.9 2581.4 174.4 15.2 
            
Paint time (min) 1.0 – 53.0 7.5 5.7 6.0 2.0  1.5 – 98.0 20.3 20.0 14.3 2.3 
Mean = arithmetic mean; SD = arithmetic standard deviation; GM = geometric mean; GSD = geometric standard deviation; PBZ = personal 
breathing-zone concentration (µg/m3); PBZ-APF = APF adjusted personal breathing-zone concentration (µg/m3); INH = inhalation exposure (µg); 




Table 1.3.  Number of tasks and visits where the measured personal breathing-zone 
concentrations were above short-term or full-shift exposure limits for 47 
automotive spray-painters in North Carolina (n = 15) and Washington State (n = 
32).   








Short-term  Tasks       
HDI PBZ  307 0 (0%) ** ** 0 (0%) 7 (2%) 205 (67%) 
HDI PBZ-APF  307 0 (0%) ** ** 0 (0%) 0 (0%) 29 (9%) 
         
ISO PBZ  307 ** ** 135 (44%) 256 (83%) 282 (92%) 298 (97%) 
ISO PBZ-APF  307 ** ** 8 (3%) 42 (14%) 108 (35%) 172 (56%) 
Full-shift  Visits       
HDI PBZ  115 0 (0%) 0 (0%) ** 0 (0%) 0 (0%) 92 (80%) 
HDI PBZ-APF  115 0 (0%) 0 (0%) ** 0 (0%) 0 (0%) 19 (17%) 
         
ISO PBZ  115 ** ** 5 (4%) 40 (35%) 40 (35%) 114 (99%) 
ISO PBZ-APF  115 ** ** 0 (0%) 3 (3%) 3 (3%) 79 (69%) 
HDI = HDI monomer; ISO = HDI isocyanurate; PBZ = personal breathing-zone concentration; PBZ-APF 
= APF adjusted personal breathing-zone concentration; ** = Agency does not have occupational exposure 
limit for this chemical; aHDI monomer or HDI isocyanurate equivalent concentration (µg/m3) of the UK 
HSE total NCO exposure limit; bHDI monomer or HDI isocyanurate equivalent concentration (µg/m3) of 
the Swedish WEA total NCO exposure limit. 
 
1.9. Specific aims 
The objective of this research was to develop a sample treatment and analytical method to 
quantify trisaminohexyl isocyanurate (TAHI), a hydrolysis product of HDI isocyanurate, in urine 
and plasma and evaluate its potential as a biomarker of exposure in workers exposed to HDI-
containing paints in the automotive refinishing industry. Little is known about the contribution of 
HDI isocyanurate to the development of adverse health effects associated with exposures to 
complex mixtures of HDI. It is not yet understood whether inhalation and skin provide equally 
important exposure pathways for rapid systemic availability and blood circulation of HDI 
isocyanurate. Therefore, the identification and quantification of a biomarker of HDI isocyanurate 
exposure represents a key step for understanding the fate of this toxicant in workers employed in 
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the automotive refinishing industry. The following specific aims were proposed to accomplish 
the objectives of this dissertation research: 
Aim 1:  Develop a sample treatment and analytical method to quantify hydrolyzed TAHI 
in urine and plasma. 
Aim 2:  Quantify hydrolyzed TAHI in urine and plasma collected from 48 automotive 
spray-painters occupationally exposed to HDI-containing paints. 
Aim 3:  Investigate the relationships between HDI isocyanurate and HDI monomer 
inhalation and skin exposures and urine and plasma TAHI and HDA levels. 
The development of a sample treatment and analytical method to quantify hydrolyzed TAHI in 
urine is detailed in Chapter 2 to fulfill Aims 1 and 2. Chapter 3 describes the adaptation of the 
sample treatment and analytical method described in Chapter 2 to quantify hydrolyzed TAHI in 
plasma to fulfill Aims 1 and 2. The associations between HDI isocyanurate and HDI monomer 
exposures, and TAHI and HDA biomarker levels measured in automotive spray-painters exposed 
to HDI-containing paints are presented in Chapter 4 to fulfill Aim 3. Chapter 5 summarizes the 
findings of Chapters 2 – 4 and presents the strengths and limitations of the research and proposes 




1This chapter previously appeared as an article in the Journal of Chromatography B. The original citation 
is as follows: Robbins, Z., Bodnar, W., Zhang, Z., Gold, A. & Nylander-French, L.A., 2018. 
Trisaminohexyl isocyanurate, a urinary biomarker of HDI isocyanurate exposure. J Chromatogr B Analyt 
Technol Biomed Life Sci, 1076, 117-129. 
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CHAPTER 2: TRISAMINOHEXYL ISOCYANURATE, A URINARY BIOMARKER OF 
HDI ISOCYANURATE EXPOSURE1 
 
2.1. Introduction 
Aromatic and aliphatic isocyanates are highly reactive, low-molecular-weight compounds 
included in the 187 hazardous air pollutants of the Clean Air Act Amendments of 1990 (U.S. 
EPA, 1990). They are used in the manufacturing of many common products containing 
polyurethane such as adhesives, spray-paints, foams, insulation, resins, sealants, and surface 
coatings (NIOSH, 1996, NIOSH, 2004). One of the most commonly used isocyanates is 1,6-
hexamethylene diisocyanate (HDI), comprised of its monomer and oligomers (Figure 2.1) 
(NIOSH, 1978). Occupational exposure occurs during industrial production or during spray-
painting operations such as auto body refinishing or application of marine coatings (NIOSH, 
1996). Exposures in the general population can occur from contact with isocyanate-containing 
consumer goods, from slow-curing isocyanate coatings or materials used in housing 
construction, in outdoor areas near industrial sites where isocyanates are used in manufacturing, 
or in neighborhoods surrounding auto-refinishing businesses (Kelly et al., 1999, Darcey et al., 





Figure 2.1.  Chemical structures of 1,6-hexamethylene diisocyanate monomer and its 
oligomers uretdione, biuret, and isocyanurate. 
 
 
Exposures to aerosols and vapors of HDI monomer and oligomers, including HDI isocyanurate, 
are associated with a high risk of contact dermatitis and asthma (Vandenplas et al., 1993c, Chan-
Yeung and Malo, 1995, Bernstein, 1996, Piirila et al., 2000, Aalto-Korte et al., 2010). Acute 
exposure can cause shortness of breath, rhinitis, irritation of the skin, eyes, and mucous 
membranes, and pulmonary edema (Bernstein, 1996, Goossens et al., 2002, Bello et al., 2007a, 
Bello et al., 2007b). 
Significant levels of inhalation and skin exposure to HDI monomer and its oligomers 
have been reported in spray-painters (Maitre et al., 1996, Pronk et al., 2006b, Fent et al., 2009a, 
Fent et al., 2009b, Reeb-Whitaker et al., 2012). The predominant inhalation and skin exposure in 
automotive spray-painting is to HDI isocyanurate (Fent et al., 2009a, Fent et al., 2009b, Reeb-
Whitaker et al., 2012), but the relative contributions of exposure to the HDI monomer and 
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isocyanurate in the etiology of immune sensitization and disease is currently unknown. The skin 
sensitization capacity of HDI isocyanurate has been indicated to be greater than the HDI 
monomer and HDI biuret in both humans and animals (Zissu et al., 1998, Aalto-Korte et al., 
2010), and occupational asthma has been linked to HDI oligomer exposure without an immune 
response to the monomer (Vandenplas et al., 1993a). Furthermore, it has been shown that HDI 
isocyanurate also penetrates skin at much faster rates (approximately 300 to 700 times) than HDI 
monomer (Thomasen and Nylander-French, 2012).  
Biological monitoring to estimate the systemic doses of HDI monomer and oligomers 
through exposure has been limited primarily to 1,6-diaminohexane (HDA), the hydrolysis 
product of HDI monomer, in urine and blood (Tinnerberg et al., 1995, Maitre et al., 1996, 
Rosenberg et al., 2002, Liu et al., 2004, Pronk et al., 2006b, Flack et al., 2010a, Flack et al., 
2010b, Gaines et al., 2010a, Flack et al., 2011). However, it has been shown that measured 
biomarker levels of HDI monomer exposure do not correlate with HDI oligomer exposure (Liu et 
al., 2004). Until now a method has not existed to detect biomarkers of HDI isocyanurate 
exposure in urine or blood. Therefore, to investigate the relationship between external exposure, 
exposure routes, and biomarker levels, it is imperative that a biomarker for HDI isocyanurate 
exposure be established. This biomarker assay is also critical for investigation of relative potency 
and dose-response relationships of HDI monomer and oligomer exposures, to establish causality 
for associated health effects from monomer and/or oligomer exposures, and, thus, to improve 
exposure and risk assessment for isocyanates. Towards this end, our goals were to: (i) design an 
extraction and derivatization protocol and liquid chromatography-mass spectrometry (LC-MS) 
method for analysis of trisaminohexyl isocyanurate (TAHI), a hydrolysis product and novel urine 
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biomarker of HDI isocyanurate, and (ii) apply this method to quantify TAHI in urine collected 
from workers exposed to HDI isocyanurate during automotive spray-painting operations. 
2.2. Experimental 
2.2.1. Instrumentation 
Proton nuclear magnetic resonance (1H NMR) spectra and carbon-13 nuclear magnetic 
resonance (13C NMR) spectra were acquired on a Varian INOVA 400 (Palo Alto, CA) at 400 
MHz for 1H NMR spectra and 100 MHz for 13C NMR spectra. Mass spectra were acquired on a 
TSQ Quantum Ultra triple-quadrupole mass spectrometer with an electrospray ionization (ESI) 
source (Thermo Scientific, Waltham, MA) coupled to an Acquity ultra-performance liquid 
chromatography (UPLC) system (UPLC-ESI-MS/MS) (Waters Corp., Milford, MA), and a TSQ 
Quantum Ultra triple-quadrupole mass spectrometer with a nano-electrospray ionization source 
coupled to a NanoAcquity UPLC system (nano-UPLC-ESI-MS/MS) (Waters Corp.). 
2.2.2. Synthesis of standards 
The analytical standards required for sample processing and quantitative analysis were 
not available commercially, therefore, they were synthesized in-house. The synthesis and 
purification was a labor-intensive process and yielded limited quantities of the following four 
standards: 1,3,5-Tris(6-aminohexyl)-1,3,5-triazinane-2,4,6-trione (trisaminohexyl isocyanurate; 
TAHI), N,N’,N”-((2,4,6-trioxo-1,3,5-triazinane-1,3,5-triyl)tris(hexane-6,1-diyl))triacetamide 
(trisacetamidohexyl isocyanurate; TAAHI), 1,3,5-tris(7-aminoheptyl)-1,3,5-triazinane-2,4,6-
trione (trisaminoheptyl isocyanurate; TAHpI), and N,N’,N”-((2,4,6-trioxo-1,3,5-triazinane-1,3,5-
triyl)tris(heptane-7,1-diyl))triacetamide (trisacetamidoheptyl isocyanurate; TAAHpI). The 
chemical structures are shown in Figure 2.2. Composition and purity of the four standards were 




Figure 2.2.  Chemical structures of [A] trisaminohexyl isocyanurate (TAHI), [B] 
trisacetamidohexyl isocyanurate (TAAHI), [C] trisaminoheptyl isocyanurate 
(TAHpI), and [D] trisacetamidoheptyl isocyanurate (TAAHpI). 
 
 
2.2.2.1. Trisaminohexyl isocyanurate (M = 426.3 g/mol; Figure 2.2A) 
Commercially available Desmodur® N 3300 (Bayer MaterialScience, Pittsburgh, PA) 
was mixed with concentrated HCl and refluxed for 30 min, during which time the initially 
heterogeneous mixture became homogeneous. The solvent was removed under vacuum to afford 
a trichloride salt. 1H NMR: (400 MHz, D2O) 1.51-1.60 (12H), 1.73-1.85 (12H), 3.14 (t, J = 7.2 
Hz, 6H), 3.98 (t, J = 7.2 Hz, 6H) ppm (Figure A.1). Fragmentation spectra of precursor ion [M + 
H]+ for TAHI (m/z 427.3) were obtained by nano-UPLC-ESI-MS/MS at collision energies 25 eV 
(Figure A.2) and 35 eV (Figure A.3).  
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2.2.2.2. Trisacetamidohexyl isocyanurate (M = 552.4 g/mol; Figure 2.2B) 
TAHI trichloride was mixed with triethylamine in tetrahydrofuran and excess acetic 
anhydride was added and the mixture stirred overnight. Tetrahydrofuran was removed under 
vacuum and the residue partitioned between water and dichloromethane. The organic extract was 
washed with brine, dried over Na2SO4, and concentrated. Pure product was isolated by 
chromatography (silicon dioxide, dichloromethane/methanol, 20:1). 1H NMR: (400 MHz, 
CDCl3) 1.33-1.35 (12H), 1.45-1.48 (6H), 1.60-1.65 (6H), 1.96 (s, 9H), 3.20 (q, J = 6.4 Hz, 6H), 
3.86 (t, J = 7.6 Hz, 6H) (Figure A.4). 13C NMR: (100 MHz, CDCl3) 170.1, 149.0, 42.7, 39.3, 
29.3, 27.6, 26.2, 26.1, 23.2 ppm (Figure A.5). Fragmentation spectra of precursor ion [M + H]+ 
for TAAHI (m/z 553.3) were obtained by direct injection on ESI-MS/MS at collision energies 25 
eV (Figure 2.3) and 50 eV (Figure 2.4). 
 
Figure 2.3.  Fragmentation spectrum of precursor ion [M + H]+ for TAAHI (m/z 553.3) 
obtained by direct injection on ESI-MS/MS operated in positive ion-mode with 





Figure 2.4.  Fragmentation spectrum of precursor ion [M + H]+ for TAAHI (m/z 553.3) 
obtained by direct injection on ESI-MS/MS operated in positive ion-mode with 
electrospray ionization (scan range, m/z 100-600; collision energy, 50 eV). 
 
2.2.2.3. 7,7',7''-(2,4,6-trioxo-1,3,5-triazinane-1,3,5-triyl)triheptanenitrile 
To a mixture of potassium isocyanate (492 mg, 6 mmol) in dimethylformamide (1 mL), 
7-bromoheptanenitrile (550 mg, 4 mmol) was added dropwise at 125°C. After heating for 2 h 
followed by cooling to room temperature, the mixture was partitioned between water and ethyl 
acetate and the organic layer was separated and washed with 0.3 N HCl, dried over Na2SO4, and 
distilled under vacuum to remove solvent. The residue was then purified by column 
chromatography (silicon dioxide, dichloromethane/methanol, 20:1) to afford the product. 1H 
NMR: (400 MHz, CDCl3) 1.35-1.39 (6 H), 1.47-1.50 (6 H), 1.62-1.68 (m, 12 H), 2.33 (t, J = 7.0 
Hz, 6H), 3.86 (t, J = 7.8 Hz, 6H) ppm (Figure A.6). 13C NMR, (100 MHz, CDCl3), 149.1, 119.8, 




2.2.2.4. Trisaminoheptyl isocyanurate (M = 468.4 g/mol; Figure 2.2C) 
7,7',7''-(2,4,6-Trioxo-1,3,5-triazinane-1,3,5-triyl)triheptanenitrile was hydrogenated (60 
PSI) in the presence of platinum dioxide in methanol and concentrated HCl overnight, the 
reaction was filtered and distilled under vacuum to remove methanol. The residue was portioned 
between water and diethyl ether and the aqueous layer was washed further with ether and then 
lyophilized to afford a trichloride salt. 1H NMR: (400 MHz, D2O) 1.40-1.50 (18H), 1.67-1.73 
(12H), 2.85 (t, J = 7.2 Hz, 6H), 3.97 (t, J = 7.2 Hz, 6H) ppm (Figure A.8). Fragmentation spectra 
of precursor ion [M + H]+ for TAHpI (m/z 469.3) were obtained by nano-UPLC-ESI-MS/MS at 
collision energies 25 eV (Figure A.9) and 35 eV (Figure A.10). 
2.2.2.5. Trisacetamidoheptyl isocyanurate (M = 594.4 g/mol; Figure 2.2D) 
TAHpI trichloride was acetylated with N,N'-dicyclohexylcarbodiimide and acetic acid. 
Fragmentation spectra of precursor ion [M + H]+ for TAAHpI (m/z 595.3) were obtained by 
nano-UPLC-ESI-MS/MS at collision energies 25 eV (Figure 2.5) and 50 eV (Figure 2.6). 
2.2.2.6. Mass spectrometric characterization of standards 
Stock solutions were analyzed with ESI-MS/MS by direct injection with isocratic flow 
(0.5 mL/min; 50:50 water:acetonitrile) and with nano-UPLC-ESI-MS/MS. Nanoflow 
chromatographic separations were carried out using the parameters described below. Instrument 
parameters were optimized for each precursor ion [M + H]+ and fragmentation spectra were 
obtained for TAHI (m/z 427.3) and TAHpI (m/z 469.3) at collision energies 25 and 35 eV (scan 
range, m/z 100 – 500), and for TAAHI (m/z 553.3) and TAAHpI (m/z 595.3) at collision energies 





Figure 2.5.  Fragmentation spectrum of precursor ion [M + H]+ for TAAHpI (m/z 595.3) 
obtained by nano-UPLC-ESI-MS/MS operated in positive ion-mode with nano-





Figure 2.6.  Fragmentation spectrum of precursor ion [M + H]+ for TAAHpI (m/z 595.3) 
obtained by nano-UPLC-ESI-MS/MS operated in positive ion-mode with nano-
electrospray ionization (scan range, m/z 100-600; collision energy, 50 eV). 
 
2.2.3. Study population 
Urine samples were collected from 15 male spray-painters (N = 111) in 11 auto body 
shops in North Carolina with workers’ consent and by approval of the Institutional Review 
Board in the Office of Human Research Ethics at the University of North Carolina at Chapel 
Hill. Spot urine samples were obtained from each participating painter before the start of work 
and during the workday each time he urinated. At a minimum, one pre-exposure sample and one 
end-of-day sample were collected. An average of 3.4 urine samples were obtained per worker per 
day. Exposure assessment for this worker cohort, which is a part of a larger spray-painter study 
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cohort, has been described previously (Fent et al., 2009a, Fent et al., 2009b, Flack et al., 2010b, 
Gaines et al., 2010a). HDI monomer and oligomer exposures were quantified using personal 
breathing-zone and skin tape-strip sampling (Fent et al., 2009a, Fent et al., 2009b), and HDA 
levels were quantified in plasma and urine (Flack et al., 2010b, Gaines et al., 2010a). 
2.2.4. Sample preparation 
The work-up procedure for TAHI analysis in urine involved acid hydrolysis, 
dichloromethane extraction, and derivatization with acetic anhydride prior to analysis by nano-
UPLC-ESI-MS/MS. In a round-bottom borosilicate-glass centrifuge tube, an aliquot of urine (1 
mL) was spiked with 10 µL of TAHpI (0.2 µg/mL) internal standard and hydrolyzed with 
sulfuric acid (100 µL) by heating at 100°C for 16 h. The sample was then adjusted to pH 14 with 
25 M sodium hydroxide (2 mL) prior to liquid-liquid extraction with dichloromethane (3 x 2 
mL). For each extraction step, dichloromethane (2 mL) was added to the aqueous layer, the 
sample was vortexed, and the tubes centrifuged at 1200 RCF for 20 min. The pooled 
dichloromethane extracts were then derivatized with acetic anhydride (100 µL) by heating at 
55°C for 16 h on an orbital shaker. Following derivatization, excess acetic anhydride was 
removed by extraction with 4 mL of 1 M monobasic potassium phosphate (pH 7). The sample 
was vortexed, centrifuged at 500 RCF for 20 min, and then 4 mL of the dichloromethane layer 
was transferred to a new tube. Remaining water was removed by absorption with anhydrous 
sodium sulfate (500 mg). The sample was vortexed, centrifuged at 500 RCF for 10 min, and the 
organic layer transferred into a round-bottom borosilicate-glass culture tube and dried under a 
gentle flow of nitrogen gas (2 psi increasing to 5 psi) in a water bath (32°C). The dried sample 
was reconstituted in 200 µL of 0.1% formic acid in acetonitrile, sonicated, and transferred to a 
plastic autosampler vial (300 µL limited volume). The sample was dried by vacuum 
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centrifugation and reconstituted in 50 µL of 0.1% formic acid in water prior to nano-UPLC-ESI-
MS/MS analysis. 
2.2.5. Chromatographic and mass spectrometric conditions 
Urine samples were analyzed with nano-UPLC-ESI-MS/MS. Reversed phase separations 
were carried out using a Symmetry C18 trapping column (5 µm, 180 µm × 20 mm; Waters 
Corp.) coupled with an Atlantis dC18 analytical column (3 µm, 100 µm × 100 mm; Waters 
Corp.). Mobile phase A consisted of 0.1% formic acid in deionized water and mobile phase B 
consisted of 0.1% formic acid in acetonitrile. Samples (2 µL) were trapped at 10 µL/min with 
95% A for 1.5 min then eluted at 0.6 µL/min through the analytical column with the linear 
gradient program: 95% A to 10% A over 17 min (Table A.1). Precursor ions [M + H]+ were 
generated by electrospray in the positive-ion mode and detected by selected reaction monitoring 
(SRM). Three reactions were monitored for TAAHI: m/z 553.3 → 494.4 (24eV), m/z 553.3 → 
212.1 (46 eV), and m/z 553.3 → 130.0 (52 eV) (Figure 2.7A), and for TAAHpI: m/z 595.3 → 





Figure 2.7.  [A] TAAHI mass spectral fragments and [B] TAAHpI mass spectral fragments. 
 
 
2.2.6. Preparation of standard curve and determination of method detection limit 
Standard curves were prepared as follows. Stock solutions were prepared in 1 M H2SO4 
using the trichloride salts of TAHI (1 mg/mL, equivalent to 0.80 mg/mL free amine) and TAHpI 
(1 mg/mL, equivalent to 0.81 mg/mL free amine). Excess stock solutions were stored at -20°C 
until further use. Dilutions of the TAHI and TAHpI stocks were prepared at 3-month intervals 
and stored at 4°C. Control urine used for calibration curves was collected from a non-exposed 
volunteer and processed by the experimental protocol without standard additions to verify the 
absence of interferences with the product ions of TAAHI and TAAHpI. Calibration standards 
were created by spiking 20 µL of TAHI at 13 different levels and 10 µL of TAHpI (0.2 µg/mL) 
into control urine (1 mL) prior to hydrolysis. Calibration standards (N = 14) included TAHpI 
internal standard at 2.0 µg/L and TAHI at the following concentrations: 0, 0.06, 0.09, 0.13, 0.19, 
0.25, 0.37, 0.50, 0.75, 1.00, 2.00, 2.99, 3.99, and 7.98 µg/L.  
Calibration curves were generated using the TAAHI/TAAHpI instrument response ratio and 
were linear from 0.06 to 7.98 µg/L (N = 13) with correlation coefficients r ≥ 0.995 (CORREL 
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function in Microsoft Excel 2016). TAAHI fragments m/z 130.0 and m/z 494.4 (m/z 212.1 for 
analyte confirmation only) and all three TAAHpI fragments were included in the 
TAAHI/TAAHpI instrument response ratio. Weighted linear regression was used to fit the 
calibration curves according to Almeida et al. (Almeida et al., 2002). CurveExpert 1.4 for 
Windows was used to evaluate linear regression weighting factors (w = x-1, x-2, y-1, y-2; where x = 
TAAHI/TAAHpI instrument response ratio and y = TAHI concentration). The mean absolute 
percentage error (MAPE) for the experimental concentrations was calculated in Excel to choose 
the best weighting scheme (MAPE < 10%). The weighting scheme (w = x-2) was determined to 
have the lowest MAPE for all calibration curves. For quality control of sample treatment, a 
control urine sample with TAHpI (2.0 µg/L) was prepared with each batch of workers’ urine 
samples to verify that no TAHI contamination was present from sample treatment or LC-MS/MS 
analysis. TAHI standards at three levels (0.06, 0.37, and 0.50 µg/L) were processed and analyzed 
in parallel with workers’ urine samples for quality control. The analytical error was less than 
15% for each quality control standard. The method detection limit (MDL) was calculated using 
the procedure established by the U.S. EPA (U.S. EPA, 2016). Ten control urine samples were 
spiked with the lowest calibration standard (0.06 µg/L TAHI; 2.0 µg/L TAHpI). Based on values 






2.3.1. Verification of TAAHI fragments in treated urine 
Extracted ion chromatograms acquired by selected reaction monitoring for three TAAHI 
fragments (m/z 553.3 → 130.0, m/z 553.3 → 212.1, and m/z 553.3 → 494.4) and the total ion 
chromatogram for TAAHpI (combined m/z 595.3 → 130.0, 226.1, and 536.4) are displayed in 
Figure 2.8. Control urine from a non-exposed volunteer (Figure 2.8A) and urine sample 8 from 
worker #7 (Figure 2.8B) were each spiked with TAHpI (2.0 µg/L) prior to sample processing. 
All three fragments of TAAHI were detected by SRM in treated samples using nano-UPLC-ESI-
MS/MS when TAHI was present while no TAAHI fragments were observed in the treated 
control urine. For mass spectral confirmation, fragmentation spectra were obtained for TAAHI 
(m/z 553.3) at collision energies 25 and 50 eV (scan range, m/z 100 – 600) in urine sample 2 
from worker #13 (Figure 2.9 and Figure 2.10) and urine sample 3 from worker #14 (Figure 
2.11 and Figure 2.12). The fragmentation spectra for both spray-painters’ urine samples closely 
resembled the spectra obtained from the purified standard (Figure 2.3 and Figure 2.4). TAAHI 
fragments m/z 130.0 and m/z 494.4 and all three TAAHpI fragments were included in the 
TAAHI/TAAHpI instrument response ratio to create calibration curves for TAHI quantification. 
The total ion chromatograms used for quantification are displayed in Figure 2.13 for control 
urine from a non-exposed volunteer spiked with 0.25 µg/L TAHI and 2.0 µg/L TAHpI (Figure 
2.13A) and urine sample 8 from worker #7 spiked with 2.0 µg/L TAHpI (Figure 2.13B). In both 
the control urine spiked with TAHI and urine sample 8 from worker #7, internal standard 
TAAHpI peaks are produced with minimal to no signal interference and TAAHI peaks are 





Figure 2.8.  Extracted ion chromatograms acquired by selected reaction monitoring for TAAHI: 
m/z 553.3 → 130.0, m/z 553.3 → 212.1, and m/z 553.3 → 494.4, and total ion 
chromatogram for TAAHpI (added intensities of mass transitions m/z 595.3 → 
130.0, 226.1, and 536.4); obtained for [A] control urine spiked with TAHpI (2.0 
µg/L), and [B] urine sample 8 from worker #7 spiked with TAHpI (2.0 µg/L) and 





Figure 2.9.  Fragmentation spectrum of precursor ion [M + H]+ for TAAHI (m/z 553.3) in 
urine sample 2 from worker #13 (TAHI 3.98 µg/L). Spectrum was obtained by 
nano-UPLC-ESI-MS/MS operated in positive ion-mode with nano-electrospray 





Figure 2.10.  Fragmentation spectrum of precursor ion [M + H]+ for TAAHI (m/z 553.3) in 
urine sample 2 from worker #13 (TAHI 3.98 µg/L). Spectrum was obtained by 
nano-UPLC-ESI-MS/MS operated in positive ion-mode with nano-electrospray 





Figure 2.11.  Fragmentation spectrum of precursor ion [M + H]+ for TAAHI (m/z 553.3) in 
urine sample 3 from worker #14 (TAHI 9.89 µg/L). Spectrum was obtained by 
nano-UPLC-ESI-MS/MS operated in positive ion-mode with nano-electrospray 





Figure 2.12.  Fragmentation spectrum of precursor ion [M + H]+ for TAAHI (m/z 553.3) in 
urine sample 3 from worker #14 (TAHI 9.89 µg/L). Spectrum was obtained by 
nano-UPLC-ESI-MS/MS operated in positive ion-mode with nano-electrospray 





Figure 2.13.  Total ion chromatograms acquired by selected reaction monitoring for TAAHI 
(added intensities of mass transitions m/z 553.3 → 130.0 and 494.4) and TAAHpI 
(added intensities of mass transitions m/z 595.3 → 130.0, 226.1, and 536.4); 
obtained for [A] control urine spiked with TAHI (0.25 µg/L) and TAHpI (2.0 
µg/L), and [B] urine sample 8 from worker #7 spiked with TAHpI (2.0 µg/L) and 




2.3.2. TAHI in urine of spray-painters 
Table 2.1 summarizes the mean paint-time adjusted breathing-zone and skin 
concentrations of HDI isocyanurate and urine levels of HDA and TAHI measured in 15 spray-
painters during 1 – 3 exposure monitoring visits. The spray-painter’s breathing-zone and skin 
HDI isocyanurate exposure was measured previously (Fent et al., 2009a, Fent et al., 2009b). The 
mean and standard deviation for the paint-time adjusted breathing-zone exposure ranged from 70 
± 39 to 34304 ± 27191 µg/m3 and for the skin exposure from 3 ± 4 to 3857 ± 3882 µg/mm3. 
TAHI was detected in the urine of 11 workers in concentrations up to 9.89 µg/L, with 33 of 111 
urine samples above the MDL of 0.03 µg/L. A positive linear correlation was observed between 
the measured paint-time adjusted daily total breathing-zone HDI isocyanurate concentration and 
the daily total urine TAHI concentration (r = 0.28 without creatinine adjustment; r = 0.14 with 
creatinine adjustment), while the respective correlation for HDI monomer and creatinine-





Table 2.1.  Mean ± standard deviation for paint-time adjusted breathing-zone and skin HDI isocyanurate levels and urine HDA and 
TAHI levels for 15 spray-painters. 
















1 3 10 5.3 ± 3.6 11802 ± 11460 887 ± 1189 10 1.72 ± 3.01 <MDLa 
2 3 5 7.9 ± 3.5 3656 ± 1820 204 ± 181 7 0.23 ± 0.27 <MDL 
3 3 3 3.8 ± 1.0 10232 ± 6570 313 ± 277 12 0.22 ± 0.38 0.32 ± 0.24 
4 1 2 8.0 ± 1.4 10752 ± 12539 1387 ± 1816 3 0.06 ± 0.06 <MDL 
5 1 1 19.5 21931 637 3 0.07 ± 0.12 0.04 ± 0.07 
6 2 6 6.2 ± 2.5 34304 ± 27191 1181 ± 570 8 0.34 ± 0.42 0.14 ± 0.18 
7 3 12 5.2 ± 3.3 17101 ± 14805 730 ± 502 19 0.42 ± 0.68 0.14 ± 0.23 
8 2 3 5.8 ± 2.8 16418 ± 4785 676 ± 520 5 0.27 ± 0.15  0.06 ± 0.13 
9 2 4 9.0 ± 5.4 12870 ± 20501 635 ± 836 6 0.19 ± 0.12 <MDL 
10 2 5 3.4 ± 1.7 18970 ± 29236 207 ± 426 6 0.55 ± 0.70 0.02b ± 0.06 
11 1 2 4.8 ± 1.8 70 ± 39 3 ± 4 3 5.96 ± 1.84 0.11 ± 0.10 
12 3 3 4.5 ± 2.5 27618 ± 32774 3857 ± 3882 6 0.32 ± 0.13 0.34 ± 0.55 
13 1 1 1.5 20927 339 2 0.18 ± 0.26 1.99 ± 2.81 
14 3 10 7.6 ± 3.1 20435 ± 22563 258 ± 228 12 0.10 ± 0.14 0.87 ± 2.84 
15 3 8 5.6 ± 2.1 8306 ± 8268 10 ± 7 9 0.08 ± 0.09 0.08 ± 0.24 





Inhalation and skin exposure to HDI monomer, isocyanurate, and other oligomers have 
been well characterized in the automotive refinishing industry using breathing-zone sampling 
and skin tape-strip sampling (Pronk et al., 2006b, Fent et al., 2009a, Fent et al., 2009b, Flack et 
al., 2010b, Gaines et al., 2010a, Flack et al., 2011, Reeb-Whitaker et al., 2012). However, 
biological monitoring has been limited to the metabolites of HDI monomer exposure (Brorson et 
al., 1990a, Tinnerberg et al., 1995, Maitre et al., 1996, Williams et al., 1999, Rosenberg et al., 
2002, Pronk et al., 2006b, Flack et al., 2010b, Gaines et al., 2010a, Flack et al., 2011) even 
though HDI isocyanurate constitutes the largest portion of isocyanate exposure for spray-painters 
(Fent et al., 2009a, Fent et al., 2009b, Reeb-Whitaker et al., 2012). With increasing concern over 
spray-painters’ predominant HDI isocyanurate exposures, it is critical to develop a method to 
quantitate HDI isocyanurate biomarkers in urine in order to delineate the biological availability 
of both HDI monomer and isocyanurate. This will allow a more informed investigation of the 
relative potency and dose-response relationships for HDI monomer and oligomer exposures, to 
establish causality for associated health effects from monomer and/or oligomer exposures, and, 
thus, to improve exposure and risk assessment for isocyanate exposures. 
Gas chromatography-mass spectrometry (GC-MS) is commonly used for HDA analysis 
in urine, plasma, and hemoglobin of workers or human volunteers exposed to HDI monomer 
(Brorson et al., 1990a, Brorson et al., 1990b, Dalene et al., 1990, Tinnerberg et al., 1995, Maitre 
et al., 1996, Skarping et al., 1996, Williams et al., 1999, Rosenberg et al., 2002, Liu et al., 2004, 
Flack et al., 2010b, Gaines et al., 2010a, Flack et al., 2011). However, the derivatizing agents 
commonly used for HDA analysis, heptafluorobutyric anhydride (HFBA) or 
pentafluoropropionic anhydride (PFPA), would yield an HDI isocyanurate product above the 
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mass limit of most GC-MS systems. Therefore, we selected LC-MS as the analytical method for 
quantitating the amine metabolite of HDI isocyanurate. LC-MS analysis has been used to analyze 
HDA as a free amine as well as HDA derivatized with HFBA or PFPA (Skarping et al., 1994b, 
Tinnerberg et al., 1995, Littorin et al., 2000, Marand et al., 2004a). LC-MS has also been used in 
analysis of biomarkers of exposure to methylene diphenyl diisocyanate (MDI) (Skarping et al., 
1994a, Robert et al., 2007) and toluene diisocyanate (TDI) (Carbonnelle et al., 1996, Sakai et al., 
2002, Marand et al., 2004b). Three methods were investigated for clean-up and concentration of 
the target analyte TAHI: (1) liquid-liquid extraction (LLE), (2) solid-phase extraction (SPE), and 
(3) HPLC. Significant interferences present in the urine matrix were not removed by SPE or 
HPLC extraction. Based on exploratory analyses, LLE was adopted for further method 
development. In addition to limiting confounding matrix effects, LLE has the advantages of low-
cost, short procedural time, and low MDL. 
The experimental protocol was based on previous studies for HDI, MDI, and TDI 
biomarkers in urine and plasma (Brorson et al., 1990a, Brorson et al., 1990b, Dalene et al., 1995, 
Tinnerberg et al., 1995, Maitre et al., 1996, Skarping et al., 1996, Rosenberg et al., 2002, 
Sennbro et al., 2003, Liu et al., 2004, Pronk et al., 2006b, Sabbioni et al., 2007, Flack et al., 
2010b, Gaines et al., 2010a). Acid hydrolysis is non-selective with a higher yield of total amine 
from acetylated, protein-conjugated, as well as unconjugated species (Brorson et al., 1990b, 
Flack et al., 2010a, Flack et al., 2010b, Gaines et al., 2010a) and is preferable to alkaline 
hydrolysis which selectively releases mono- and di-acetylated HDA (Brorson et al., 1990b, Sepai 
et al., 1995a, Sepai et al., 1995b, Pauluhn, 2002a, Flack et al., 2010a). Dichloromethane, an 
extraction solvent reported in the analytical literature (Sepai et al., 1995a, Sepai et al., 1995b, 
Kaaria et al., 2001, Sakai et al., 2005, Sabbioni et al., 2007, Flack et al., 2010a, Flack et al., 
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2011), was observed to be the most suitable solvent in our exploratory analysis for LLE, 
combining low matrix effects with high sensitivity. Sakai et al. reported dichloromethane was 
the most efficient extraction solvent for isomeric diaminotoluenes 2,4- and 2,6-TDA (Sakai et 
al., 2002). Three additional extraction solvents reported in the analytical literature were also 
investigated in this study for analysis by nano-UPLC-ESI-MS/MS analysis: toluene, the most 
commonly used solvent (Brorson et al., 1990a, Tinnerberg et al., 1995, Maitre et al., 1996, 
Skarping et al., 1996, Rosenberg et al., 2002, Sennbro et al., 2003, Liu et al., 2004, Marand et 
al., 2004a, Pronk et al., 2006b, Flack et al., 2010b, Gaines et al., 2010a), hexane, and ethyl 
acetate (Bailey et al., 1990, Sepai et al., 1995b, Sakai et al., 2002). No analyte could be detected 
by extraction with hexane or toluene, and confounding matrix effects persisted with ethyl 
acetate. 
MDLs for nano-UPLC-ESI-MS/MS analysis were determined for the free amine, and the 
acetyl and HFBA derivatives. MDLs for TAHI and TAHI-HFBA were poor, ranging from 0.6 to 
2.0 µg/L following work-up by LLE, SPE, or HPLC. By contrast, the MDL of the acetylated 
derivative generated by treatment of the free amine with acetic anhydride was 20- to 60-fold 
lower than that of TAHI or TAHI-HFBA. Acetylated amines (acetamides) protonate well with 
positive electrospray ionization under acidic conditions and are highly sensitive with LC-MS 
analysis. The MDL (0.03 µg/L) and the calibration curve range 0.06 to 7.98 µg/L (w = x-2, R2 = 
0.995) determined for TAHI are similar to those recently reported in the literature for HDA 
analysis in urine by GC-MS (0.04 µg/L and 0.08 to 20.0 µg/L; w = y-2, R2 = 0.98, respectively) 
(Gaines et al., 2010a). 
This new method for analysis of TAHI is key to understanding the toxicokinetics of this 
biomarker and to establish the urinary half-life of TAHI. Currently, it is unknown whether the 
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metabolism and excretion of HDI isocyanurate follows a pattern similar to that of HDI monomer. 
The observed difference between the number of urine samples with detectable HDA and TAHI 
cannot be solely explained by the breathing-zone and skin exposure levels to HDI monomer and 
HDI isocyanurate. HDI monomer comprised <1% of total HDI species (monomer, uretdione, 
biuret, and isocyanurate) while HDI isocyanurate comprised >90% of all HDI species quantified 
in the breathing-zone, skin tape-stripping, and spray-paint mixtures. The mean HDI isocyanurate 
concentration in the spray-paint mixtures used was 66637 mg/L compared to 196 mg/L for HDI 
monomer, which is reflected in the significant differences observed between the mean paint-time 
adjusted breathing-zone concentration for HDI isocyanurate and HDI monomer (15946 µg/m3 
and 65 µg/m3, respectively) and the mean skin concentration (670 µg/mm3 and 3 µg/mm3, 
respectively). Despite the greater exposures to HDI isocyanurate, TAHI was detected in 11 of 15 
workers’ urine samples while HDA was detected in all 15 workers’ urine samples. However, the 
maximum concentration detected for both biomarkers was comparable (9.89 µg/L for TAHI; 
10.11 µg/L for HDA). In this study, urine samples were collected during the same day that the 
exposure monitoring was conducted and, thus, limited our ability to determine the exact half-life 
of urinary TAHI, which may be longer than the half-life of 2.9 h for HDA (Gaines et al., 2010a). 
The HDA and TAHI biomarker analyses developed in our laboratory can be applied in future 
studies to discern the metabolism and elimination of TAHI to inform the toxicokinetics of HDI 
isocyanurate exposure. 
2.5. Conclusions 
This is the first report of an LC-MS determination (nano-UPLC-ESI-MS/MS) and 
quantification of a biomarker, TAHI, in the urine of HDI isocyanurate exposed workers. As is 
the case for the urine biomarker HDA, the urine biomarker TAHI quantified in our analysis is the 
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sum of free, acetylated, and protein-conjugated metabolites. In the short term, measurement of 
TAHI as a biomarker for HDI isocyanurate exposure allows investigation of the relationship 
between inhalation and skin exposure, work practices and work environment, and the source of 
variance in biomarker levels in the spray-painter cohort. It is noteworthy that the positive linear 
correlation observed between the measured paint-time adjusted daily total breathing-zone HDI 
isocyanurate concentration and the daily total urine TAHI concentration (r = 0.28 without 
creatinine adjustment; r = 0.14 with creatinine adjustment) was much stronger than the 
respective correlation for HDI monomer and creatinine-adjusted HDA in urine (r = 0.06) in this 
study population of North Carolina automotive spray-painters (n = 15). Measurement of HDA in 
urine of spray-painters has established a biphasic urinary half-life (Gaines et al., 2010a). This 
new method for biomarker analysis of TAHI will allow us to determine whether urinary TAHI 
follows a similar pattern in future studies. Such studies will improve isocyanate exposure 
assessment through characterization of exposure-dose relationships for both HDI monomer and 
HDI isocyanurate in occupationally exposed populations. Additional studies will be necessary to 
apportion the individual monomer and oligomer contributions to total dose. Since HDI 
isocyanurate inhalation and skin exposure levels are significantly higher than levels of HDI 
monomer in the spray-painting environment and HDI isocyanurate is potentially more potent 
sensitizing agent (Zissu et al., 1998, Aalto-Korte et al., 2010), the measurement of TAHI as a 
direct biomarker of HDI isocyanurate dose will be critical in evaluating the potency and role of 
HDI isocyanurate exposure in the development of sensitization and adverse respiratory effects. 
The widespread occupational exposure to HDI isocyanurate makes research of uptake and 
metabolism imperative. In the long term, the utility of TAHI as a biomarker will be important in 
toxicological studies directed at establishing the mode of action of HDI isocyanurate. 
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CHAPTER 3: TRISAMINOHEXYL ISOCYANURATE (TAHI) 





Exposure to isocyanates is a leading cause of occupationally-induced asthma and is also 
associated with a multitude of adverse health effects including irritation of the upper respiratory 
system, hypersensitivity pneumonitis, and allergic contact dermatitis (Vandenplas et al., 1993c, 
Chan-Yeung and Malo, 1995, Bernstein, 1996, Piirila et al., 2000, Bello et al., 2007a, Aalto-
Korte et al., 2010). In the automotive refinishing industry, spray-painters are exposed to high 
levels of 1,6-hexamethylene diisocyanate (HDI) monomer and its oligomers (uretdione, biuret, 
and isocyanurate) during application of polyurethane clearcoat paints (Janko et al., 1992, Maitre 
et al., 1996, Sparer et al., 2004, Pronk et al., 2006a, Pronk et al., 2006b, Fent et al., 2008, Fent et 
al., 2009a, Fent et al., 2009b, Reeb-Whitaker et al., 2012). HDI isocyanurate exposures are of 
increasing concern in the workplace due to its greater skin sensitization capacity (Zissu et al., 
1998, Aalto-Korte et al., 2010) and faster skin penetration rate (Thomasen and Nylander-French, 
2012) compared to HDI monomer and HDI biuret. Despite these concerns, biomarkers of HDI 
exposure have been limited to unconjugated plasma and urine biomarkers such as 1,6-
diaminohexane (HDA), the hydrolysis product of HDI monomer (Dalene et al., 1994, Skarping 
et al., 1994b, Tinnerberg et al., 1995, Maitre et al., 1996, Liu et al., 2004, Pronk et al., 2006b, 
Flack et al., 2010b, Gaines et al., 2010a, Flack et al., 2011).
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In previous studies, hydrolyzed HDA levels in plasma and urine were significantly correlated 
with HDI monomer inhalation and skin exposures (Flack et al., 2010b, Gaines et al., 2010a). 
However, in a controlled inhalation challenge study where volunteers were exposed to HDI 
biuret aerosols containing HDI monomer and trace levels of HDI uretdione, hydrolyzed HDA 
levels in urine were not significantly correlated with either HDI biuret or total NCO inhalation 
exposures (Liu et al., 2004). Recently, we published a method to detect hydrolyzed 
trisaminohexyl isocyanurate (TAHI) in processed urine as a biomarker of HDI isocyanurate 
exposure (Robbins et al., 2018). We have now adapted this method to measure hydrolyzed TAHI 
in plasma to improve exposure assessment for oligomeric isocyanates. 
3.2. Experimental 
3.2.1. Standards and materials 
High-performance liquid chromatography (HPLC) grade dichloromethane was obtained 
from Sigma-Aldrich (St. Louis, MO, USA). American Chemical Society (ACS) grade acetic 
anhydride was obtained from Acros Organics (Fair Lawn, NJ, USA). ACS grade sodium hydroxide 
(pellets) was obtained from VWR International, LLC (Solon, OH, USA). Laboratory grade 
monobasic potassium phosphate, ACS grade anhydrous sodium sulfate and sulfuric acid, and 
Optima® LC-MS grade acetonitrile and formic acid were obtained from Fisher Scientific (Fair 
Lawn, NJ, USA). Both K3EDTA and Li-Heparin anticoagulated plasma from healthy human 
volunteers were purchased from Biological Specialty Corporation (Colmar, PA). 
The following analytical standards were synthesized in house: 1,3,5-Tris(6-aminohexyl)-
1,3,5-triazinane-2,4,6-trione (trisaminohexyl isocyanurate, TAHI); N,N’,N”-((2,4,6-trioxo-1,3,5-
triazinane-1,3,5-triyl)tris(hexane-6,1-diyl))triacetamide (trisacetamidohexyl isocyanurate, 




amide (trisacetamidoheptyl isocyanurate, TAAHpI). Composition and purity of the synthesized 
standards were confirmed by proton and carbon-13 nuclear magnetic resonance (NMR) 
spectroscopy and by liquid chromatography-tandem mass spectrometry (LC-MS/MS) (Robbins 
et al., 2018). 
3.2.2. Study population and sample collection 
Blood samples (N = 112) were collected from automotive spray-painters in North 
Carolina (n = 14) and Washington State (n = 32) during 1 – 3 visits to 35 automotive repair 
shops according to a protocol approved by the Institutional Review Boards at the University of 
North Carolina at Chapel Hill and Washington State (Flack et al., 2010b). Blood was drawn from 
workers near the end of the work-shift and collected in separate tubes containing K3EDTA or Li-
Heparin anticoagulants. Exposure assessment for this worker cohort has been described 
previously (Fent et al., 2009a, Fent et al., 2009b, Flack et al., 2010b, Gaines et al., 2010a). HDI 
monomer and oligomer exposures were quantified by personal breathing-zone and skin tape-strip 
sampling (Fent et al., 2009a, Fent et al., 2009b). Hydrolyzed HDA levels in plasma were 
quantified as described previously (Flack et al., 2010b). 
3.2.3. Instrumental analysis 
Mass spectra were acquired on a TSQ Quantum Ultra triple-quadrupole mass 
spectrometer with a nano-electrospray ionization (ESI) source (Thermo Scientific, Waltham, 
MA) coupled to a NanoAcquity UPLC system (Waters Corporation, Milford, MA). Reverse 
phase separations were carried out on a Waters’ Symmetry C18 trapping column (5 µm, 180 µm 
× 20 mm) coupled to a Waters’ Atlantis dC18 analytical column (3 µm, 100 µm × 100 mm). 
Mobile phase A consisted of 0.1% formic acid in deionized water and mobile phase B consisted 
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of 0.1% formic acid in acetonitrile. Xcalibur 3.0 software (Thermo Scientific, Waltham, MA) 
was utilized to create the following nano-UPLC-ESI-MS/MS method and to acquire and process 
the chromatographic data.  Samples (2 µL) were injected and trapped with 10 µL/min of 95% A 
for 1.5 min then eluted at 0.6 µL/min through the analytical column (maintained at 35°C) with 
the linear gradient program: 95% A to 10% A over 17 min. Precursor ions [M + H]+ were 
generated by electrospray (2000 V) in the positive-ion mode and detected by selected reaction 
monitoring (SRM) with 1.5 mTorr argon as the collision gas. Five mass transitions were 
monitored for TAAHI (collision energies denoted in parentheses): m/z 553.3 → 494.4 (24 eV), 
m/z 553.3 → 452.3 (32 eV), m/z 553.3 → 393.3 (38 eV), m/z 553.3 → 212.1 (46 eV), and m/z 
553.3 → 130.0 (52 eV), and three transitions were monitored for the internal standard TAAHpI: 
m/z 595.3 → 536.4 (24 eV), m/z 595.3 → 226.1 (45 eV), and m/z 595.3 → 130.0 (55 eV). 
Structures of the TAAHI mass spectral fragments and the fragmentation spectra at collision 
energies 50 eV (A) and 25 eV (B) are shown in Figure 3.1. 
 
 
Figure 3.1.  TAAHI mass transitions: m/z 553.3 → 494.4 (24eV), m/z 553.3 → 452.3 (32 eV), 
m/z 553.3 → 393.3 (38 eV), m/z 553.3 → 212.1 (46 eV), and m/z 553.3 → 130.0 
(52 eV). Fragmentation spectrum of precursor ion [M + H]+ for TAAHI (m/z 
553.3) obtained by direct injection into ESI-MS/MS operated in positive ion-
mode with electrospray ionization (scan range, m/z 100-600) at [A] collision 
energy 50 eV and [B] collision energy 25 eV.  
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3.2.4. Plasma sample preparation 
The work-up procedure for analysis of hydrolyzed TAHI in plasma was adapted from 
Robbins et al. (Robbins et al., 2018). Briefly, an aliquot of plasma (1 mL) was spiked with 10 µL 
of TAHpI (0.2 µg/mL) and hydrolyzed with sulfuric acid (100 µL) by heating at 100°C for 16 h. 
Sodium hydroxide (2 mL of 25 M) was added to the hydrolyzed plasma to raise the pH above the 
amine pKa prior to liquid-liquid extraction with dichloromethane (3 x 2 mL). For each extraction 
step, the sample was vortexed and then centrifuged at 1200 RCF for 20 min. The pooled 
dichloromethane extracts were then derivatized with acetic anhydride (100 µL) by heating at 
55°C for 16 h. Following derivatization, excess acetic anhydride was removed by extraction with 
4 mL of 1 M monobasic potassium phosphate (pH 7). The sample was vortexed and centrifuged 
at 500 RCF for 20 min, and then the dichloromethane layer (4 mL) was transferred to a new tube 
and remaining water was removed with anhydrous sodium sulfate (500 mg). The sample was 
vortexed, centrifuged at 500 RCF for 10 min, and the organic layer was transferred to a new tube 
and taken to dryness under a gentle flow of nitrogen gas in a water bath (32°C). The dried 
sample was reconstituted in 200 µL of 0.1% formic acid in acetonitrile, sonicated, and 
transferred to an autosampler vial. The sample was dried by vacuum centrifugation and 
reconstituted in 50 µL of 0.1% formic acid in water prior to nano-UPLC-ESI-MS/MS analysis. 
3.2.5. Standard curve and method detection limit 
Previously described preparation of hydrolyzed TAHI standard curves in urine (Robbins 
et al., 2018) were modified for analysis of hydrolyzed TAHI in plasma. Standard curves were 
prepared using K3EDTA or Li-Heparin control plasma for matrix matching with samples of 
workers’ plasma. Limited volume of 112 worker plasma samples (81 plasma samples were 
collected with K3EDTA and 31 plasma samples were collected with Li-Heparin) was available 
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from prior analysis (Flack et al., 2010b). Calibration standards were generated by spiking 10 µL 
of TAHI at 11 different levels and 10 µL of TAHpI (0.2 µg/mL) into control plasma (1 mL) and 
hydrolyzed following the same protocol used for samples. Calibration standards (N = 12) 
included TAHpI internal standard at 2.0 µg/L and TAHI at the following concentrations: 0, 0.03, 
0.06, 0.09, 0.12, 0.19, 0.25, 0.37, 0.50, 0.75, 1.00, and 3.99 µg/L. Standard curves were 
generated using the TAAHI/TAAHpI instrument response ratio and were linear with correlation 
coefficients r ≥ 0.995 in both K3EDTA and Li-Heparin plasma from 0.03 to 3.99 µg/L (N = 11). 
CurveExpert 1.4 (Hyams Development) was used for weighted linear regression (w = x-1, x-2, y-1, 
y-2; where x = TAAHI/TAAHpI instrument response ratio and y = TAHI concentration) to fit the 
calibration curves according to Almeida et al. (Almeida et al., 2002). The weighting scheme was 
determined using the lowest mean absolute percentage error (MAPE < 10%) of calibration 
standards, and subsequently w = y-2 was chosen for K3EDTA curves and w = x-2 was chosen for 
Li-Heparin. The experimental method detection limit (MDL) was calculated using the procedure 
established by the U.S. EPA (U.S. EPA, 2016) using data from ten control plasma samples 
spiked with the lowest calibration standard (0.03 µg/L TAHI; 2.0 µg/L TAHpI). The TAAHI 
signal-to-noise (s/n) ratio of each MDL sample was calculated by averaging the baseline noise 60 
s before the TAAHI peak and 30 s after the TAAHI peak. The geometric mean (GM) and 
geometric standard deviation (GSD) of the TAAHI s/n ratio for all ten MDL samples was GM = 
20.3 s/n ratio (GSD = 1.4) with a range of 13 - 37 s/n ratio. Based on values in our study 
[standard deviation (SD) = 6.2 ng/L, N = 10, and t = 2.821 at α = 0.1], the experimental MDL 
was calculated to be 0.02 µg/L. Analytical carryover was evaluated by injecting mobile phase 
blanks (50:50, mobile phase A:B) after the highest calibration standard (3.99 µg/L) and the 
highest observed carryover was inconsequential (0.8% abundance).  
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3.3. Results and discussion 
Figure 3.2 displays representative extracted ion chromatograms for TAAHI (analyte) and 
TAAHpI (internal standard) mass transitions in (3.2A) control plasma spiked with 2.0 µg/L 
TAHpI, (3.2B) control plasma spiked with 0.06 µg/L TAHI and 2.0 µg/L TAHpI, and (3.2C) a 
plasma sample collected from a worker spiked with 2.0 µg/L TAHpI (calculated concentration of 
0.10 µg/L TAHI). For the five TAAHI mass transitions monitored (m/z 553.3 → 494.4, m/z 
553.3 → 452.3, m/z 553.3 → 393.3, m/z 553.3 → 212.1, and m/z 553.3 → 130.0), signals were 
detected in the control plasma spiked with TAHI and also in the worker sample, however no 
TAAHI signals were observed in the control plasma sample spiked with TAHpI internal standard 
only.  
The SRM method previously developed for analysis of TAAHI in processed urine 
included three mass transitions (m/z 553.3 → 494.4, m/z 553.3 → 212.1, and m/z 553.3 → 130.0) 
and three mass transitions for TAAHpI internal standard m/z 595.3 → 536.4, m/z 595.3 → 226.1, 
and m/z 595.3 → 130.0) (Robbins et al., 2018). TAAHI mass transitions m/z 553.3 → 494.4 and 
m/z 553.3 → 130.0 were combined for quantification, while m/z 553.3 → 212.1 was used as a 
qualifier. For plasma samples, higher background and lower analyte signal intensity were 
observed for TAAHI mass transitions (m/z 553.3 → 212.1 and m/z 553.3 → 130.0) at the highest 
collision energies. Therefore, the method was optimized by replacing those two mass transitions 
with m/z 553.3 → 452.3 and m/z 553.3 → 393.3, resulting in lower background and higher s/n 
ratios. Figure 3.3 displays this difference in background noise and s/n ratio for TAAHI extracted 
ion chromatograms used for hydrolyzed TAHI quantification in a control urine sample (3.3A) 
and control plasma sample (3.3B), both spiked with 0.06 µg/L TAHI (and 2.0 µg/L TAHpI). 
Modification of the urine SRM analytical method improved sensitivity of the MS assay for 
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plasma by extending the lower range of the plasma calibration curve and MDL (0.03 – 3.99 
µg/L; 0.02 µg/L) relative to the TAHI urine calibration curve (0.06 – 7.99 µg/L; 0.03 µg/L) 
(Robbins et al., 2018). 
 
 
Figure 3.2.  Individual extracted ion chromatograms acquired by selected reaction monitoring 
for TAAHI: m/z 553.3 → 130.0, m/z 553.3 → 212.1, m/z 553.3 → 393.3, m/z 
553.3 → 452.3, and m/z 553.3 → 494.4, and total ion chromatogram for TAAHpI 
(summed intensities of mass transitions m/z 595.3 → 130.0, 226.1, and 536.4); 
obtained for [A] control plasma spiked with TAHpI (2.0 µg/L), [B] control 
plasma spiked with TAHI (0.06 µg/L) and TAHpI (2.0 µg/L), and [C] a plasma 
sample collected from a worker spiked with TAHpI (2.0 µg/L) and a calculated 





Figure 3.3.  Comparison of extracted ion chromatograms for TAAHI in [A] control urine and 
[B] control plasma, both spiked with TAHI (0.06 µg/L) and TAHpI (2.0 µg/L). 
TAAHI ion chromatograms are displayed as summed intensities of mass 
transitions m/z 553.3 → 130.0 and 494.4 and summed intensities of mass 




Hydrolyzed TAHI was observed in 24 of 112 (21%) plasma samples in 14 of 46 (30%) 
workers and had a concentration range of <MDL to 0.32 µg/L [arithmetic mean (AM) and SD of 
<MDL ± 0.04 µg/L and GM (GSD) of <MDL µg/L (GSD = 12.03)]. In the same population, 
hydrolyzed HDA was reported in 82 of 112 (73%) plasma samples in 45 of 46 (98%) workers 
and had a concentration range of <MDL to 0.92 µg/L [AM and SD of 0.10 ± 0.14 µg/L and GM 





The sensitive method we developed for analysis of urine biomarker TAHI by nano-
UPLC-ESI-MS/MS was successfully adapted and further optimized for the analysis of this 
biomarker in plasma of automotive spray-painters occupationally exposed to HDI isocyanurate. 
No changes in sample treatment were required for plasma samples, however, two additional 
TAAHI mass transitions (m/z 553.3 → 452.3 and m/z 553.3 → 393.3) were included in the SRM 
method. These two mass transitions were utilized for quantification due to better s/n ratio 
compared to mass transitions m/z 553.3 → 494.4, m/z 553.3 → 212.1, and m/z 553.3 → 130.0 
previously monitored for urine samples. The modified protocol improved sensitivity of the MS 
method, decreasing the MDL from 0.03 µg/L in urine to 0.02 µg/L in plasma. The measurement 
of hydrolyzed TAHI in plasma in combination with analysis of hydrolyzed TAHI in urine will be 
key in future development of toxicokinetic models for HDI isocyanurate exposure. In addition, 
these methods will improve exposure assessment and evaluation of the relative effectiveness of 
workplace safety measures such as personal protective equipment for reducing occupational 
exposures to oligomeric HDI isocyanates. While hydrolyzed HDA is the currently established 
biomarker for exposure to HDI monomer, continued monitoring of HDA and the addition of a 
marker for oligomeric HDI isocyanates is important because relative and cumulative 





CHAPTER 4: BIOMARKERS TO DIFFERENTIATE AND DEFINE EXPOSURE TO 




Spray-painters in vehicle manufacturing and refinishing industries during clearcoat 
applications are commonly exposed to higher levels of HDI isocyanurate than HDI monomer and 
HDI biuret (Janko et al., 1992, Carlton and England, 2000, Bello et al., 2004, Pronk et al., 
2006a, Pronk et al., 2006b, Fent et al., 2008, Fent et al., 2009a, Fent et al., 2009b, Reeb-
Whitaker et al., 2012, Ceballos et al., 2017). HDI isocyanurate is a respiratory irritant (Ferguson 
et al., 1987, Pauluhn, 2000, Pauluhn and Mohr, 2001, Pauluhn, 2002b, Pauluhn, 2004, Ma-Hock 
et al., 2007) and a respiratory sensitizer that is linked to the development of isocyanate-induced 
asthma (Vandenplas et al., 1993a, Pronk et al., 2007). HDI isocyanurate also exhibits skin 
sensitizing capacity without inhalation exposure and without concomitant exposure to HDI 
monomer or HDI biuret (Zissu et al., 1998, Pauluhn, 2002b, Pauluhn et al., 2002, Aalto-Korte et 
al., 2010). 
Because HDI isocyanurate exposure markedly overshadows exposure to other isocyanate 
species in vehicle refinishing industries, it is important to understand the magnitude and 
variability of inhalation and skin exposures to this compound as well as to gauge the 




Exposure assessment of HDI oligomers in occupational settings is challenged by sampling 
methods required for multiple exposure routes, diverse work environments, inconsistent use of 
personal protective equipment (PPE), and inter-individual differences in physical health, 
metabolism, and genetics (Sparer et al., 2004, Bello et al., 2007a, Henneken et al., 2007, 
Whittaker and Reeb-Whitaker, 2009). Sampling methods to measure personal breathing-zone 
HDI oligomers exposures are well-established (Bello et al., 2002, Pronk et al., 2006b, Henneken 
et al., 2007, Fent et al., 2008, Reeb-Whitaker et al., 2012), but measurements are potentially 
confounded by respirator use, smoking, preexisting respiratory conditions (e.g., asthma, COPD), 
and breathing rate (Sparer et al., 2004, Woskie et al., 2004, Liu et al., 2006, Fent et al., 2009a). 
By contrast, isocyanate skin sampling is a nascent field lacking standardized methods. 
SWYPE™ and tape-strip sampling have been previously used to measure HDI oligomer skin 
exposures in automotive refinishing shops after painting or after unrelated tasks (e.g., buffing, 
sanding, compounding, mechanical work, taping and untaping) (Liu et al., 2007, Bello et al., 
2008, Fent et al., 2009b), yet these removal techniques are prone to underestimate exposure due 
to absorption, physical removal, or chemical reactions (Wisnewski et al., 2000, Bello et al., 
2006, Thomasen and Nylander-French, 2012). Interception techniques have been developed to 
capture skin exposures during spray applications, however, these techniques have either not been 
replicated in a large study cohort (Thomasen et al., 2011) or have not been utilized to measure 
HDI exposures (i.e., both HDI monomer and its oligomers) (Blake et al., 2012, Harari et al., 
2016, Bello et al., 2019). [Note: from hereon, concomitant exposure to HDI monomer and its 
oligomers is referred to as “HDI exposure”.] 
Biomonitoring of HDI exposure complements exposure assessment by conveying 
knowledge of how chemical mixtures, workplace safety measures, PPE use, as well as intra- and 
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inter-individual physical characteristics may modify exposures and subsequent systemic 
availability of the toxicant (Flack et al., 2010a, Flack et al., 2010b, Gaines et al., 2010a). 
Biomonitoring of HDI exposure has been primarily limited to quantification of 1,6-
diaminohexane (HDA), the hydrolysis product of HDI monomer, in urine and plasma as a 
marker for a short-term or cumulative exposure (Brorson et al., 1990a, Tinnerberg et al., 1995, 
Maitre et al., 1996, Liu et al., 2004, Creely et al., 2006, Pronk et al., 2006b, Flack et al., 2010b, 
Gaines et al., 2010a, Jones et al., 2013). Although significant associations between HDI 
monomer exposures and hydrolyzed HDA levels in urine and plasma have been observed in 
automotive spray-painters (Maitre et al., 1996, Pronk et al., 2006b, Flack et al., 2010b, Gaines et 
al., 2010a, Gaines et al., 2011), hydrolyzed HDA levels have not been found to be associated 
with HDI oligomer or total NCO exposures (Liu et al., 2004). HDI isocyanurate-specific 
immunoglobulin E (IgE) and immunoglobulin G (IgG) in human serum have been identified in 
workers exposed to HDI (Campo et al., 2007, Pronk et al., 2007), however, neither were 
significantly associated with estimated HDI isocyanurate exposures (Pronk et al., 2007).   
Recently, we published a method to measure a biomarker of HDI isocyanurate exposure 
in urine (Robbins et al., 2018). Because toxicokinetics of oligomeric isocyanates in humans may 
differ from the corresponding monomers, methods to monitor biomarkers of oligomer exposures 
are vital to understanding how oligomeric isocyanate exposures contribute to the development of 
adverse health effects observed in exposed workers. In this study, we analyzed levels of HDI 
isocyanurate biomarker, trisaminohexyl isocyanurate (TAHI), in urine and plasma of automotive 
spray-painters and investigated the associations between HDI isocyanurate exposure and these 
biomarker levels. Concurrently, we also investigated whether biomarkers of HDI isocyanurate 
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and HDI monomer exposures can be used interchangeably to estimate exposure to either 
compound. 
4.2. Experimental 
4.2.1. Study population and sample collection 
Exposure assessment and biological sample collection was conducted at automotive 
refinishing shops with the participation of 47 spray-painters in North Carolina (n = 15) and 
Washington (n = 32) according to a protocol approved by the Institutional Review Boards at the 
University of North Carolina at Chapel Hill and Washington State (Fent et al., 2009a, Fent et al., 
2009b, Flack et al., 2010b, Gaines et al., 2010a). Automotive refinishing shops were visited 1 to 
3 times with a minimum of 3 weeks between visits for a total of 115 sampling visits (mean 2.4 
visits per worker). Inhalation exposures to HDI monomer and HDI isocyanurate were monitored 
during 307 paint tasks (mean 2.7 tasks per worker per visit; range 1 – 8 tasks) by personal 
breathing-zone sampling. Skin exposures were monitored after 276 paint tasks (mean 2.4 tasks 
per worker per visit; range 1 – 5 tasks) by skin tape-stripping (Fent et al., 2009a, Fent et al., 
2009b). Urine samples (N = 400; mean 3.5 samples per worker per visit; range 2 – 9 samples) 
were collected during the work-shift with at least one urine sample collected before the first paint 
task (Gaines et al., 2010a). A blood sample was drawn near the end of the work-shift from each 
of the 46 workers who consented to blood biomarker analysis (N = 108). Blood samples were 
collected into separate tubes containing K3EDTA or Li-Heparin anticoagulants (Flack et al., 
2010b). Inhalation and skin exposure measures of HDI monomer and HDI isocyanurate, urine 
and plasma HDA levels, and plasma TAHI levels in the whole study cohort and urine TAHI 
levels from workers in North Carolina have been published previously (Fent et al., 2009a, Fent et 
al., 2009b, Flack et al., 2010b, Gaines et al., 2010a, Robbins et al., 2018). For this study, we also 
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analyzed urine TAHI levels in the workers from Washington State who were not part of the 
previously published method development study of HDI isocyanurate urine biomarker (Robbins 
et al., 2018). 
4.2.2. Sample treatment and quantitative analysis 
Treatment for urine and plasma samples has been described previously (Sections 2.2.4 
and 3.2.4) (Robbins et al., 2018). Briefly, aliquots of urine and plasma (1 mL) were spiked with 
TAHpI (2.0 µg/L) and hydrolyzed with sulfuric acid (100 µL) by heating (100°C) for 16 h. Two 
milliliters of sodium hydroxide (25 M) was added and the samples were extracted with 
dichloromethane (3 x 2 mL). Each time dichloromethane was added, the sample was vortexed 
and then centrifuged at 1200 RCF for 20 min. Pooled dichloromethane extracts were derivatized 
with acetic anhydride (100 µL) and heated (55°C) for 16 h. The sample was washed with 4 mL 
monobasic potassium phosphate (1 M), vortexed, and then centrifuged at 500 RCF for 20 min. 
The dichloromethane layer (4 mL) was transferred then anhydrous sodium sulfate (500 mg) was 
added to remove remaining water. The sample was vortexed, centrifuged at 500 RCF for 10 min, 
the dichloromethane layer was transferred to a new vial and taken to dryness under nitrogen gas 
in a heated water bath (32°C). The dried sample was reconstituted with 0.1% formic acid in 
acetonitrile (200 µL), sonicated, and transferred to an autosampler vial and dried by vacuum 
centrifugation. The sample was then reconstituted with 0.1% formic acid in water (50 µL) for 
nano-UPLC-ESI-MS/MS analysis. 
Preparation of standard curves with control urine and control plasma has been described 
previously (Sections 2.2.6 and 3.2.5) (Robbins et al., 2018). Briefly, control urine and control 
plasma (1 mL) were spiked with internal standard TAHpI (2.0 µg/L) and with TAHI at the 
concentration ranges 0.06 – 7.99 µg/L and 0.03 – 3.99 µg/L, respectively. Standard curves were 
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generated using the TAAHI/TAAHpI instrument response ratio and were linearly correlated (r ≥ 
0.995). Weighting schemes for weighted linear regression of standard curves were chosen based 
on the lowest mean absolute percentage error (Almeida et al., 2002), and subsequently, w = y-2 
was selected for urine and K3EDTA plasma, and w = x-2 was selected for Li-Heparin plasma. The 
method detection limit (MDL) was generated by spiking 10 control samples with the same level 
of the internal standard (2.0 µg/L) and the lowest standard used in calibration curves (0.06 µg/L 
for urine; 0.03 µg/L for plasma) in accordance with the procedure established by the U.S. EPA 
(U.S. EPA, 2016). The calculated MDLs for TAHI analysis in urine (Section 2.2.6) (Robbins et 
al., 2018) and plasma were 0.03 µg/L and 0.02 µg/L (Section 3.2.5), respectively. 
Urine and plasma samples were analyzed using nano-UPLC-ESI-MS/MS. Mass spectra 
were acquired on a TSQ Quantum Ultra triple-quadrupole mass spectrometer with a nano-
electrospray ionization (nano-ESI) source (Thermo Scientific, Waltham, MA) coupled to a 
NanoAcquity UPLC system (nano-UPLC-ESI-MS/MS) (Waters Corp.). Reverse phase 
separations were carried out on a Waters’ Symmetry C18 trapping column (5 µm, 180 µm × 20 
mm) coupled to a Waters’ Atlantis dC18 analytical column (3 µm, 100 µm × 100 mm). Mobile 
phase A and B consisted of 0.1% formic acid in water and 0.1% formic acid in acetonitrile, 
respectively. Samples were injected (2 µL) and trapped with 10 µL/min of 95% A for 1.5 min 
then eluted at 0.6 µL/min through the analytical column (35°C) with the gradient program 95% 
A to 10% A over 17 min. Precursor ions were generated by positive electrospray and detected in 
the selected reaction monitoring (SRM) mode. Three mass transitions were monitored for 
TAAHI (collision energies denoted in parentheses) in processed urine: m/z 553.3 → 494.4 (24 
eV), m/z 553.3 → 212.1 (46 eV), and m/z 553.3 → 130.0 (52 eV). Two additional mass 
transitions for TAAHI were monitored in processed plasma [m/z 553.3 → 452.3 (32 eV) and m/z 
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553.3 → 393.3 (38 eV)] due to matrix effects and lower signal intensity for the three mass 
transitions monitored in urine. Three mass transitions were monitored for TAAHpI in processed 
urine and plasma: m/z 595.3 → 536.4 (24 eV), m/z 595.3 → 226.1 (45 eV), and m/z 595.3 → 
130.0 (55 eV). For quantification of TAHI in processed urine, the signal intensities of TAAHI 
mass transitions m/z 553.3 → 494.4 and m/z 553.3 → 130.0 (52 eV) were summed and then 
divided by the summed intensities of all three TAAHpI mass transitions (Robbins et al., 2018). 
For quantification of TAHI in processed plasma, the signal intensities of TAAHI mass transitions 
m/z 553.3 → 452.3 and m/z 553.3 → 393.3 were summed and then divided by the summed 
intensities of all three TAAHpI mass transitions. The TAAHI mass transitions that were not 
included in quantification were used as qualifiers. 
4.2.3. Statistical analysis 
Daily personal breathing-zone concentration (PBZ) was calculated as a time-weighted 
average (µg/m3) using the sum of HDI monomer or HDI isocyanurate mass (µg) collected on air 
sampling filters from all tasks divided by the summation of paint time (min). Daily inhalation 
exposure (INH; µg) was calculated by multiplying PBZ by the summed paint time (min) and the 
average male breathing rate (0.0232 m3/min) (Adams, 1993). PBZ and INH were also adjusted 
for respirator use by dividing by the OSHA assigned protection factor (APF) based on respirator 
type [none = 1; half-face negative-pressure air purifying = 10; full-face negative-pressure air 
purifying = 50; full-face powered air purifying (PAPR) = 1000; full-face continuous flow 
supplied-air = 1000] (OSHA, 2009). Daily skin exposure (µg) was calculated by summing the 
mass of HDI monomer or HDI isocyanurate collected on three consecutive tape strips (10 cm2) 
applied to six different sites on the worker’s body (e.g., right and left forearms, hands, neck) 
after each paint task (Fent et al., 2009b). When a paint task was performed after blood 
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withdrawal or after post-shift urine collection, those tasks were excluded from calculating daily 
inhalation (N = 20 tasks post-plasma; N = 7 tasks post-urine) and skin (N = 18 tasks post-plasma; 
N = 6 tasks post-urine) exposure measures. 
Urine samples collected before the first paint task (N = 117) were included in descriptive 
statistics but were excluded for exposure-biomarker analysis because these biomarker levels 
reflect exposures received prior to the monitored spray-painting task and sampling visit. Daily 
mean urine levels were calculated by averaging urine samples without creatinine adjustment 
(µg/L) and with creatinine adjustment (µg/g creatinine). A total of 283 urine samples from 47 
workers were available to calculate daily mean urine levels for 115 visits (mean 2.5 samples per 
worker per visit). Plasma levels (µg) were calculated by multiplying the plasma concentration 
(µg/L) by the plasma volume estimated using individual’s estimated body surface area 
(Haycock BSA = 0.024265 × height(cm) . × weight(kg) . ) (Hurley, 1975, Haycock 
et al., 1978). 
Data analysis was carried out using Microsoft Excel and SAS statistical software (SAS 
9.4, SAS Institute Cary, NC). Prior to natural log-transformation, all exposure and biological 
samples measured below the MDL or limit of detection (LOD) were imputed to non-zero values 
using equations (MDL/√2)/100 or (LOD/√2)/100. The PROC UNIVARIATE, PROC CORR, 
PROC GLM, and PROC MIXED procedures and natural log-transformed exposure measures and 
biomarker levels were used in SAS analyses (SAS codes for each procedure can be found in 
Appendix B). The Shapiro-Wilks test (W > 0.95; PROC UNIVARIATE) for normality were 
statistically significant (p < 0.05) for natural log-transformed urine and plasma TAHI and HDA 
levels due to the large number of samples below the MDL. However, upon visual inspection, the 
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natural log-transformed data for non-zero urine and plasma TAHI and HDA levels appeared to 
be normally distributed.  
Correlations between natural log-transformed exposure measures and biomarker levels 
were investigated by linear regression (PROC CORR) to calculate Pearson correlation 
coefficients (r) and p values. The associations between workplace factors (e.g., respirator type, 
glove type, coverall use, booth type) and biomarker levels were evaluated by Tukey-Kramer 
multiple comparisons tests at α-level 0.05 (PROC GLM TUKEY). Workplace factors were 
combined to create dichotomous variables based on less protective and more protective 
groupings. Dichotomous respirator type was grouped as follows: 0 = no respirator or half-face air 
purifying; 1 = full-face air purifying, PAPR, or supplied-air. Dichotomous glove type was 
grouped as follows: 0 = no gloves or latex gloves; 1 = nitrile or neoprene gloves. Two workers 
during five visits wore gloves but the glove type was not recorded, consequently, these visits 
were included in glove use (0 = no gloves; 1 = gloves) but were excluded from dichotomous 
glove type analyses. Dichotomous booth type was grouped as follows: 0 = crossdraft or semi-
downdraft booths; 1 = downdraft booth. 
Multiple linear regression by linear mixed-effects modeling was used to investigate the 
relative influences of observed fixed effects (e.g., exposure measures, creatinine level, workplace 
factors) and random effects associated with the ith individual on the jth visit on biomarker level. 
Mixed models were constructed (PROC MIXED) with compound symmetry as the covariance 
structure for repeated measurements. The general form of the mixed model used to investigate 
the influences of fixed and random effects on biomarker level was: 
𝑌 =  𝛽 + 𝛽 𝑋 + 𝛽 𝑋 + 𝛽 𝑋 + 𝛽 𝑋 + 𝛼 + 𝜀  
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where Yij represents the natural logarithm of the urine biomarker level (with or without creatinine 
adjustment) or the plasma biomarker level for the ith individual on the jth visit, β0 is the intercept, 
X1ij represents the natural logarithm of the air exposure level (with or without APF adjustment), 
X2ij represents the natural logarithm of the skin exposure level, X3ij represents the natural 
logarithm of the creatinine level if it is included as an explanatory variable, X4ij represents the 
workplace factors (e.g., coverall use, respirator type), αi represents the random effects associated 
with the ith individual, and εij represents the random errors associated with the jth visit for the ith 
individual. This approximate mixed model structure has been used previously to evaluate the 
associations between HDI monomer breathing-zone and skin exposures, urine HDA levels, and 
plasma HDA levels in this study population (Fent et al., 2009a, Fent et al., 2009b, Flack et al., 
2010b, Gaines et al., 2010a, Gaines et al., 2011). 
 With biomarker level as the response variable, base mixed models were constructed with 
air and skin exposure as explanatory variables. Initially, air exposure was included in base mixed 
models as a PBZ or INH variable, with or without APF adjustment (data not shown). Although 
PBZ and INH provided similar model fit statistics, PBZ was chosen for further base mixed 
model analyses because paint time could be included as an explanatory variable with PBZ or 
PBZ-APF in mixed models. Urine level as the response variable was modeled both with and 
without creatinine adjustment. A stepwise model selection was used by introducing continuous 
and categorical variables into base mixed models to estimate significance (p value cutoff < 0.10) 
and model fit by the Akaike’s Information Criterion (AIC) and marginal R2 statistic. We also 
evaluated model fit with the marginal R2 statistic for the goodness-of-fit of fixed effects (Vonesh, 
1997, Orelien and Edwards, 2008). The marginal R2 statistic was determined by replicating the 




4.3.1. Biomarker levels in urine and plasma 
Table 4.1 displays the descriptive statistics of the measured urine and plasma TAHI and 
HDA levels. TAHI was measured above the MDL in 127 of 400 (32%) urine samples in 35 of 47 
(74%) workers and had a mean and standard deviation of 0.22 ± 0.92 µg/g creatinine. HDA was 
measured above the MDL in 252 of 400 (63%) urine samples in all 47 workers and had a mean 
and standard deviation of 0.29 ± 1.20 µg/g creatinine. The maximum urine level was 12.91 µg/g 
creatinine for TAHI and 21.58 µg/g creatinine for HDA. TAHI was measured in 19% of pre-shift 
urine samples, 37% of samples collected after the first task, and 32% of post-shift samples. By 
contrast, HDA was measured in 56% of pre-shift urine samples, 66% of samples collected after 
the first task, and 71% of post-shift samples.  
TAHI was measured above the MDL in 24 of 108 (22%) plasma samples in 14 of 46 
(30%) workers and had a mean and standard deviation of <MDL ± 0.14 µg. HDA was measured 
above the MDL in 80 of 108 (74%) plasma samples in 45 of 46 (98%) workers and had a mean 
and standard deviation of 0.35 ± 0.50 µg. The maximum plasma level was 1.12 µg for TAHI and 
3.25 µg for HDA. 
4.3.2. Linear regression analysis 
Pearson correlation coefficients (r) and significance of the correlations (p value) between 
exposure measures and biomarker levels are shown in Table 4.2. Creatinine-adjusted urine 
TAHI levels were significantly correlated with both HDI isocyanurate PBZ (r = 0.27, p = 
0.0038) and INH (r = 0.34, p = 0.0002), but not after APF adjustment (for both PBZ-APF and 
INH-APF p ≥ 0.1536). To the contrary, APF-adjusted HDI monomer inhalation exposure levels 
were significantly correlated with creatinine-adjusted urine HDA levels (PBZ-APF r = 0.23, p = 
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0.0132 and INH-APF r = 0.27, p = 0.0038) while correlation with unadjusted INH exposure level 
was much weaker (r = 0.18, p = 0.0485) and PBZ was not significantly correlated (r = 0.14, p = 
0.1229). HDI isocyanurate and HDI monomer skin exposures were significantly correlated with 
creatinine-adjusted urine TAHI (r = 0.22, p = 0.0162) and HDA (r = 0.29, p = 0.0016) levels, 
respectively. 
Unlike for urine, plasma TAHI levels were not significantly correlated with either HDI 
isocyanurate PBZ or PBZ-APF (for both p ≥ 0.0824). However, plasma TAHI levels were 
significantly correlated with all other HDI isocyanurate exposure measures (for all p ≤ 0.0223) as 
well as paint time (r = 0.43, p < 0.0001). By contrast, none of HDI monomer exposure measures 





Table 4.1.  Summary statistics of TAHI and HDA levels in urine (µg/g creatinine) collected pre-shift, after the first paint task, and 
post-shift as well as in plasma samples (µg) collected from automotive spray-painters. 
 Workers  Samples  Urine (µg/g creatinine) and plasma (µg) levels 
 n n > MDL (%)  N N > MDL (%)  Range Mean SD GM GSD 
            
Urine TAHI            
Pre-shift 47 16 (34%)  117 22 (19%)  <MDL – 1.57 0.08 0.22 <MDL 20.61 
After first task 47 33 (70%)  283 105 (37%)  <MDL – 12.91 0.28 1.08 <MDL 42.76 
Mean after first task 47 33 (70%)  115 51 (44%)  <MDL – 4.30 0.24 0.61 <MDL 22.69 
Post-shift 47 25 (53%)  115 37 (32%)  <MDL – 2.95 0.18 0.44 <MDL 41.05 
Total 47 35 (75%)  400 127 (32%)  <MDL – 12.91 0.22 0.92 <MDL 36.97 
            
Plasma TAHI 46 14 (30%)  108 24 (22%)  <MDL – 1.12 <MDL 0.14 <MDL 12.53 
            
            
Urine HDA            
Pre-shift 47 36 (77%)  117 66 (56%)  <MDL – 6.07 0.22 0.61 <MDL 29.85 
After first task 47 47 (100%)  283 186 (66%)  <MDL – 21.58 0.32 1.37 <MDL 24.47 
Mean after first task 47 45 (96%)  115 87 (76%)  <MDL – 11.16 0.34 1.12 <MDL 16.28 
Post-shift 47 42 (89%)  115 82 (71%)  <MDL – 21.58 0.46 2.09 0.03 22.94 
Total 47 47 (100%)  400 252 (63%)  <MDL – 21.58 0.29 1.20 <MDL 26.23 
            
Plasma HDA 46 45 (98%)  108 80 (74%)  <MDL – 3.25 0.35 0.50 <MDL 25.05 
            
n = number of workers; N = number of samples; MDL = method detection limit; Mean = arithmetic mean; SD = arithmetic standard deviation; 





Table 4.2.  Pearson correlations between HDI isocyanurate and HDI monomer exposure measures and levels of TAHI and HDA in 
urine and plasma. 
HDI isocyanurate Exposure-Urine Correlations  Exposure-Plasma Correlations 
 Exposure level TAHI (µg/g) HDA (µg/g)  Exposure level TAHI (µg) HDA (µg) 
Explanatory GM GSD r p valuea r p valuea  GM GSD r p valuea r p valuea 
PBZ (µg/m3) 1969.2 2.9 0.27 0.0038 -0.07 0.4775  1801.4 4.6 0.12 0.2223 0.02 0.8784 
PBZ-APF (µg/m3) 65.3 9.4 0.05 0.5622 0.12 0.2210  62.6 11.4 0.17 0.0824 0.01 0.9450 
INH (µg) 635.0 3.9 0.34 0.0002 0.02 0.8382  556.9 6.0 0.31 0.0013 0.07 0.4652 
INH-APF (µg) 21.1 9.9 0.13 0.1536 0.15 0.0990  19.4 12.1 0.31 0.0011 0.05 0.6191 
Skin (µg) 170.2 15.4 0.22 0.0162 0.26 0.0045  152.2 15.9 0.22 0.0223 0.09 0.3407 
              
HDI monomer Exposure-Urine Correlations  Exposure-Plasma Correlations 
 Exposure level TAHI (µg/g) HDA (µg/g)  Exposure level TAHI (µg) HDA (µg) 
Explanatory GM GSD r p valuea r p valuea  GM GSD r p valuea r p valuea 
PBZ (µg/m3) 5.7 5.1 0.22 0.0182 0.14 0.1229  5.3 6.4 0.10 0.3271 0.09 0.3789 
PBZ-APF (µg/m3) 0.2 11.5 0.08 0.3876 0.23 0.0132  0.2 12.4 0.16 0.0958 0.06 0.5336 
INH (µg) 1.9 6.1 0.30 0.0011 0.18 0.0485  1.6 7.5 0.27 0.0049 0.13 0.1791 
INH-APF (µg) 0.1 11.8 0.16 0.0973 0.27 0.0038  0.1 12.5 0.31 0.0013 0.10 0.2954 
Skin (µg) 0.005 331.7 0.18 0.0535 0.29 0.0016  0.003 337.3 0.21 0.0285 0.14 0.1526 
              
Paint time (min) 13.9 2.4 0.22 0.0194 0.12 0.2191  13.3 2.4 0.43 <0.0001 0.12 0.2206 
µg/g = µg/g creatinine; GM = geometric mean; GSD = geometric standard deviation; r = Pearson correlation coefficient (asignificance was 
determined at α-level 0.05); PBZ = personal breathing-zone (µg/m3); PBZ-APF = APF adjusted personal breathing-zone (µg/m3); INH = inhalation 




4.3.3. Influences of workplace factors 
 Summaries of TAHI and HDA biomarker data stratified twice by workplace factors and 
the significant associations determined by multiple comparisons tests are shown in Tables 4.3 
and 4.4. The biomarker data were first stratified by booth type, respirator type, coverall use, or 
glove type, and then followed by a second stratification by these variables. Other workplace 
factors (e.g., shop location, glove use, hat use, weekday) were also investigated but no significant 
associations were observed (data not shown). Creatinine-adjusted urine TAHI levels were 
significantly higher in workers who painted in crossdraft or semi-downdraft booths (mean and 
SD of 0.34 ± 0.55 µg/g creatinine) than workers who painted in downdraft booths (mean and SD 
of 0.19 ± 0.63 µg/g creatinine) before stratification by another workplace factor (p = 0.0004; data 
not shown). When urine biomarker data were stratified by booth type and then stratified a second 
time by workplace factors, painting in crossdraft or semi-downdraft booths remained 
significantly associated with increased creatinine-adjusted urine TAHI levels. For example, 
workers who painted in crossdraft or semi-downdraft booths and wore coveralls (TAHI > MDL 
in 65% of visits) had significantly higher creatinine-adjusted urine TAHI levels (p = 0.0048; 
Table 4.3) than workers who painted in downdraft booths and wore coveralls (TAHI > MDL in 
35% of visits). Workers who painted in crossdraft or semi-downdraft booths also had 
significantly higher creatinine-adjusted urine TAHI levels than workers who painted in 
downdraft booths when coveralls were not worn, when no gloves or latex gloves were worn, 
when no respirator or half-face air purifying respirators were worn, and when full-face air 
purifying, PAPR, or supplied-air respirators were worn (for all p ≤ 0.0423). Interestingly, no 
significant differences were observed in creatinine-adjusted urine HDA levels with any 




Table 4.3.  Associations between workplace factors and the mean creatinine-adjusted urine TAHI or HDA levels (µg/g creatinine) 
by stratification. General linear modeling was used to evaluate the significance of the compared variable in predicting 







 TAHI (µg/g creatinine)  HDA (µg/g creatinine) 
 N > MDL (%) p valuea  N > MDL (%) p valuea 
Booth type Cross/Semi Respirator None/Half-face 24  14 (58%) 0.5313  22 (92%) 0.4749 
   Full-faceb 13  9 (69%)   10 (77%)  
Booth type Downdraft Respirator None/Half-face 61  23 (38%) 0.7842  45 (74%) 0.1563 
   Full-faceb 17  5 (29%)   10 (59%)  
Respirator None/Half-face Glove type None/Latex 50  24 (48%) 0.1670  41 (82%) 0.9191 
   Nitrile/Neoprene 30  11 (37%)   22 (73%)  
Respirator Full-faceb Glove type None/Latex 14  7 (50%) 0.8687  10 (71%) 0.9251 
   Nitrile/Neoprene 16  7 (44%)   10 (63%)  
Coverall No Glove type None/Latex 28  14 (50%) 0.5699  25 (89%) 0.9094 
   Nitrile/Neoprene 5  2 (40%)   4 (80%)  
Coverall Yes Glove type None/Latex 36  17 (47%) 0.4191  26 (72%) 0.7100 
   Nitrile/Neoprene 41  16 (39%)   28 (68%)  
Respirator None/Half-face Booth type Cross/Semi 24  14 (58%) 0.0113  22 (92%) 0.1946 
   Downdraft 61  23 (38%)   45 (74%)  
Respirator Full-faceb Booth type Cross/Semi 13  9 (69%) 0.0191  10 (77%) 0.2016 
   Downdraft 17  5 (29%)   10 (59%)  
Coverall No Booth type Cross/Semi 17  10 (59%) 0.0423  15 (88%) 0.9199 
   Downdraft 21  8 (38%)   18 (86%)  
Coverall Yes Booth type Cross/Semi 20  13 (65%) 0.0048  17 (85%) 0.0902 
   Downdraft 57  20 (35%)   37 (65%)  
Glove type None/Latex Booth type Cross/Semi 22  15 (68%) 0.0040  20 (91%) 0.2601 
   Downdraft 42  16 (38%)   31 (74%)  
Glove type Nitrile/Neoprene Booth type Cross/Semi 15  8 (53%) 0.0707  12 (80%) 0.2096 
   Downdraft 31  10 (32%)   20 (65%)  
N = number of samples (mean urine level by visit); MDL = method detection limit; aSignificance was determined by Tukey-Kramer multiple 




Table 4.4.  Associations between workplace factors and the plasma TAHI and HDA levels (µg) by stratification. General linear 
modeling was used to evaluate the significance of the compared variable in predicting plasma biomarker levels given 







 TAHI (µg)  HDA (µg) 
 N > MDL (%) p valuea  N > MDL (%) p valuea 
Booth type Cross/Semi Respirator None/Half-face 22  5 (23%) 0.8059  19 (86%) 0.7039 
   Full-faceb 12  3 (25%)   10 (83%)  
Booth type Downdraft Respirator None/Half-face 59  16 (27%) 0.0211  42 (71%) 0.5436 
   Full-faceb 15  0 (0%)   9 (60%)  
Respirator None/Half-face Glove type None/Latex 46  12 (26%) 0.4351  37 (80%) 0.2708 
   Nitrile/Neoprene 30  6 (20%)   21 (70%)  
Respirator Full-faceb Glove type None/Latex 11  3 (27%) 0.0365  7 (64%) 0.5196 
   Nitrile/Neoprene 16  0 (0%)   12 (75%)  
Coverall No Glove type None/Latex 25  5 (20%) 0.9956  20 (80%) 0.8367 
   Nitrile/Neoprene 5  1 (20%)   4 (80%)  
Coverall Yes Glove type None/Latex 32  10 (31%) 0.0284  24 (75%) 0.8408 
   Nitrile/Neoprene 41  5 (12%)   29 (71%)  
Respirator None/Half-face Booth type Cross/Semi 22  5 (23%) 0.8130  19 (86%) 0.1377 
   Downdraft 59  16 (27%)   42 (71%)  
Respirator Full-faceb Booth type Cross/Semi 12  3 (25%) 0.0320  10 (83%) 0.1284 
   Downdraft 15  0 (0%)   9 (60%)  
Coverall No Booth type Cross/Semi 15  2 (13%) 0.1428  12 (80%) 0.8905 
   Downdraft 20  7 (35%)   15 (75%)  
Coverall Yes Booth type Cross/Semi 19  6 (32%) 0.0907  17 (89%) 0.0153 
   Downdraft 54  9 (17%)   36 (67%)  
Glove type None/Latex Booth type Cross/Semi 19  5 (26%) 0.7918  16 (84%) 0.3106 
   Downdraft 38  10 (26%)   28 (74%)  
Glove type Nitrile/Neoprene Booth type Cross/Semi 15  3 (20%) 0.2318  13 (87%) 0.0563 
   Downdraft 31  3 (10%)   20 (65%)  
N = number of samples; MDL = method detection limit; aSignificance was determined by Tukey-Kramer multiple comparisons tests at α-level 
0.05; bFull-face variable includes full-face air purifying, PAPR, or supplied-air respirators. 
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The results obtained for TAHI levels in plasma are less clear than for urine and most 
likely because TAHI was detected in fewer plasma samples. TAHI was measured above the 
MDL in 16 of 59 (27%) plasma samples collected from workers who painted in downdraft 
booths and wore half-face air purifying respirators, while TAHI was not detected in any of the 
plasma samples (N = 15) collected from workers who painted in downdraft booths and wore full-
face air purifying, PAPR, or supplied-air respirators (p = 0.0211; Table 4.4). Workers who did 
not wear gloves or who wore latex gloves had significantly higher plasma TAHI levels than 
workers who wore nitrile or neoprene gloves when coveralls were worn (p = 0.0284), or when 
full-face air purifying, PAPR, or supplied-air respirators were worn (p = 0.0365). 
Stratification of plasma biomarker data by booth type and then a second stratification by 
respirator type, coverall use, or glove type did not clearly indicate that painting in crossdraft or 
semi-downdraft booths would lead to higher plasma TAHI or HDA levels (Table 4.4). Workers 
who wore full-face air purifying, PAPR, or supplied-air respirators and painted in crossdraft or 
semi-downdraft booths had significantly higher plasma TAHI levels (p = 0.0320) than workers 
with similar respirator protection and who painted in downdraft booths. However, no significant 
difference was observed in plasma TAHI levels between booth types when workers wore no 
respirator or half-face air purifying respirators (p = 0.8130), or after both stratifications of 
coverall use and glove type (for all p ≥ 0.0907). Significantly higher plasma HDA levels (p = 
0.0153) were only observed in workers who painted in crossdraft or semi-downdraft booths 
compared to those who painted in downdraft booths when coveralls were worn. For any other 





4.3.4. Linear mixed models 
The results from the linear mixed models for urine TAHI and HDA levels are displayed 
in Table 4.5. The final model (Model 1-C) for urine TAHI levels included HDI isocyanurate 
PBZ (p = 0.0123) and booth type (p = 0.0068) as significant variables and paint time (p = 
0.0591) as a borderline significant variable with model fit statistics AIC = 554.9 and marginal R2 
= 0.21. It is noteworthy that HDI isocyanurate skin exposure or creatinine level were not 
significant predictors of TAHI levels in either base model (p ≥ 0.0712 and p ≥ 0.8220, 
respectively). HDI isocyanurate skin exposure remained non-significant when paint time and 
booth type were added to Model 1-A, and therefore, skin exposure was removed from the final 
model (Model 1-C). Respirator type was not significant when it was added to Model 1-A (data 
not shown), which was in agreement with the non-significance of HDI isocyanurate PBZ-APF in 
Model 1-B (p = 0.6833). Other workplace factors were also introduced to Models 1-A and 1-B 
but were observed to be non-significant (data not shown). 
The final model (Model 1-F) for urine HDA levels included creatinine level (p < 0.0001) 
and HDI monomer skin exposure (p = 0.0344) as significant variables and respirator type (p = 
0.0961) as a borderline significant variable with model fit statistics AIC = 541.7 and marginal R2 
= 0.29 (Table 4.5). HDI monomer PBZ-APF was a significant predictor in Model 1-E (p = 
0.0237). HDI monomer PBZ was not a significant predictor of urine HDA levels when respirator 
type was added to Model 1-D (p = 0.3944; data not shown) and, therefore, was removed from the 
final model (Model 1-F). Paint time and other workplace factors were also introduced to Models 
1-D and 1-E but were non-significant (data not shown). 
Table 4.6 displays the linear mixed model results for plasma TAHI and HDA levels. The 
final model (Model 2-C) for plasma TAHI levels included paint time (p = 0.0019) as a 
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significant variable and HDI isocyanurate PBZ-APF (p = 0.0676) as a borderline significant 
variable with model fit statistics AIC = 464.1 and marginal R2 = 0.30. HDI isocyanurate 
exposure measures were not significant predictors of plasma TAHI levels in the base models 
(Model 2-A p = 0.4209; Model 2-B p = 0.2893). Workplace factors were added to both base 
models but were not observed to be significant predictors of plasma TAHI levels (data not 
shown).  
HDI monomer skin exposure was a borderline significant predictor of plasma HDA levels 
in all three models (for all p ≤ 0.0871; Table 4.6). HDI monomer PBZ and PBZ-APF were not 
significant predictors of plasma HDA levels (for both p ≥ 0.8026) even when additional variables 
were included in the models (data not shown), and therefore, was removed from the final model 
(Model 2-F). Paint time and workplace factors were added to both base models but were not 
observed to be significant predictors of plasma HDA levels (data not shown). The final model for 
plasma HDA levels only included HDI monomer skin exposure as a borderline significant 
variable (Model 2-F, AIC = 551.0, marginal R2 = 0.05), however, this model did not have better 





Table 4.5.  Summary of linear mixed models for predicting mean urine TAHI and HDA levels (µg/L). 
TAHI level Explanatory Estimate 
Standard 
Error 
p value AIC R2  HDA level Explanatory Estimate 
Standard 
Error 
p value AIC R2 
Base Intercept -11.33 3.47 0.0021 561.7 0.07  Base Intercept -13.39 2.30 <0.0001 546.4 0.28 
Model 1-A ISO PBZ 0.58 0.29 0.0467    Model 1-D HDI PBZ 0.15 0.17 0.3944   
 ISO Skin 0.13 0.11 0.2262     HDI Skin 0.09 0.05 0.0888   
 Creatinine 0.11 0.49 0.8220     Creatinine 2.08 0.44 <0.0001   
 Worker var 3.89 1.40 0.0054     Worker var 1.68 0.91 0.0659   
 Residual var 5.16 0.91 <0.0001     Residual var 5.29 0.92 <0.0001   
               
Base Intercept -6.70 2.67 0.0154 566.8 0.05  Base Intercept -13.43 2.14 <0.0001 542.7 0.29 
Model 1-B ISO PBZ-APF 0.06 0.16 0.6833    Model 1-E HDI PBZ-APF 0.27 0.12 0.0237   
 ISO Skin 0.20 0.11 0.0712     HDI Skin 0.06 0.05 0.1737   
 Creatinine -0.06 0.49 0.8962     Creatinine 2.21 0.43 <0.0001   
 Worker var 4.08 1.47 0.0055     Worker var 1.63 0.87 0.0612   
 Residual var 5.32 0.94 <0.0001     Residual var 5.07 0.87 <0.0001   
               
Final Intercept -11.07 2.24 <0.0001 554.9 0.21  Final Intercept -12.88 2.15 <0.0001 541.7 0.29 
Model 1-C ISO PBZ 0.65 0.25 0.0123    Model 1-F HDI Skin 0.10 0.04 0.0344   
 Paint time 0.66 0.34 0.0591     Creatinine 2.10 0.43 <0.0001   
 Booth type -1.95 0.69 0.0068     Respirator type -1.12 0.66 0.0961   
 Worker var 2.58 1.19 0.0293     Worker var 1.74 0.91 0.0546   
 Residual var 5.29 0.94 <0.0001     Residual var 5.13 0.88 <0.0001   
AIC = Akaike’s Information Criterion; R2 = marginal R2 statistic calculated with the PROC GLM procedure in SAS; ISO = HDI isocyanurate; 





Table 4.6.  Summary of linear mixed models for predicting plasma TAHI and HDA levels (µg). 
TAHI level Explanatory Estimate 
Standard 
Error 
p value AIC R2  HDA level Explanatory Estimate 
Standard 
Error 
p value AIC R2 
Base Intercept -7.71 1.08 <0.0001 468.4 0.09  Base Intercept -2.55 0.60 0.0001 547.7 0.05 
Model 2-A ISO PBZ 0.12 0.15 0.4209    Model 2-D HDI PBZ 0.04 0.18 0.8026   
 ISO Skin 0.05 0.08 0.5622     HDI Skin 0.10 0.06 0.0871   
 Worker var 3.55 1.01 0.0004     Worker var -1.34 1.02 0.1915   
 Residual var 2.61 0.47 <0.0001     Residual var 11.53 2.02 <0.0001   
               
Base Intercept -7.28 0.60 <0.0001 468.5 0.10  Base Intercept -2.42 0.41 <0.0001 548.5 0.05 
Model 2-B ISO PBZ-APF 0.12 0.11 0.2893    Model 2-E HDI PBZ-APF 0.03 0.12 0.8226   
 ISO Skin 0.04 0.08 0.6058     HDI Skin 0.10 0.05 0.0712   
 Worker var 3.51 1.00 0.0005     Worker var -1.29 1.03 0.2129   
 Residual var 2.60 0.47 <0.0001     Residual var 11.47 2.01 <0.0001   
               
Final Intercept -9.69 0.92 <0.0001 464.1 0.30  Final Intercept -2.45 0.40 <0.0001 551.0 0.05 
Model 2-C ISO PBZ-APF 0.18 0.10 0.0676    Model 2-F HDI Skin 0.10 0.05 0.0528   
 Paint time 0.93 0.29 0.0019     Worker var -1.19 0.99 0.2301   
 Worker var 2.45 0.80 0.0023     Residual var 11.24 1.94 <0.0001   
 Residual var 2.64 0.47 <0.0001           
AIC = Akaike’s Information Criterion; R2 = marginal R2 statistic calculated with the PROC GLM procedure in SAS; ISO = HDI isocyanurate; 





Even though significant levels of inhalation and skin exposure to HDI isocyanurate have 
been measured concomitantly with HDI monomer exposure, validation of biomarkers of HDI 
isocyanurate exposure are lacking. Here, we observed that urine and plasma biomarkers of HDI 
isocyanurate exposures are readily detectable in automotive spray-painters. HDI isocyanurate 
inhalation exposure appears to be a significant source of TAHI in urine and plasma (Tables 4.2, 
4.5, and 4.6). Significant correlations were observed between HDI isocyanurate skin exposure 
and TAHI levels in urine (creatinine-adjusted p = 0.0162) and plasma (p = 0.0223; Table 4.2) 
but, interestingly, skin exposure did not significantly predict TAHI levels in urine or plasma in 
the mixed model analyses (Tables 4.5 and 4.6). However, in concordance with our earlier 
reported findings (Gaines et al., 2010a, Gaines et al., 2011), HDI monomer skin exposure was 
significantly correlated with urine HDA levels (creatinine-adjusted p = 0.0016; Table 4.2) and 
was also a significant predictor of urine HDA levels in the mixed model analyses (p = 0.0344; 
Table 4.5). It is noteworthy that creatinine level, which was a highly significant predictor for 
urine HDA levels in this study (p < 0.0001; Table 4.5) as also reported in other studies (Gaines 
et al., 2010a, Gaines et al., 2011), was not a significant predictor of urine TAHI levels.  
In this cohort, some type of respirator was used by every worker except one. Among 
workers who wore half-face air purifying respirators, the most commonly worn respirator in this 
study cohort, urine TAHI and HDA levels were measured above the MDL during 72% and 75% 
of the visits, respectively. Adjustment for the OSHA APF value has been used to estimate HDI 
exposure from breathing-zone measurements because it is not feasible to measure inhalation 
exposure due to respirator occlusion and intra- and inter-individual differences in breathing rate 
and pulmonary absorption (Liu et al., 2006, OSHA, 2009). Unpredictably, we observed that APF 
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adjustment did not affect associations with urine and plasma TAHI and HDA levels in the same 
fashion. APF adjustment of HDI isocyanurate inhalation exposures weakened associations with 
creatinine-adjusted urine TAHI levels but strengthened associations between HDI monomer 
inhalation exposures and creatinine-adjusted urine HDA levels (Table 4.2). Previously, Gaines et 
al. reported that APF adjustment improved the associations between HDI monomer PBZ and 
creatinine-adjusted urine HDA levels (discrete spot sample concentration and average 
concentration between-task) in this same study cohort (Gaines et al., 2010a, Gaines et al., 2011). 
Additionally, respirator type was significantly associated with pooled between-tasks urine HDA 
levels (Gaines et al., 2011). These trends were supported by the results observed in the mixed 
model analyses where HDI isocyanurate PBZ was a significant predictor of urine TAHI levels 
and HDI monomer PBZ-APF was a significant predictor of urine HDA levels (Table 4.5). INH 
and INH-APF variables were more strongly correlated with creatinine-adjusted urine TAHI and 
HDA levels than PBZ and PBZ-APF variables (Table 4.2), indicating that duration of exposure 
may be more consequential for systemic availability than high short-term airborne 
concentrations. This is also supported by the significant correlation of paint time with creatinine-
adjusted urine TAHI levels (p = 0.0194; Table 4.2) and its borderline significance observed in 
the mixed model analyses (p = 0.0591; Table 4.5).  
Our results clearly show that painting in downdraft booths is significantly associated with 
lower urine TAHI levels compared to painting in crossdraft or semi-downdraft booths, which is 
supported by previous studies that demonstrated downdraft booths significantly reduced HDI 
isocyanurate inhalation and skin exposures (Fent et al., 2009a, Fent et al., 2009b). Creatinine-
adjusted urine TAHI levels were significantly higher in workers who painted in crossdraft or 
semi-downdraft booths than in workers who painted in downdraft booths after urine biomarker 
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data were stratified by respirator type and coverall use, and when workers wore no gloves or 
wore latex gloves (for all p ≤ 0.0423; Table 4.3). Additionally, booth type was a significant 
predictor of urine TAHI levels by mixed model analyses (p = 0.0068; Table 4.5). We previously 
reported that booth type was significantly associated with HDA levels in pooled urine samples 
(i.e., spot urine samples collected during the work-shift), but not with HDA levels in single post-
shift urine samples (Gaines et al., 2011). The calculated geometric mean urine HDA level (both 
unadjusted and creatinine-adjusted) was not significantly associated with booth type after urine 
biomarker data were stratified by respirator type, coverall use, or glove type (for all p ≥ 0.0902; 
Table 4.3) or in mixed model analyses (data not shown). Based on these results, painting in 
downdraft booths significantly reduces exposure and urine TAHI levels, but it is unclear whether 
reduced HDI monomer exposures from painting in downdraft booths is associated with lower 
urine HDA levels.  
The differences between the levels of TAHI and HDA measured above the MDL (Table 
4.1) was more pronounced in plasma samples (22% and 74%, respectively) than in urine samples 
(32% and 63%, respectively) despite equivalent MDLs for the analytical protocols (Flack et al., 
2010b). Although HDI monomer skin exposure was a significant predictor of plasma HDA 
levels, the AIC (range 547.7 – 551.0) and marginal R2 (0.05) indicated weaker model fit than for 
plasma TAHI levels (AIC range 464.1 – 468.5 and marginal R2 range 0.09 – 0.30) in mixed 
model analyses (Table 4.6). The weak associations between plasma HDA levels and HDI 
monomer exposures may be a result of significant covalent binding of HDI monomer and/or 
partially hydrolyzed HDA to albumin and other long-lived macromolecules in plasma 
(Wisnewski et al., 2000, Flack et al., 2010b, Wisnewski et al., 2013). Thus, plasma HDA levels 
may not be a suitable biomarker of same-day HDI monomer exposure due to significant 
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contributions from past HDI monomer exposures to hydrolyzed HDA levels. By contrast, plasma 
TAHI levels were significantly associated with HDI isocyanurate inhalation exposures in this 
cohort (Table 4.2), suggesting that HDI isocyanurate remain unreacted longer (i.e., not readily 
available for binding with macromolecules) or is hydrolyzed more readily than HDI monomer in 
plasma. 
The results indicate that half-face air purifying respirators did not adequately reduce HDI 
isocyanurate inhalation exposures in this study cohort, which led to increased levels of TAHI in 
plasma. Among workers who painted in downdraft booths, TAHI was measured above the MDL 
in 27% of plasma samples collected from workers wearing half-face air purifying respirators 
while no TAHI was detected in the plasma samples collected from workers wearing full-face air 
purifying, PAPR, or supplied-air respirators (p = 0.0211; Table 4.4). On the other hand, HDI 
isocyanurate PBZ with APF adjustment was borderline significantly associated with plasma 
TAHI levels in linear regression (p = 0.0824; Table 4.2) and in mixed model analyses (p = 
0.0676; Table 4.6). Because paint time was significantly associated with plasma TAHI levels in 
linear regression (p < 0.0001; Table 4.2) and mixed model analyses (p = 0.0019; Table 4.6), it is 
probable that the protection provided by a half-face air purifying respirator decreases with a 
longer paint task, thus, leading to increased exposure and plasma TAHI levels. 
We observed that wearing no gloves or wearing latex gloves was significantly associated 
with increased plasma TAHI levels when workers wore coveralls (p = 0.0284; Table 4.4). This is 
in accordance with previous studies in which little to no permeation of HDI isocyanurate through 
gloves or coveralls was reported (Ceballos et al., 2014b, Mellette et al., 2019). The relationships 
between booth type and plasma TAHI levels are more difficult to interpret due to the low 
prevalence of TAHI above the MDL concentration, which likely contributed to the lack of 
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associations observed for booth type after plasma biomarker data was stratified by coverall use 
and glove type (for all p ≥ 0.0907), and for workers who wore no respirators or wore half-face air 
purifying respirators (p = 0.8130; Table 4.4).  
Evaluation of HDA as a biomarker of HDI isocyanurate exposures has been largely 
ignored and associations between HDI isocyanurate exposures and urine or plasma HDA levels 
have not been previously reported. Significant associations between HDI monomer inhalation or 
skin exposures and urine or plasma HDA levels have been reported in numerous studies (Brorson 
et al., 1990a, Tinnerberg et al., 1995, Maitre et al., 1996, Liu et al., 2004, Pronk et al., 2006b, 
Flack et al., 2010b, Gaines et al., 2010a, Budnik et al., 2011, Gaines et al., 2011). Urine HDA 
levels were not significantly associated with HDI oligomer exposures in a controlled inhalation 
study (Liu et al., 2004). Our linear regression analyses indicate that urine HDA level is not a 
suitable biomarker of HDI isocyanurate inhalation exposures (for all p ≥ 0.0990; Table 4.2), and 
plasma HDA level is not a suitable biomarker of HDI isocyanurate inhalation or skin exposures 
(for all p ≥ 0.3407). By contrast, urine TAHI levels were significantly correlated with HDI 
monomer inhalation exposures without APF adjustment (PBZ p = 0.0182 and INH p = 0.0011). 
Additionally, plasma TAHI levels were significantly correlated with HDI monomer inhalation 
(paint time-adjusted) and skin exposures (for all three p ≤ 0.0285). These results show TAHI 
levels in urine and plasma are stronger biomarkers of HDI exposures than HDA biomarker 
levels.  
The following issues that may have affected the measured biomarker levels are important 
to acknowledge. Previous studies have shown that when half- or full-face air purifying 
respirators are worn, the presence of facial hair decreases the respirator fit factor resulting in 
leakage (Skretvedt and Loschiavo, 1984, Stobbe et al., 1988, Floyd et al., 2018). We did not 
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record facial hair status for this study but did observe that workers were not always clean-shaven, 
and some had beards. It is unclear how respirator leakage may have affected inhalation 
exposures in this study because HDI isocyanurate is predominantly in the aerosol phase and HDI 
monomer partitions between the vapor and aerosol phases (Bello et al., 2004). Bello et al. 
sampled skin surfaces occluded by half-face air purifying respirators after painting and detected 
HDI oligomers in 80% of samples and HDI monomer in 30% of samples (Bello et al., 2008). 
The differences in volatility and phase between HDI isocyanurate and HDI monomer and the 
analyses presented in this paper suggest APF does not similarly adjust inhalation exposures to 
HDI isocyanurate and HDI monomer. It would be prudent in future surveys to record facial hair 
status to investigate its associations with biomarker levels when half- or full-face air purifying 
respirators are worn.  
Tape-strip sampling utilized in this study may have underestimated HDI isocyanurate and 
HDI monomer skin exposures received during spray-painting (Fent et al., 2009b, Thomasen et 
al., 2011). Two previous studies of HDI penetration rates into excised skin demonstrated 10 – 
25% of topical HDI isocyanurate or HDI monomer doses were absorbed during short and long 
exposures (Bello et al., 2006, Thomasen and Nylander-French, 2012). These permeation studies 
suggest that a longer task would lead to higher absorptions of HDI isocyanurate and HDI 
monomer into layers of the skin beyond what is measured by tape-strips before skin exposure 
sampling could be performed, resulting in an underestimation of the worker’s exposure. Contact 
with surfaces may be another source of skin exposure missed by tape-strip sampling. Unreacted 
HDI oligomers have been found on surfaces hours after painting, and workers are less likely to 
wear coveralls and gloves when performing other tasks (Pronk et al., 2006b, Bello et al., 2007b, 
Liu et al., 2007, Bello et al., 2008). However, skin exposures from direct contact with unreacted 
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HDI species on surfaces was minimal in a study of 18 workers in 5 auto body shops (De Vries et 
al., 2012). Tape-strip sampling may underestimate HDI isocyanurate skin absorption during 
spray-painting, but it is uncertain whether exposures from unknown sources substantively 
contribute to overall dose. Underestimation of skin exposure by tape-strip sampling may partially 
explain weaker associations between HDI isocyanurate skin exposure and TAHI biomarker 
levels if significant levels of HDI isocyanurate were absorbed during spray-painting. 
4.5. Conclusions 
 This study provides evidence that levels of hydrolyzed TAHI in urine and plasma are 
important biomarkers of HDI isocyanurate inhalation and skin exposures in the automotive 
refinishing industry. Although TAHI was measured in 32% of urine samples and 22% of plasma 
samples collected from occupationally exposed workers, exposures and workplace factors (e.g., 
booth type, glove type) were more strongly associated with TAHI biomarker levels than with 
HDA biomarker levels. HDI isocyanurate inhalation exposure and paint time were significantly 
associated with urine and plasma TAHI levels. The results indicate that painting in crossdraft or 
semi-downdraft booths is significantly associated with increased TAHI levels in urine, stressing 
the importance of utilizing downdraft booths to reduce HDI isocyanurate exposures in the 
automotive refinishing industry. Additionally, wearing full-face air purifying, PAPR, or 
supplied-air respirators was significantly associated with decreased plasma TAHI levels 
indicating that half-face air purifying respirators may not adequately protect against HDI 
isocyanurate inhalation exposures. TAHI was detected in fewer urine and plasma samples than 
HDA despite higher exposures to HDI isocyanurate. The metabolism and excretion of HDI 
isocyanurate may be longer than HDI monomer. This study was designed to obtain optimal 
exposure and biomarker data for HDI monomer as no information existed for HDI isocyanurate, 
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and therefore, the optimal sample collection time for TAHI may have been somewhat missed in 
this study. Future exposure assessments in other exposed populations are warranted to better 
understand the relationships between short-term and/or cumulative HDI isocyanurate exposures 
and the associated biomarkers. In summary, the results obtained in this study confirm TAHI as a 
biomarker of HDI isocyanurate exposure and may eventually prove to be a stronger and more 





CHAPTER 5: DISCUSSION AND CONCLUSIONS 
 
This dissertation includes three related manuscripts (Chapters 2 – 4) focused on the 
identification and quantification of hydrolyzed TAHI as a biomarker of HDI isocyanurate 
exposure. The sample treatment and analytical methods developed to quantify hydrolyzed TAHI 
in urine and plasma are described in Chapters 2 and 3. Chapter 2 details the synthesis and 
verification of analytical standards TAHI, TAAHI, TAHpI, and TAAHpI that were subsequently 
used for the development of a sensitive and specific sample treatment and analytical method. 
Hydrolyzed TAHI was quantified in urine of 15 spray-painters from North Carolina to validate 
the method. Chapter 3 details the adaptation of the sample treatment and analytical method to 
extract and analyze hydrolyzed TAHI in plasma of 46 spray-painters from North Carolina and 
Washington State. Because no changes were required to the sample treatment method, the work 
focused on the modification of the nano-UPLC-ESI-MS/MS method in order to improve 
sensitivity and specificity for quantification of hydrolyzed TAHI. Chapter 4 incorporates the 
levels of hydrolyzed TAHI measured in urine and plasma (as reported in Chapters 2 and 3) and 
previously published exposure and biomarker data for this worker population (Fent et al., 2009a, 
Fent et al., 2009b, Flack et al., 2010b, Gaines et al., 2010a) to investigate relationships between 




The following sections outline the biomarker analysis (Section 5.1), the relationships 
between exposures, workplace factors, and biomarker levels (Section 5.2), urine levels compared 
to recommended limit values (Section 5.3), limitations of the biomarker analysis and study 
design (Section 5.4), and how these findings could translate for future research of HDI oligomer 
exposures and oligomeric isocyanate exposures in other occupations (Section 5.5). 
5.1. Quantification of HDI isocyanurate biomarkers in urine and plasma 
The significant and unique contribution of this research to the exposure science is the 
development of a sample treatment and analytical method to quantify TAHI in hydrolyzed urine 
and plasma samples as a biomarker of HDI isocyanurate exposures. The hazards associated with 
HDI monomer and oligomer exposures in occupational settings have been known for decades 
(NIOSH, 1978, Bernstein, 1996, NIOSH, 1996, Bello et al., 2004), yet, exposure assessment and 
biomonitoring efforts have only focused on measurement of diisocyanate monomers and 
corresponding biomarkers. 
HDI biomarker analysis has mostly been limited to metabolites of HDI monomer (free or 
conjugated) in urine or plasma (Brorson et al., 1990a, Dalene et al., 1990, Tinnerberg et al., 
1995, Maitre et al., 1996, Williams et al., 1999, Liu et al., 2004, Creely et al., 2006, Pronk et al., 
2006b, Flack et al., 2010b, Gaines et al., 2010a, Jones et al., 2013). In addition, HDI biuret- and 
HDI isocyanurate-specific IgE and IgG in human serum have been identified (Campo et al., 
2007, Pronk et al., 2007), but attempts to relate HDI isocyanurate-specific IgE and IgG levels to 
HDI isocyanurate exposure levels in exposed individuals have been unsuccessful (Pronk et al., 
2007). This research demonstrates that biomarkers of HDI isocyanurate inhalation and skin 
exposures are measurable in hydrolyzed urine and plasma and is also the first study to identify 
biomarkers of oligomeric isocyanate exposures in urine or plasma. 
 
 104
Sample treatment methods from prior analysis of hydrolyzed HDA in urine and plasma 
(Flack et al., 2010b, Gaines et al., 2010a) were successfully adapted to extract and derivatize 
hydrolyzed TAHI using dichloromethane and acetic anhydride (Robbins et al., 2018). The 
traditional methods of derivatizing HDA with polyfluorinated acid anhydrides proved difficult or 
non-applicable for analysis of TAHI derivatives by GC-MS. The reaction with HFBA creates 
semi-volatile and/or non-volatile products that are not suitable for GC-MS analysis. Although 
PFPA has been used in previous studies to derivatize HDA for GC-MS analysis (Flack et al., 
2010a), this reaction was not tested since it was presumed that the reaction would also create 
semi-volatile and/or non-volatile products.  
Acetic anhydride was chosen as the derivatizing chemical, forming secondary amides by 
reaction with TAHI (TAAHI product) and TAHpI (TAAHpI product). The secondary amide 
products could not be volatilized for GC-MS analysis. On the other hand, since secondary 
amides are readily protonated, they are appropriate analytes for positive ESI for LC-MS analysis. 
The sample treatment and nano-UPLC-ESI-MS/MS analytical method that was developed to 
analyze the derivative TAAHI from extracted urine and plasma was as sensitive (urine MDL = 
0.03 µg/L; plasma MDL = 0.02 µg/L) as recent analytical methods used to quantify HDA-HFBA 
in urine (MDL = 0.04 µg/L) and plasma (MDL = 0.02 µg/L) (Flack et al., 2010b, Gaines et al., 
2010a, Robbins et al., 2018). The combination of acetic anhydride derivatization and nano-
UPLC-ESI-MS/MS analysis may have widespread applicability to monitor other potential 
biomarkers of oligomeric isocyanate exposures in urine and plasma. However, there are 
limitations and improvements to the sample treatment and analytical method that need to be 
addressed before it can be adapted for other toxicants of interest. These issues are discussed in 
Section 5.4.1.  
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5.2. HDI isocyanurate exposure and biomarker levels in exposed workers 
5.2.1. The effects of exposures and workplace factors on biomarker levels 
A major aim in this study was to investigate the relationships between HDI isocyanurate 
biomarker (i.e., TAHI) levels and HDI exposure measures. As presented in Chapter 4, TAHI 
biomarker levels were significantly associated with HDI isocyanurate inhalation exposure levels 
and the duration of spray-painting task (i.e., paint time) in both linear regression and linear 
mixed model analyses (Tables 4.2, 4.5, and 4.6). Significant correlations were also observed 
between HDI isocyanurate skin exposure and TAHI levels in creatinine-adjusted urine and 
plasma (Table 4.2), but interestingly, HDI isocyanurate skin exposure did not predict urine or 
plasma TAHI levels in the mixed model analyses (Tables 4.5 and 4.6). 
HDI monomer skin exposure was significantly associated urine HDA levels in both linear 
regression (Table 4.2) and mixed model analyses (Table 4.5), corroborating previous findings in 
this study cohort (Gaines et al., 2010a, Gaines et al., 2011). We also observed that APF 
adjustment improved the significance of the associations between HDI monomer inhalation 
exposure and urine HDA levels in both linear regression (Table 4.2) and mixed model analyses 
(Table 4.5). Contrary to previous findings (Flack et al., 2010b), we did not observe significant 
associations between HDI monomer inhalation or skin exposures and plasma HDA levels. 
Further, no exposure measures were significantly correlated with plasma HDA levels (Table 
4.2), and the model fit statistics of the mixed models were poor compared to mixed models 
predicting plasma TAHI levels (Table 4.6). These differing results may be due to the calculation 
of the exposure variables. Flack et al. calculated daily exposure measures that included 20 
inhalation exposure tasks and 18 skin exposure tasks after plasma samples were collected (Flack 
et al., 2010b). Because linear correlations between HDI monomer exposures and plasma HDA 
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levels were close to the significance level of α = 0.05 (HDI monomer inhalation p = 0.026, and 
HDI monomer skin p = 0.040) (Flack et al., 2010b), it is likely that excluding exposures after 
plasma collection affected the statistical analyses presented in Chapter 4.  
Multiple comparisons tests and linear mixed models showed that booth type was 
significantly associated with urine TAHI levels measured in the exposed workers (Tables 4.3 
and 4.5). Workers who painted in downdraft booths had significantly lower creatinine-adjusted 
urine TAHI levels than workers who painted in crossdraft or semi-downdraft booths (Table 4.3), 
and booth type also significantly predicted urine TAHI levels in the mixed model analyses 
(Table 4.5). HDA biomarker levels were not significantly associated with booth type contrary to 
previous findings in this worker cohort (Flack et al., 2010b, Gaines et al., 2011). However, 
crossdraft and semi-downdraft booths were grouped together for multiple comparisons and 
mixed model analyses while previous studies considered booth types separately. Coverall use or 
glove type were not significantly associated with urine TAHI levels, however, workers who wore 
no gloves or wore latex gloves had significantly higher plasma TAHI levels when they wore 
coveralls or when they wore full-face air purifying, PAPR, or supplied-air respirators (Table 
4.4). When painting in downdraft booths, workers who wore no respirator or wore half-face air 
purifying respirators had significantly higher plasma TAHI levels than workers who wore full-
face air purifying, PAPR, or supplied-air respirators (Table 4.4). Respirator type was a 
borderline significant predictor of urine HDA levels (Table 4.5), but as shown in previous 
studies (Gaines et al., 2010a, Gaines et al., 2011), APF-adjusted HDI monomer inhalation 
exposure was more strongly associated with urine HDA levels than either unadjusted HDI 
monomer inhalation exposure or respirator type as independent variables. 
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HDA has been monitored in urine as a biomarker of short-term HDI monomer exposure 
in controlled exposure studies (Brorson et al., 1990a, Dalene et al., 1990, Tinnerberg et al., 1995, 
Liu et al., 2004, Budnik et al., 2011) and in occupationally exposed populations (Maitre et al., 
1996, Pronk et al., 2006b, Gaines et al., 2010a, Gaines et al., 2011). Additionally, HDA levels in 
plasma and hemoglobin were confirmed as biomarkers of short-term and cumulative exposures 
(Flack et al., 2010b, Flack et al., 2011). HDA levels in urine were not observed to be 
significantly associated with HDI biuret or total NCO inhalation exposures in a controlled 
inhalation challenge study (Liu et al., 2004). However, associations between HDI oligomer 
exposures and HDA levels in urine or plasma in exposed workers have not been reported 
previously. Therefore, we sought to investigate whether biomarkers of HDI isocyanurate and 
HDI monomer exposures can be used interchangeably to estimate exposure to either compound. 
We observed that creatinine-adjusted urine TAHI levels were significantly correlated with HDI 
monomer inhalation exposures (INH p = 0.0011; Table 4.2), and plasma TAHI levels were 
significantly correlated with HDI monomer inhalation and skin exposures (INH p = 0.0049, and 
skin p = 0.0285). Creatinine-adjusted urine HDA levels were only significantly correlated with 
HDI isocyanurate skin exposure (p = 0.0045), and plasma HDA levels were not correlated with 
HDI isocyanurate inhalation or skin exposures (for all p ≥ 0.3407; Table 4.2). These results 
show that TAHI biomarker levels are significantly associated with HDI monomer exposures but 
HDA levels in urine or plasma are not suitable biomarkers of HDI isocyanurate exposures. 
5.2.2. Creatinine adjustment for urine biomarkers 
Typically in the published scientific literature, urine HDA levels have been reported as 
creatinine-adjusted values (Maitre et al., 1996, Williams et al., 1999, Liu et al., 2004, UK HSE, 
2005b, Creely et al., 2006, Pronk et al., 2006b, Gaines et al., 2010a, Budnik et al., 2011, Gaines 
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et al., 2011, Jones et al., 2013, ACGIH, 2015, Hu et al., 2017, Jones et al., 2017) because 
creatinine adjustment normalizes urine biomarker levels to account for variability in urine water 
content (Gaines et al., 2010b). Also, the limit values for HDA in urine are published as 
creatinine-adjusted by ACGIH and UK HSE (UK HSE, 2005b, ACGIH, 2015). Therefore, the 
urine HDA and TAHI values reported in this thesis were also adjusted for creatinine level in the 
statistical analyses. 
Consistent with previous studies (Gaines et al., 2010a, Gaines et al., 2011), we observed 
that creatinine level was a significant predictor of daily mean and post-shift urine HDA levels in 
mixed model analyses (Tables 4.5 and C.3). On the contrary, creatinine level was not a 
significant predictor for daily mean or post-shift urine TAHI levels in mixed model analyses 
(Tables 4.5 and C.3). The results indicate that creatinine adjustment is not necessary for HDI 
isocyanurate urine biomarker analyses, thus, it is likely that urine TAHI excretion is not related 
to the urine creatinine excretion rate in this worker population. However, this observation should 
be confirmed in future exposure assessment studies. 
5.2.3. Daily mean urine concentration for exposure assessment 
Many recommended limit values for urine biomarkers are determined for the 
concentration measured in the last urine sample collected during the work-shift (UK HSE, 
2005b, ACGIH, 2019). Here, we report the measured urine biomarker levels as a geometric mean 
value of the samples collected during the workday for each worker. To evaluate the implications 
of averaging urine biomarker levels, we investigated the associations between daily HDI 
isocyanurate and HDI monomer exposures and the geometric means of urine TAHI and HDA 
levels measured in all urine samples collected during the work-shift in parallel with TAHI and 
HDA levels in spot urine samples collected post-shift. In order to minimize the impact of 
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exposure carryover from previous day exposure, a geometric mean of all individual urine 
samples collected after the first paint task of the day for each visit was calculated. The results of 
the statistical analyses using the spot urine samples collected post-shift are presented in 
Appendix C. 
Mean urine TAHI levels were more strongly correlated with HDI isocyanurate inhalation 
and skin exposures than post-shift urine TAHI levels (Tables C.1). Painting in crossdraft or 
semi-downdraft booths was also significantly associated with higher post-shift TAHI levels after 
urine biomarker data was stratified by respirator type, coverall use, or glove type (for all p ≤ 
0.0782; Table C.2). Linear mixed model analyses in Chapter 4 (Table 4.5) for predicting mean 
urine levels were replicated with post-shift urine levels (Table C.3). Although paint time and 
booth type were significant predictors (p = 0.0188 and p = 0.0024, respectively) of post-shift 
urine TAHI levels in the final model (Model 3-C), HDI isocyanurate PBZ was not significant (p 
= 0.1068) and the AIC values for all three models were higher (Models 3A-C, AIC range 595.4 – 
606.3) than the AIC values for mixed models predicting mean urine TAHI levels (Models 1A-C, 
AIC range 554.9 – 566.8). The linear regression and mixed model analyses indicate that the 
geometric mean of TAHI levels in spot urine samples collected during the work-shift is more 
strongly associated with HDI isocyanurate exposures than the TAHI levels in a single spot urine 
sample collected post-shift, emphasizing the need to collect urine throughout the work-shift.   
5.3. Urine biomarker levels and recommended limit values 
The ACGIH and UK HSE recommend maximum HDA levels in post-shift urine samples 
of 15 µg/g creatinine and 1 µmol/mol creatinine, respectively (UK HSE, 2005b, ACGIH, 2015). 
In this study, HDA was measured above the ACGIH BEI in one urine sample while 14 urine 
samples had HDA levels above the UK HSE BMGV (Table 5.1). In pre-shift urine, HDA was 
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measured above the BMGV in four samples indicating that HDA is systemically available and 
gradually released post-exposure excretion (i.e., elimination kinetics is at least biphasic), as is 
also reported elsewhere (Tinnerberg et al., 1995, Gaines et al., 2010a, Budnik et al., 2011). 
No recommended biomarker limits exist for TAHI because an analytical method to detect 
it in biological media has not been available until now (Robbins et al., 2018). However, 
hypothetical biomarker limits could be calculated by multiplying the HDA BEI and HDA 
BMGV with the TAHI:HDA molar ratio of 3.67. As a result of using the molar ratio, these 
hypothetical limit values assume that no differences in absorption, metabolism, and urinary 
excretion exist between HDI isocyanurate and HDI monomer in humans. The hypothetical TAHI 
BEI and TAHI BMGV were calculated to be 55.07 µg/g creatinine and 3.77 µg/g creatinine, 
respectively. It is noteworthy, that TAHI concentration was below the hypothetical TAHI BEI 
limit value in all urine samples in this study population. The HDA BEI originates from the 
estimated HDA level excreted in urine after full work-shift exposure (8 h) to TWA HDI 
monomer level of 34 µg/m3 (ACGIH, 2015). Because the toxicokinetics and excretion of HDI 
isocyanurate are poorly understood, this hypothetical TAHI BEI concentration may not reflect a 
level of TAHI in urine when a worker is exposed day after day for a working lifetime to HDI 
isocyanurate at TWA level. On the other hand, TAHI was measured above the hypothetical 
TAHI BMGV in three urine samples. Interestingly, none of these samples were collected post-
shift but instead after the first task. This may suggest that some absorbed HDI isocyanurate is 
rapidly metabolized and excreted in urine (i.e., within an hour).  
The UK HSE BMGV is not directly associated with an exposure limit. Instead it is 
determined as the 90th percentile of all UK biomonitoring data for exposures to HDI, IPDI, MDI, 
and TDI (Cocker, 2007). In this study cohort, the TAHI 90th percentile level from all the urine 
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samples was 0.46 µg/g creatinine. This 90th percentile level is markedly lower than the 
hypothetical TAHI BMGV calculated from the HDA BMGV using the molar ratio, but follows 
the same methodology used to calculate BMGV limits for urinary amine levels associated with 
diisocyanate monomer exposures. Additional studies monitoring TAHI concentrations in urine of 
workers exposed to HDI isocyanurate is warranted to further investigate these associations to 
determine if UK HSE methodology to calculate a recommended biomarker limit for urinary 
TAHI is appropriate. 
 
Table 5.1.  Urine concentrations above the MDL and above biomarker limits recommended 
by the ACGIH and UK HSE measured in samples collected from 47 automotive 
spray-painters in North Carolina (n = 15) and Washington State (n = 32). 
    ACGIH UK HSE 
TAHI  N N > MDL (%) N > BEIa (%) N > BMGVb (%) 
Pre-shift  117 22 (19%) 0 (0%) 0 (0%) 
After first task  283 105 (37%) 0 (0%) 3 (1%) 
Post-shift  115 37 (32%) 0 (0%) 0 (0%) 
All samples  400 127 (32%) 0 (0%) 3 (1%) 
Daily mean  115 58 (50%) 0 (0%) 0 (0%) 
Mean after first task  115 51 (44%) 0 (0%) 1 (1%) 
HDA  N N > MDL (%) N > BEIa (%) N > BMGVb (%) 
Pre-shift  117 66 (56%) 0 (0%) 4 (3%) 
After first task  283 186 (68%) 1 (0%) 10 (4%) 
Post-shift  115 82 (71%) 1 (1%) 5 (4%) 
All samples  400 252 (63%) 1 (0%) 14 (4%) 
Daily mean  115 100 (87%) 0 (0%) 5 (4%) 
Mean after first task  115 87 (76%) 0 (0%) 6 (5%) 
N = number of samples; MDL = method detection limit; HDA = 1,6-diaminohexane; TAHI = 
trisaminohexyl isocyanurate; aACGIH BEI = 15 µg/g creatinine for urinary HDA, and 55.07 µg/g 
creatinine for urinary TAHI calculated from HDA BEI; bUK HSE BMGV = 1.03 µg/g creatinine (1 
µmol/mol creatinine) for urinary HDA, and 3.77 µg/g creatinine (1 µmol/mol creatinine) for urinary 





5.4.1. Limitations of the sample treatment and the analytical method 
Some limitations for the quantification of TAHI in urine and plasma samples collected 
from this worker cohort may have affected the exposure-biomarker associations observed in this 
study. The sample treatment methods described in Sections 2.2.4 and 3.2.4 are similar to sample 
treatment methods for extraction and derivatization of HDA from hydrolyzed urine and plasma 
samples (Flack et al., 2010b, Gaines et al., 2010a). However, the sample treatment method to 
extract TAHI is laborious and chemically intensive for processing large quantities of samples. 
Additionally, the sample treatment method was partly developed when free TAHI and TAHI-
HFBA were analyzed by UPLC-ESI-MS/MS with poorer detection limits before the integration 
of acetic anhydride derivatization and the transition to the more sensitive nano-UPLC-ESI-
MS/MS system. Therefore, the alternative extraction methods discussed in Section 2.4 (SPE and 
HPLC) cannot be ruled out for extracting TAHI from hydrolyzed urine or plasma. The recovery 
of the sample treatment method has not been investigated since low quantities of standards were 
synthesized (Robbins et al., 2018). Developing a reproducible sample treatment method that is 
sensitive and specific for quantitative TAHI analysis was prioritized over efficiency of the 
method. The hydrolysis and derivatization times of 16 h should be evaluated, and one of the 
drying steps (nitrogen gas or vacuum centrifugation) could be eliminated to reduce sample 
processing time and potential sample loss. Optimizing the sample treatment method may reduce 
total preparation time from 3 – 4 days to 2 – 3 days if the steps listed above can be modified.  
The non-specific approach of sample treatment with acid hydrolysis left us unable to 
ascertain levels of macromolecule or acetylated TAHI conjugates in urine or plasma. Because the 
systemic availability of HDI isocyanurate in urine and plasma was unknown, acid hydrolysis was 
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chosen to maximize the quantifiable concentration in biological samples over identifying specific 
conjugates that may be present at low levels in the samples collected during the work-shift. 
Previous investigations of acetylated amines in urine indicate basic hydrolysis cleaves TAHI-
macromolecule conjugates but would not revert amides to amines (Sepai et al., 1995a, Sepai et 
al., 1995b, Flack et al., 2010a). Identifying TAHI-albumin conjugates in plasma and acetylated 
TAHI in urine would be relevant for investigating the favored metabolic processes of HDI 
isocyanurate after absorption. 
Another limitation for TAHI analysis is the use of nano-UPLC for chromatographic 
separation. This is not readily available instrumentation and may limit the widespread 
applicability of the analytical method in its current form. Additionally, analysis time per sample 
was approximately 48 min with nano-UPLC-ESI-MS/MS, significantly longer than standard 
HPLC- and UPLC-MS/MS methods. It is possible the analytical method can be adapted for more 
accessible UPLC-ESI-MS/MS systems without significant loss in sensitivity or specificity. 
UPLC-ESI-MS/MS would also reduce analysis to an estimated time range of 15 – 20 min, more 
than doubling sample output. 
Lastly, the SRM method for nano-UPLC-ESI-MS/MS analysis was modified for plasma 
TAAHI analysis. The original method was described in Sections 2.2.5 and 2.4, and the 
modification was described in Sections 3.2.3 and 3.3. Two additional mass transitions were 
added for plasma TAAHI analysis that were not included in the original urine TAAHI analysis. 
As a result, the calculated MDL for plasma TAHI analysis was lower (0.02 µg/L) than the 
calculated MDL for urine TAHI analysis (0.03 µg/L). The chromatograms of the mass transitions 
used for quantification in Chapters 2 and 3 are shown in Figure 3.3. Due to time and monetary 
constraints, urine samples with visible TAAHI mass transitions that either fell below the MDL or 
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below an s/n ratio = 3 were not reanalyzed. It is likely that some of these urine samples would be 
quantifiable with the addition of the two mass transitions described in Section 3.2.3. If more 
urine samples from this study cohort had TAHI levels above the MDL, this may affect the 
statistical associations and conclusions described in Chapter 4. It is estimated that 5 – 20 urine 
samples may have TAHI levels between 0.02 – 0.03 µg/L, which is the range between the MDLs 
calculated for plasma and urine TAHI analysis. Thus, the urine TAHI levels presented in this 
research should be considered a conservative estimate of measurable TAHI in these urine 
samples. 
5.4.2. Limitations in study design and sample collection 
HDI isocyanurate was measured in the breathing-zone and on the skin at considerably 
higher levels than HDI monomer (Fent et al., 2009a, Fent et al., 2009b), yet, TAHI was detected 
in 32% of urine samples and 22% of plasma samples (Section 4.3.1) while HDA was detected in 
63% of urine samples and 74% of plasma samples (Flack et al., 2010b, Gaines et al., 2010a). 
Although, the limitations in the sample treatment and analytical method may have affected the 
detection of biomarkers in the biological samples, the low prevalence of TAHI may have been 
also affected by sample collection, and particularly timing of the sample collection. 
Based on previous studies of HDI monomer exposures and calculated half-lives of 
urinary HDA excretion, it is probable that urinary TAHI excretion half-life is longer. In previous 
studies on human volunteers exposed to aerosols and vapors of HDI monomer and HDI biuret in 
exposure chambers or closed-circuit breathing apparatuses, half-life for urinary HDA excretion 
was observed to be 2.5 – 2.8 h (Tinnerberg et al., 1995, Liu et al., 2004, Budnik et al., 2011). 
Gaines et al. corroborated these measured half-lives with an occupationally exposed population, 
calculating a urinary HDA excretion half-life of 2.9 h (Gaines et al., 2010a). Budnik et al. did 
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observe a major, rapid excretion peak for HDA at 2 h. Major peaks were observed for 2,4- and 
2,6-TDA at 4.1 h and 4.8 h, respectively, but no major peaks were observed for MDA or 
isophorone diamine (IPDA). Additionally, elevated excretion peaks with slower elimination 
kinetics were observed in groups with higher HDI, MDI, and IPDI exposures (Budnik et al., 
2011). 
Exposures to IPDI, a cycloaliphatic isocyanate with a cyclohexane moiety, and urinary 
excretion of its metabolite IPDA may provide clues for the metabolism of HDI isocyanurate and 
urinary excretion of TAHI. The cycloaliphatic HDI isocyanurate with its isocyanurate moiety 
may have more similarities to the excretion kinetics of IPDI than to the excretion kinetics of HDI 
monomer. Budnik et al. exposed 9 volunteers to IPDI and estimated urinary IPDA excretion 
half-lives of 4 h after low IPDI exposure and 5.5 h after high IPDI exposure (Budnik et al., 
2011). IPDA excretion peaked at 5.6 h and was not fully eliminated after 24 h. By contrast, HDA 
peaked at 2 h with a small peak at 15 h and was fully eliminated after 24 h. The elongated 
excretion pattern was more pronounced in higher IPDI exposure groups and this pattern was not 
observed for low and high exposures to HDI monomer (Budnik et al., 2011). The sample 
collection for this study was designed to obtain optimal exposure and biomarker data for HDI 
monomer and HDA (Fent et al., 2009a, Fent et al., 2009b, Flack et al., 2010b, Gaines et al., 
2010a) as no information existed for HDI isocyanurate and associated biomarkers. If HDI 
isocyanurate excretion is similar to IPDI excretion, it is possible that TAHI was slowly excreted 
in urine hours after the sample collection ended and, thus, the optimal sample collection time 
was missed in this study. For future exposure assessments it is advisable to collect urine 24 h 




5.5. Future research 
The sample treatment and analytical methods presented in Chapters 2 and 3 combined 
with the exposure assessment analyses presented in Chapter 4 provides significant new 
information and knowledge to guide future research efforts to investigate isocyanate exposures 
and associated adverse health effects. The exposure assessment of automotive spray-painters 
utilized for this research was comprehensive with ample worker participation and robust sample 
size. However, future exposure assessments in other exposed populations are warranted to better 
understand the relationships between short-term and/or cumulative HDI isocyanurate exposures 
and the associated biomarkers. Because of the constraints of the study design in this study cohort 
(i.e., the sample collection regimen was designed to capture biomarkers of HDI monomer 
exposure and not specifically biomarkers of HDI isocyanurate exposure), this dissertation 
research clearly indicates that these two compounds have different elimination characteristics in 
humans. The spray-painters who participated in this study worked full-time but samples were 
only collected during 1 – 3 full workday visits with a minimum of 3 weeks in between each visit. 
Thus, we were only able to investigate the relationship between the same-day exposure and 
biomarker levels and could not ascertain the possible contribution of past exposures to measured 
biomarker levels. We will not fully understand the metabolism and excretion of HDI 
isocyanurate, or the other HDI oligomers for that matter, in exposed populations unless post-
exposure biological monitoring is extended beyond end of work-shift (i.e., 24 h after shift, or 
even longer). Ideally, monitoring workers over a week and weekend to evaluate biomarker 
concentrations on days the workers are not exposed would be best practice. This data would 
provide valuable insight on excretion, variability, and factors that may influence TAHI and HDA 
biomarker levels long after the work-shift has ended. Most significantly this data would provide 
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information on setting a robust sampling scheme for exposure assessment and setting appropriate 
exposure limit values. 
Future studies can build on this research to validate TAHI as a biomarker of HDI 
isocyanurate exposure in other exposed populations and to develop accurate exposure limit 
values to protect worker health. The results derived in this study can also be utilized investigate 
the toxicokinetics of HDI isocyanurate exposures and to identify additional biomarkers of 
exposure and effect. For example, TAHI macromolecule conjugates may be present in urine, 
blood, lung fluid, or skin in exposed workers and could potentially serve as biomarkers of 
exposure or early markers of adverse health effects. Because HDI and other isocyanates are 
known sensitizers and limit laboratory studies in human volunteers, murine studies to investigate 
biomarker levels after controlled inhalation and skin exposures would be useful for assessing 
metabolism and excretion in urine and feces. It would be advisable to use radiolabeled HDI 
monomer and HDI isocyanurate for controlled exposures because radioactivity can be measured 
to estimate isocyanate dose in lungs, skin, organs, urine, blood, and feces. Measuring levels of 
radioactivity would simplify the biomarker analysis, removing the laborious sample treatment 
and analytical methods for TAHI and HDA analysis. Our knowledge on HDI isocyanurate 
metabolism and excretion will remain limited unless comprehensive exposure assessment and 
biomonitoring can be performed for extended periods post-exposure; this is only achieved using 
appropriate murine models for isocyanates due to their strong sensitizing characteristics. 
The current research in our laboratory continues to address issues with HDI exposure 
assessment and biomarker analyses in automotive and aircraft spray-painters. HDI exposure 
assessment and biomonitoring is far less common in the aircraft refinishing industry (Carlton and 
England, 2000, Wisnewski et al., 2012, Ceballos et al., 2017), thus, additional studies on other 
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worker cohorts, apart from automotive spray-painters, would provide further information on 
isocyanate exposure patterns and adverse health effects. The biological samples collected in 
these studies offer a unique opportunity to investigate associations between biomarkers measured 
in post-shift urine and end-of-week urine and plasma. In addition, the low HDI monomer and 
HDI oligomer exposures monitored by area and PBZ sampling in aircraft spray-painters will 
provide information on potential differences in biomarkers due to variability in exposure levels 
and products used. The data collected in these two studies presents a rare opportunity to evaluate 
and compare two skin exposure sampling methods and whether and how much the measured 
HDI isocyanurate and HDI monomer skin exposures contribute to systemic exposure (i.e., urine 
and plasma TAHI and HDA levels) in these workers. 
5.6. Conclusions 
This dissertation research demonstrates that HDI isocyanurate, the oligomeric trimer of 
HDI monomer, is systemically available and circulated in blood for metabolism and excretion in 
exposed workers. Hydrolyzed trisaminohexyl isocyanurate (TAHI) in urine and plasma is a 
significant biomarker for HDI isocyanurate exposures in the automotive refinishing industry. 
Here, TAHI was measured in urine and plasma via acid hydrolysis, dichloromethane extraction, 
acetic anhydride derivatization, and quantitative analysis with nano-UPLC-ESI-MS/MS. The 
sample treatment and analytical method developed to quantify TAHI in hydrolyzed urine and 
plasma samples may also be adapted for biomonitoring of other oligomeric isocyanate 
exposures, although the method in its current form may require modifications to retain sensitivity 
and specificity. 
Although TAHI was measured in fewer urine and plasma samples collected from 
occupational exposed workers, both HDI exposures and workplace factors were more strongly 
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associated with TAHI biomarker levels than with HDA biomarker levels. We observed that HDI 
isocyanurate inhalation exposure and paint time were significantly associated with TAHI levels 
in urine and plasma of exposed automotive spray-painters. HDI isocyanurate skin exposure was 
correlated with TAHI biomarker levels, however, skin exposure was not a significant predictor in 
mixed model analyses. We also observed that HDI monomer skin exposure was significantly 
associated with HDA levels in urine and plasma, corroborating previous findings in this study 
cohort (Gaines et al., 2010a, Gaines et al., 2011). Contrary to previously reported findings (Flack 
et al., 2010b), HDI monomer inhalation or skin exposures were not significantly associated with 
plasma HDA levels. The disagreement between these observations is likely due to the altered 
approach for calculating both exposure and plasma variables.  
Painting in downdraft booths significantly reduced exposure to HDI isocyanurate and 
urine TAHI levels, while more protective full-face air purifying, PAPR, and supplied-air 
respirators significantly reduced plasma TAHI and urine HDA levels. Additionally, workers who 
wore nitrile or neoprene gloves had significantly lower plasma TAHI levels. Based on the 
observations in this study, painting in downdraft booths, wearing nitrile or neoprene gloves, and 
wearing full-face air purifying, PAPR, or supplied-air respirators offers the greatest combination 
of respiratory and skin protection to reduce hazardous HDI exposures and, consequently, the 
amounts of the biomarkers of exposure in automotive spray-painters.  
The associations between the exposure and biomarker levels presented here confirm 
TAHI as a biomarker of HDI isocyanurate exposure and may eventually prove to be a stronger 
indicator than HDA of HDI exposures in occupational settings. We observed that biomarkers of 
HDI isocyanurate are associated with HDI monomer exposures but HDA levels in urine or 
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plasma are not suitable biomarkers of HDI isocyanurate exposure. However, this observation 
needs to be confirmed in future studies.  
In summary, HDI isocyanurate biomarker, TAHI, in urine and plasma can be used as a 
biomarker of HDI isocyanurate exposure in an occupational setting. The developed method for 
quantification of HDI isocyanurate biomarker, TAHI, in urine and plasma is a significant 
advancement for HDI exposure assessment and will advance future investigations to oligomeric 




APPENDIX A: SUPPLEMENTAL TABLE AND FIGURES FOR CHAPTER 2 
A.1. Supplemental table for Chapter 2 
Table A.1. Gradient program for the NanoAcquity ultra-performance liquid chromatography 
system (Waters Corp., Milford, MA) using a Symmetry C18 trapping column, 5 
µm, 180 µm × 20 mm (Waters Corp.) and an Atlantis dC18 analytical column, 3 
µm, 100 µm × 100 mm (Waters Corp.). Mobile phase A consisted of 0.1% formic 
acid in deionized water and mobile phase B consisted of 0.1% formic acid in 
acetonitrile. 
Mobile Phase A Mobile Phase B Time (min) Flow Rate (nL/min) 
95 5 0 600 
10 90 17 600 
10 90 29 600 
95 5 30 600 




A.2. Supplemental figures for Chapter 2 
 
 





Figure A.2. Fragmentation spectrum of precursor ion [M + H]+ for TAHI (m/z 427.3) obtained 
by nano-UPLC-ESI-MS/MS operated in positive ion-mode with nano-





Figure A.3. Fragmentation spectrum of precursor ion [M + H]+ for TAHI (m/z 427.3) obtained 
by nano-UPLC-ESI-MS/MS operated in positive ion-mode with nano-

































Figure A.9. Fragmentation spectrum of precursor ion [M + H]+ for TAHpI (m/z 469.3) 
obtained by nano-UPLC-ESI-MS/MS operated in positive ion-mode with nano-





Figure A.10.  Fragmentation spectrum of precursor ion [M + H]+ for TAHpI (m/z 469.3) 
obtained by nano-UPLC-ESI-MS/MS operated in positive ion-mode with nano-




APPENDIX B: SAS CODES FOR CHAPTERS 4 AND 5 
 
SAS code B1: PROC UNIVARIATE and PROC CORR procedures for evaluating the normality 
of each variable in the data set and the Pearson correlation coefficients. Non-transformed 
exposure and biomarker levels were calculated prior to the last urine sample collected. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExposureBeforeUrine.xlsx"  
 OUT = test.S1_Day_ExposureBeforeUrine DBMS=xlsx REPLACE; 
RUN; 
 
*Shapiro-Wilk test for normality including distribution plot of the non-
transformed exposure and biomarker levels; 
 
PROC UNIVARIATE DATA = test.S1_Day_ExposureBeforeUrine NORMAL PLOT; 
VAR Day_Ptime TWAp_HDI TWAp_ISO TWAp_HDI_APF TWAp_ISO_APF DayHDI_IHug  
DayISO_IHug DayHDI_IHugAPF DayISO_IHugAPF TotSkin_HDI_ug TotSkin_ISO_ug 
AvgUR_HDA AvgUR_HDA_CR AvgUR_TAHI AvgUR_TAHI_CR EndUR_HDA EndUR_HDA_CR 
EndUR_TAHI EndUR_TAHI_CR Pma_HDA Pma_TAHI PmaBSA_HDAug PmaBSA_TAHIug; 
RUN; 
 
*Shapiro-Wilk test for normality including distribution plot of the natural 
log-transformed exposure and biomarker levels; 
 
PROC UNIVARIATE DATA = test.S1_Day_ExposureBeforeUrine NORMAL PLOT; 
VAR lnDay_Ptime lnTWAp_HDI lnTWAp_ISO lnTWAp_HDI_APF lnTWAp_ISO_APF  
lnDayHDI_IHug lnDayISO_IHug lnDayHDI_IHugAPF lnDayISO_IHugAPF 
lnTotSkin_HDI_ug lnTotSkin_ISO_ug AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI 
AvgLnUR_TAHI_CR lnEndUR_HDA lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR 
lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug; 
RUN; 
 
*Pearson correlation coefficient calculation for natural log-transformed 
exposure and biomarker levels; 
 
PROC CORR DATA = test.S1_Day_ExposureBeforeUrine PEARSON; 
VAR lnDay_Ptime lnTWAp_HDI lnTWAp_ISO lnTWAp_HDI_APF lnTWAp_ISO_APF  
lnDayHDI_IHug lnDayISO_IHug lnDayHDI_IHugAPF lnDayISO_IHugAPF 
lnTotSkin_HDI_ug lnTotSkin_ISO_ug AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI 
AvgLnUR_TAHI_CR lnEndUR_HDA lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR 





SAS code B2: PROC UNIVARIATE and PROC CORR procedures for evaluating the normality 
of each variable in the data set and the Pearson correlation coefficients. Natural log-transformed 
exposure and biomarker levels were calculated prior to the plasma sample collection. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExposureBeforePL.xlsx"  
 OUT = test.S1_Day_ExposureBeforePL DBMS=xlsx REPLACE; 
RUN; 
 
*Shapiro-Wilk test for normality including distribution plot of the non-
transformed exposure and biomarker levels; 
 
PROC UNIVARIATE DATA = test.S1_Day_ExposureBeforePL NORMAL PLOT; 
VAR Day_Ptime TWAp_HDI TWAp_ISO TWAp_HDI_APF TWAp_ISO_APF DayHDI_IHug  
DayISO_IHug DayHDI_IHugAPF DayISO_IHugAPF TotSkin_HDI_ug TotSkin_ISO_ug 




*Shapiro-Wilk test for normality including distribution plot of the natural 
log-transformed exposure and biomarker levels; 
 
PROC UNIVARIATE DATA = test.S1_Day_ExposureBeforePL NORMAL PLOT; 
VAR lnDay_Ptime lnTWAp_HDI lnTWAp_ISO lnTWAp_HDI_APF lnTWAp_ISO_APF  
lnDayHDI_IHug lnDayISO_IHug lnDayHDI_IHugAPF lnDayISO_IHugAPF 
lnTotSkin_HDI_ug lnTotSkin_ISO_ug AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI 
AvgLnUR_TAHI_CR lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug; 
RUN; 
 
*Pearson correlation coefficient calculation for natural log-transformed 
exposure and biomarker levels; 
 
PROC CORR DATA = test.S1_Day_ExposureBeforePL PEARSON; 
VAR lnDay_Ptime lnTWAp_HDI lnTWAp_ISO lnTWAp_HDI_APF lnTWAp_ISO_APF  
lnDayHDI_IHug lnDayISO_IHug lnDayHDI_IHugAPF lnDayISO_IHugAPF 
lnTotSkin_HDI_ug lnTotSkin_ISO_ug AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI 





SAS code B3: PROC GLM procedure to perform Tukey-Kramer multiple comparisons tests for 
daily mean and post-shift urine TAHI and HDA levels. Urine samples were stratified by booth 
type with the BY statement and then by respirator type, coverall use, or glove type with the 
CLASS statement. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExpBefUR_CrossSemi.xlsx"  
 OUT = test.S1_Day_ExpBefUR_CrossSemi DBMS=xlsx REPLACE; 
RUN; 
 
*Urine samples stratified by booth type and then by respirator type; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_CrossSemi; 
Class Resp_protC; 
By CrossSemi; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = Resp_protC; 
Means Resp_protC / Tukey; 
RUN; 
 
*Urine samples stratified by booth type and then by coverall use; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_CrossSemi; 
Class Cov; 
By CrossSemi; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = Cov; 
Means Cov / Tukey; 
RUN; 
 
*Urine samples stratified by booth type and then by glove type; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_CrossSemi; 
Class OrNitrile; 
By CrossSemi; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = OrNitrile; 





SAS code B4: PROC GLM procedure to perform Tukey-Kramer multiple comparisons tests for 
daily mean and post-shift urine TAHI and HDA levels. Urine samples were stratified by coverall 
use with the BY statement and then by respirator type, glove type, or booth type with the CLASS 
statement. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExpBefUR_Coverall.xlsx"  
 OUT = test.S1_Day_ExpBefUR_Coverall DBMS=xlsx REPLACE; 
RUN; 
 
*Urine samples stratified by coverall use and then by respirator type; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_Coverall; 
Class Resp_protC; 
By Cov; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = Resp_protC; 
Means Resp_protC / Tukey; 
RUN; 
 
*Urine samples stratified by coverall use and then by glove type; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_Coverall; 
Class OrNitrile; 
By Cov; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = OrNitrile; 
Means OrNitrile / Tukey; 
RUN; 
 
*Urine samples stratified by coverall use and then by booth type; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_Coverall; 
Class CrossSemi; 
By Cov; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = CrossSemi; 





SAS code B5: PROC GLM procedure to perform Tukey-Kramer multiple comparisons tests for 
daily mean and post-shift urine TAHI and HDA levels. Urine samples were stratified by 
respirator type with the BY statement and then by coverall use, glove type, or booth type with 
the CLASS statement. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExpBefUR_RespProtC.xlsx"  
 OUT = test.S1_Day_ExpBefUR_RespProtC DBMS=xlsx REPLACE; 
RUN; 
 
*Urine samples stratified by respirator type and then by coverall use; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_RespProtC; 
Class Cov; 
By Resp_protC; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = Cov; 
Means Cov / Tukey; 
RUN; 
 
*Urine samples stratified by respirator type and then by glove type; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_RespProtC; 
Class OrNitrile; 
By Resp_protC; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = OrNitrile; 
Means OrNitrile / Tukey; 
RUN; 
 
*Urine samples stratified by respirator type and then by booth type; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_RespProtC; 
Class CrossSemi; 
By Resp_protC; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = CrossSemi; 





SAS code B6: PROC GLM procedure to perform Tukey-Kramer multiple comparisons tests for 
daily mean and post-shift urine TAHI and HDA levels. Urine samples were stratified by glove 
type with the BY statement and then by respirator type, coverall use, or booth type with the 
CLASS statement. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExpBefUR_OrNitrile.xlsx"  
 OUT = test.S1_Day_ExpBefUR_OrNitrile DBMS=xlsx REPLACE; 
RUN; 
 
*Urine samples stratified by glove type and then by respirator type; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_OrNitrile; 
Class Resp_protC; 
By OrNitrile; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = Resp_protC; 
Means Resp_protC / Tukey; 
RUN; 
 
*Urine samples stratified by glove type and then by coverall use; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_OrNitrile; 
Class Cov; 
By OrNitrile; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = Cov; 
Means Cov / Tukey; 
RUN; 
 
*Urine samples stratified by glove type and then by booth type; 
 
PROC GLM DATA = test.S1_Day_ExpBefUR_OrNitrile; 
Class CrossSemi; 
By OrNitrile; 
Model AvgLnUR_HDA AvgLnUR_HDA_CR AvgLnUR_TAHI AvgLnUR_TAHI_CR lnEndUR_HDA 
lnEndUR_HDA_CR lnEndUR_TAHI lnEndUR_TAHI_CR = CrossSemi; 





SAS code B7: PROC GLM procedure to perform Tukey-Kramer multiple comparisons tests for 
plasma TAHI and HDA levels. Plasma samples were stratified by booth type with the BY 
statement and then by respirator type, coverall use, or glove type with the CLASS statement. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExpBefPL_CrossSemi.xlsx"  
 OUT = test.S1_Day_ExpBefPL_CrossSemi DBMS=xlsx REPLACE; 
RUN; 
 
*Plasma samples stratified by booth type and then by respirator type; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_CrossSemi; 
Class Resp_protC; 
By CrossSemi; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = Resp_protC; 
Means Resp_protC / Tukey; 
RUN; 
 
*Plasma samples stratified by booth type and then by coverall use; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_CrossSemi; 
Class Cov; 
By CrossSemi; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = Cov; 
Means Cov / Tukey; 
RUN; 
 
*Plasma samples stratified by booth type and then by glove type; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_CrossSemi; 
Class OrNitrile; 
By CrossSemi; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = OrNitrile; 





SAS code B8: PROC GLM procedure to perform Tukey-Kramer multiple comparisons tests for 
plasma TAHI and HDA levels. Plasma samples were stratified by coverall use with the BY 
statement and then by respirator type, glove type, or booth type with the CLASS statement. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExpBefPL_Coverall.xlsx"  
 OUT = test.S1_Day_ExpBefPL_Coverall DBMS=xlsx REPLACE; 
RUN; 
 
*Plasma samples stratified by coverall use and then by respirator type; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_Coverall; 
Class Resp_protC; 
By Cov; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = Resp_protC; 
Means Resp_protC / Tukey; 
RUN; 
 
*Plasma samples stratified by coverall use and then by glove type; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_Coverall; 
Class OrNitrile; 
By Cov; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = OrNitrile; 
Means OrNitrile / Tukey; 
RUN; 
 
*Plasma samples stratified by coverall use and then by booth type; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_Coverall; 
Class CrossSemi; 
By Cov; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = CrossSemi; 





SAS code B9: PROC GLM procedure to perform Tukey-Kramer multiple comparisons tests for 
plasma TAHI and HDA levels. Plasma samples were stratified by respirator type with the BY 
statement and then by coverall use, glove type, or booth type with the CLASS statement. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExpBefPL_RespProtC.xlsx"  
 OUT = test.S1_Day_ExpBefPL_RespProtC DBMS=xlsx REPLACE; 
RUN; 
 
*Plasma samples stratified by respirator type and then by coverall use; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_RespProtC; 
Class Cov; 
By Resp_protC; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = Cov; 
Means Cov / Tukey; 
RUN; 
 
*Plasma samples stratified by respirator type and then by glove type; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_RespProtC; 
Class OrNitrile; 
By Resp_protC; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = OrNitrile; 
Means OrNitrile / Tukey; 
RUN; 
 
*Plasma samples stratified by respirator type and then by booth type; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_RespProtC; 
Class CrossSemi; 
By Resp_protC; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = CrossSemi; 





SAS code B10: PROC GLM procedure to perform Tukey-Kramer multiple comparisons tests for 
plasma TAHI and HDA levels. Plasma samples were stratified by glove type with the BY 
statement and then by respirator type, coverall use, or booth type with the CLASS statement. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExpBefPL_OrNitrile.xlsx"  
 OUT = test.S1_Day_ExpBefPL_OrNitrile DBMS=xlsx REPLACE; 
RUN; 
 
*Plasma samples stratified by glove type and then by respirator type; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_OrNitrile; 
Class Resp_protC; 
By OrNitrile; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = Resp_protC; 
Means Resp_protC / Tukey; 
RUN; 
 
*Plasma samples stratified by glove type and then by coverall use; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_OrNitrile; 
Class Cov; 
By OrNitrile; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = Cov; 
Means Cov / Tukey; 
RUN; 
 
*Plasma samples stratified by glove type and then by booth type; 
 
PROC GLM DATA = test.S1_Day_ExpBefPL_OrNitrile; 
Class CrossSemi; 
By OrNitrile; 
Model lnPma_HDA lnPma_TAHI lnPmaBSA_HDAug lnPmaBSA_TAHIug = CrossSemi; 





SAS code B11: PROC MIXED procedure to build linear mixed models with restricted maximum 
likelihood estimation of repeated measures of each visit per worker. The TYPE statement sets 
the covariance structure as compound symmetry. The following PROC MIXED code was used to 
build mixed models predicting daily mean urine TAHI and HDA levels discussed in Chapter 4 
(Models 1A-F; Table 4.5). 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExposureBeforeUrine.xlsx"  
 OUT = test.S1_Day_ExposureBeforeUrine DBMS=xlsx REPLACE; 
RUN; 
 
*Compare base models with and without creatinine adjustment for urine TAHI 
level; 
*Compare base models with and without creatinine adjustment for urine TAHI 
level; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug AvgLnCRT / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI_CR = lnTWAp_ISO lnTotSkin_ISO_ug / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug AvgLnCRT / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI_CR = lnTWAp_ISO_APF lnTotSkin_ISO_ug / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 





*Stepwise introduction of variables with urine TAHI level and TWAp_ISO; 
*Stepwise introduction of variables with urine TAHI level and TWAp_ISO; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug AvgLnCRT / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add paint time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug AvgLnCRT lnDay_Ptime / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Remove creatinine due to very low estimate and significance; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add booth type; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add respirator type, glove use, coverall use, shop location, weekday, and 
smoking status one at a time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime CrossSemi Gloves 
/ CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime CrossSemi Cov / 
CL; 




PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
Location / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
Day_week / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime CrossSemi Smoker 
/ CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Retain paint time, booth type, and gloves, and remove skin; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnDay_Ptime CrossSemi Gloves / CL; 





*Final urine TAHI model with ISO air, paint time, and booth type; 
*Final urine TAHI model with ISO air, paint time, and booth type; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnDay_Ptime CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Stepwise introduction of variables with urine TAHI level and TWAp_ISO_APF; 
*Stepwise introduction of variables with urine TAHI level and TWAp_ISO_APF; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug AvgLnCRT / CL; 





*Add paint time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug AvgLnCRT lnDay_Ptime / 
CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Remove creatinine due to very low estimate and significance; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add booth type; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug AvgLnCRT lnDay_Ptime 
CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add glove use, coverall use, shop location, weekday, and smoking status one 
at a time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
Gloves / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
Cov / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
Location / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
Day_week / CL; 




PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
Smoker / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Retain gloves and remove skin; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnDay_Ptime CrossSemi Gloves / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add back skin and remove gloves; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime CrossSemi / 
CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTotSkin_ISO_ug lnDay_Ptime CrossSemi / CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnDay_Ptime CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Models are similar when air or skin are removed; 
 
*Compare base models with and without creatinine adjustment for urine HDA 
level; 
*Compare base models with and without creatinine adjustment for urine HDA 
level; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT / CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA_CR = lnTWAp_HDI lnTotSkin_HDI_ug / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug AvgLnCRT / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA_CR = lnTWAp_HDI_APF lnTotSkin_HDI_ug / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Higher AIC with creatinine-adjusted HDA level, keep creatinine as 
independent variable; 
 
*Stepwise introduction of variables with urine HDA level and TWAp_HDI; 
*Stepwise introduction of variables with urine HDA level and TWAp_HDI; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add paint time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT lnDay_Ptime / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Paint time does not help, remove, and add respirator type; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add booth type, glove use, coverall use, shop location, weekday, and smoking 
status one at a time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT Resp_protC CrossSemi 
/ CL; 




PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT Resp_protC Gloves / 
CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT Resp_protC Cov / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT Resp_protC Location 
/ CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT Resp_protC Day_week 
/ CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT Resp_protC Smoker / 
CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Remove additional variables and retain respirator type; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug AvgLnCRT Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Remove air or skin one at a time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTotSkin_HDI_ug AvgLnCRT Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI AvgLnCRT Resp_protC / CL; 





*Retain skin and add other workplace factors back in one at a time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTotSkin_HDI_ug AvgLnCRT Resp_protC CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTotSkin_HDI_ug AvgLnCRT Resp_protC Gloves / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTotSkin_HDI_ug AvgLnCRT Resp_protC Cov / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTotSkin_HDI_ug AvgLnCRT Resp_protC Location / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTotSkin_HDI_ug AvgLnCRT Resp_protC Day_week / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTotSkin_HDI_ug AvgLnCRT Resp_protC Smoker / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Workplace factors did not improve model with skin and respirator type; 
 
*Final urine HDA model with HDI skin, creatinine, and respirator type; 
*Final urine HDA model with HDI skin, creatinine, and respirator type; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTotSkin_HDI_ug AvgLnCRT Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Stepwise introduction of variables with urine HDA level and TWAp_HDI_APF; 
*Stepwise introduction of variables with urine HDA level and TWAp_HDI_APF; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug AvgLnCRT / CL; 




*Add paint time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug AvgLnCRT lnDay_Ptime / 
CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Paint time did not help, remove, add booth type, glove use, coverall use, 
shop location, weekday, and smoking status one at a time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug AvgLnCRT CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug AvgLnCRT Gloves / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug AvgLnCRT Cov / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug AvgLnCRT Location / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug AvgLnCRT Day_week / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL AvgLnUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug AvgLnCRT Smoker / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Additional workplace factors did not improve base model with HDI_APF; 
*Additional workplace factors did not improve base model with HDI_APF; 
 
 151
SAS code B12: PROC MIXED procedure to build linear mixed models with restricted maximum 
likelihood estimation of repeated measures of each visit per worker. The TYPE statement sets 
the covariance structure as compound symmetry. The following PROC MIXED code was used to 
build mixed models predicting plasma TAHI and HDA levels discussed in Chapter 4 (Models 
2A-F; Table 4.6). 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExposureBeforePlasma.xlsx"  
 OUT = test.S1_Day_ExposureBeforePlasma DBMS=xlsx REPLACE; 
RUN; 
 
*Stepwise introduction of variables with plasma TAHI level and TWAp_ISO; 
*Stepwise introduction of variables with plasma TAHI level and TWAp_ISO; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnTotSkin_ISO_ug / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add paint time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Retain paint time, add respirator type; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime Resp_protC / 
CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add booth type, glove use, coverall use, shop location, weekday, and smoking 
status one at a time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime Resp_protC 
CrossSemi / CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime Resp_protB 
Gloves / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime Resp_protB 
Cov / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime Resp_protB 
Location / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime Resp_protB 
Day_week / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnTotSkin_ISO_ug lnDay_Ptime Resp_protB 
Smoker / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Retain respirator type and remove air or skin; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTotSkin_ISO_ug lnDay_Ptime Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnDay_Ptime Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Minimal difference between models with paint time and respirator type, and 




*Stepwise introduction of variables with plasma TAHI level and TWAp_ISO_APF; 
*Stepwise introduction of variables with plasma TAHI level and TWAp_ISO_APF; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add paint time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Retain paint time, add booth type, glove use, coverall use, shop location, 
weekday, and smoking status one at a time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
/ CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime Gloves / 
CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime Cov / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime Location 
/ CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime Day_week 
/ CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime Smoker / 
CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Retain paint time and booth type; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
/ CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add glove use; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
Gloves / CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnDay_Ptime CrossSemi Gloves / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add skin back in, remove glove use; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnDay_Ptime CrossSemi 
/ CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Retain paint time and booth type, remove air or skin; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTotSkin_ISO_ug lnDay_Ptime CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnDay_Ptime CrossSemi / CL; 





*Retain paint time and booth type, remove booth type; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTotSkin_ISO_ug lnDay_Ptime / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Final plasma TAHI model with TWAp_ISO and paint time; 
*Final plasma TAHI model with TWAp_ISO and paint time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnDay_Ptime / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Stepwise introduction of variables with plasma HDA level and TWAp_HDI; 
*Stepwise introduction of variables with plasma HDA level and TWAp_HDI; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI lnTotSkin_HDI_ug / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add paint time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI lnTotSkin_HDI_ug lnDay_Ptime / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Paint time did not improve, remove, add respirator type, booth type, glove 
use, coverall use, shop location, weekday, and smoking status one at a time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI lnTotSkin_HDI_ug Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI lnTotSkin_HDI_ug CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI lnTotSkin_HDI_ug Gloves / CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI lnTotSkin_HDI_ug Cov / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI lnTotSkin_HDI_ug Location / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI lnTotSkin_HDI_ug Day_week / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI lnTotSkin_HDI_ug Smoker / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Workplace factors did not improve base model with TWAp_HDI and skin; 
 
*Stepwise introduction of variables with plasma HDA level and TWAp_HDI_APF; 
*Stepwise introduction of variables with plasma HDA level and TWAp_HDI_APF; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF lnTotSkin_HDI_ug / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Add paint time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF lnTotSkin_HDI_ug lnDay_Ptime / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Paint time did not improve, remove, add respirator type, booth type, glove 
use, coverall use, shop location, weekday, and smoking status one at a time; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF lnTotSkin_HDI_ug Resp_protC / CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF lnTotSkin_HDI_ug CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF lnTotSkin_HDI_ug Gloves / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF lnTotSkin_HDI_ug Cov / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF lnTotSkin_HDI_ug Location / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF lnTotSkin_HDI_ug Day_week / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF lnTotSkin_HDI_ug Smoker / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Workplace factors did not improve base model with TWAp_HDI_APF and skin; 
 
*Repeat base models adding respirator type, booth type, glove use, coverall 
use, shop location, weekday, and smoking status one at a time; 
*This time remove TWAp_HDI, TWAp_HDI_APF, or skin for each added variable; 
 
*Retain TWAp_HDI and remove skin; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI CrossSemi / CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI Gloves / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI Cov / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI Location / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI Day_week / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI Smoker / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Retain TWAp_HDI_APF and remove skin; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF Gloves / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF Cov / CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF Location / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF Day_week / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF Smoker / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Retain skin and remove TWAp_HDI; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTotSkin_HDI_ug Resp_protC / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTotSkin_HDI_ug CrossSemi / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTotSkin_HDI_ug Gloves / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTotSkin_HDI_ug Cov / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTotSkin_HDI_ug Location / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTotSkin_HDI_ug Day_week / CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTotSkin_HDI_ug Smoker / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Try TWAp_HDI, TWAp_HDI_APF, and skin individually; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforePlasma METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnPmaBSA_HDAug = lnTotSkin_HDI_ug / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
*Skin has best model fit individually, but does not improve base models; 




SAS code B13: PROC GLM procedure to evaluate mixed model fit by calculating the marginal 
R2 statistic for the goodness-of-fit of fixed effects. Because a REPEATED statement cannot be 
used within PROC GLM, geometric mean values for each worker were calculated with the daily 
exposure and biomarker levels. The following PROC GLM code was used to calculate the 
marginal R2 statistics for mixed models predicting daily mean urine TAHI and HDA levels 
discussed in Chapter 4 (Models 1A-F; Table 4.5). 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Worker_ExposureBeforeUrine.xlsx"  
 OUT = test.S1_Worker_ExposureBeforeUrine DBMS=xlsx REPLACE; 
RUN; 
 
*Calculating the marginal R2 statistic for goodness-of-fit of fixed effects 
for Models 1A-C predicting daily urine TAHI levels; 
 
*marginal R2 statistic for Model 1-A; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug AvgLnCRT; 
RUN; 
 
*marginal R2 statistic for Model 1-B; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug AvgLnCRT; 
RUN; 
 
*marginal R2 statistic for Model 1-C; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 
MODEL AvgLnUR_TAHI = lnTWAp_ISO lnDay_Ptime CrossSemi; 
RUN; 
 
*Calculating the marginal R2 statistic for goodness-of-fit of fixed effects 
for Models 1D-F predicting daily urine HDA levels; 
 
*marginal R2 statistic for Model 1-D; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 





*marginal R2 statistic for Model 1-E; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 
MODEL AvgLnUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug AvgLnCRT; 
RUN; 
 
*marginal R2 statistic for Model 1-F; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 





SAS code B14: PROC GLM procedure to evaluate mixed model fit by calculating the marginal 
R2 statistic for the goodness-of-fit of fixed effects. Because a REPEATED statement cannot be 
used within PROC GLM, geometric mean values for each worker were calculated with the daily 
exposure and biomarker levels. The following PROC GLM code was used to calculate the 
marginal R2 statistics for mixed models predicting plasma TAHI and HDA levels discussed in 
Chapter 4 (Models 2A-F; Table 4.6). 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Worker_ExposureBeforePlasma.xlsx"  
 OUT = test.S1_Worker_ExposureBeforePlasma DBMS=xlsx REPLACE; 
RUN; 
 
*Calculating the marginal R2 statistic for goodness-of-fit of fixed effects 
for Models 2A-C predicting plasma TAHI levels; 
 
*marginal R2 statistic for Model 2-A; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforePlasma; 
CLASS WorkerNo; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO lnTotSkin_ISO_ug; 
RUN; 
 
*marginal R2 statistic for Model 2-B; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforePlasma; 
CLASS WorkerNo; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnTotSkin_ISO_ug; 
RUN; 
 
*marginal R2 statistic for Model 2-C; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforePlasma; 
CLASS WorkerNo; 
MODEL lnPmaBSA_TAHIug = lnTWAp_ISO_APF lnDay_Ptime; 
RUN; 
 
*Calculating the marginal R2 statistic for goodness-of-fit of fixed effects 
for Models 2D-F predicting plasma HDA levels; 
 
*marginal R2 statistic for Model 2-D; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforePlasma; 
CLASS WorkerNo; 





*marginal R2 statistic for Model 2-E; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforePlasma; 
CLASS WorkerNo; 
MODEL lnPmaBSA_HDAug = lnTWAp_HDI_APF lnTotSkin_HDI_ug; 
RUN; 
 
*marginal R2 statistic for Model 2-F; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforePlasma; 
CLASS WorkerNo; 





SAS code B15: PROC MIXED procedure to build linear mixed-effects models with restricted 
maximum likelihood estimation of repeated measures. The TYPE statement sets the covariance 
structure as compound symmetry. 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Day_ExposureBeforeUrine.xlsx"  




PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnEndUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug lnCRT / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnEndUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnCRT / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnEndUR_TAHI = lnTWAp_ISO lnDay_Ptime CrossSemi / CL; 





PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnEndUR_HDA = lnTWAp_HDI lnTotSkin_HDI_ug lnEndCRT / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnEndUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug lnCRT / CL; 
REPEATED Visit / Type=CS Subject=WorkerNo; 
RUN; 
 
PROC MIXED DATA = test.S1_Day_ExposureBeforeUrine METHOD = reml Covtest; 
CLASS WorkerNo Visit; 
MODEL lnEndUR_HDA = lnTotSkin_HDI_ug lnCRT Resp_protC / CL; 





SAS code B16: PROC GLM procedure to evaluate mixed model fit by calculating the marginal 
R2 statistic for the goodness-of-fit of fixed effects. Because a REPEATED statement cannot be 
used within PROC GLM, geometric mean values for each worker were calculated with the daily 
exposure and biomarker levels. The following PROC GLM code was used to calculate the 
marginal R2 statistics for mixed models predicting post-shift urine TAHI and HDA levels 
discussed in Chapter 5 (Models 3A-F; Table C.3). 
 
*Make a new library; 
 
LIBNAME test "C:\Users\Zachary Robbins\Desktop\SAS_Input"; 
 
*Import exposure and biomarker data from Excel; 
 
PROC IMPORT DATAFILE = "C:\Users\Zachary 
Robbins\Desktop\SAS_Input\S1_Worker_ExposureBeforeUrine.xlsx"  
 OUT = test.S1_Worker_ExposureBeforeUrine DBMS=xlsx REPLACE; 
RUN; 
 
*Calculating the marginal R2 statistic for goodness-of-fit of fixed effects 
for Models 3A-C predicting post-shift urine TAHI levels; 
 
*marginal R2 statistic for Model 3-A; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 
MODEL lnEndUR_TAHI = lnTWAp_ISO lnTotSkin_ISO_ug lnCRT; 
RUN; 
 
*marginal R2 statistic for Model 3-B; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 
MODEL lnEndUR_TAHI = lnTWAp_ISO_APF lnTotSkin_ISO_ug lnCRT; 
RUN; 
 
*marginal R2 statistic for Model 3-C; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 
MODEL lnEndUR_TAHI = lnTWAp_ISO lnDay_Ptime CrossSemi; 
RUN; 
 
*Calculating the marginal R2 statistic for goodness-of-fit of fixed effects 
for Models 3D-F predicting post-shift urine HDA levels; 
 
*marginal R2 statistic for Model 3-D; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 





*marginal R2 statistic for Model 3-E; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 
MODEL lnEndUR_HDA = lnTWAp_HDI_APF lnTotSkin_HDI_ug lnCRT; 
RUN; 
 
*marginal R2 statistic for Model 3-F; 
 
PROC GLM DATA = test.S1_Worker_ExposureBeforeUrine; 
CLASS WorkerNo; 





APPENDIX C: SUPPLEMENTAL TABLES FOR CHAPTER 5 
Table C.1.  Pearson correlations between HDI isocyanurate and HDI monomer exposure 
measures and creatinine-adjusted daily mean and post-shift urine TAHI and HDA 
levels (µg/g creatinine). 
 
Table C.2.  Associations between workplace factors and the post-shift creatinine-adjusted 
urine TAHI and HDA levels (µg/g creatinine) by stratification. General linear 
modeling was used to evaluate the significance of the compared variable in 
predicting urine biomarker levels given the indicated workplace condition. 
 






Table C.1.  Pearson correlations between HDI isocyanurate and HDI monomer exposure measures and creatinine-adjusted daily 
mean and post-shift urine TAHI and HDA levels. 
HDI isocyanurate    Daily Mean Urine  Post-shift Urine 
 Exposure level  TAHI (µg/g) HDA (µg/g)  TAHI (µg/g) HDA (µg/g) 
Explanatory GM GSD  r p value r p valuea  r p value r p valuea 
PBZ (µg/m3) 1969.2 2.9  0.27 0.0038 -0.07 0.4775  0.18 0.0485 -0.08 0.4006 
PBZ-APF (µg/m3) 65.3 9.4  0.05 0.5622 0.12 0.2210  -0.03 0.7763 0.04 0.6607 
INH (µg) 635.0 3.9  0.34 0.0002 0.02 0.8382  0.29 0.0014 0.02 0.8249 
INH-APF (µg) 21.1 9.9  0.13 0.1536 0.15 0.0990  0.06 0.5081 0.09 0.3434 
Skin (µg) 170.2 15.4  0.22 0.0162 0.26 0.0045  0.18 0.0550 0.20 0.0371 
             
HDI monomer    Daily Mean Urine  Post-shift Urine 
 Exposure level  TAHI (µg/g) HDA (µg/g)  TAHI (µg/g) HDA (µg/g) 
Explanatory GM GSD  r p value r p valuea  r p value r p valuea 
PBZ (µg/m3) 5.7 5.1  0.22 0.0182 0.14 0.1229  0.17 0.0686 0.18 0.0591 
PBZ-APF (µg/m3) 0.2 11.5  0.08 0.3876 0.23 0.0132  0.01 0.9185 0.19 0.0425 
INH (µg) 1.9 6.1  0.30 0.0011 0.18 0.0485  0.27 0.0040 0.22 0.0173 
INH-APF (µg) 0.1 11.8  0.16 0.0973 0.27 0.0038  0.09 0.3296 0.23 0.0122 
Skin (µg) 0.005 331.7  0.18 0.0535 0.29 0.0016  0.19 0.0488 0.27 0.0032 
             
Paint time (min) 13.9 2.4  0.22 0.0194 0.12 0.2191  0.24 0.0101 0.13 0.1519 
µg/g = µg/g creatinine; GM = geometric mean; GSD = geometric standard deviation; r = Pearson correlation coefficient (asignificance was 
determined at α-level 0.05); PBZ = personal breathing-zone (µg/m3); PBZ-APF = APF-adjusted personal breathing-zone (µg/m3); INH = 





Table C.2.  Associations between workplace factors and the post-shift creatinine-adjusted urine TAHI and HDA levels (µg/g 
creatinine) by stratification. General linear modeling was used to evaluate the significance of the compared variable in 







 TAHI (µg/g creatinine)  HDA (µg/g creatinine) 
 N > MDL (%) p valuea  N > MDL (%) p valuea 
Booth type Cross/Semi Respirator None/Half-face 24  12 (50%) 0.6691  18 (75%) 0.9588 
   Full-faceb 13  8 (62%)   10 (77%)  
Booth type Downdraft Respirator None/Half-face 61  12 (20%) 0.4963  43 (70%) 0.3773 
   Full-faceb 17  5 (29%)   11 (65%)  
Respirator None/Half-face Glove type None/Latex 50  17 (34%) 0.2832  38 (76%) 0.9015 
   Nitrile/Neoprene 30  6 (20%)   20 (67%)  
Respirator Full-faceb Glove type None/Latex 14  7 (50%) 0.5030  9 (64%) 0.6596 
   Nitrile/Neoprene 16  6 (38%)   12 (75%)  
Coverall No Glove type None/Latex 28  9 (32%) 0.7949  23 (82%) 0.7830 
   Nitrile/Neoprene 5  1 (20%)   3 (60%)  
Coverall Yes Glove type None/Latex 36  15 (42%) 0.2086  24 (67%) 0.5265 
   Nitrile/Neoprene 41  11 (27%)   29 (71%)  
Respirator None/Half-face Booth type Cross/Semi 24  12 (50%) 0.0030  18 (75%) 0.5052 
   Downdraft 61  12 (20%)   43 (70%)  
Respirator Full-faceb Booth type Cross/Semi 13  8 (62%) 0.0782  10 (77%) 0.2968 
   Downdraft 17  5 (29%)   11 (65%)  
Coverall No Booth type Cross/Semi 17  8 (47%) 0.0348  13 (76%) 0.9113 
   Downdraft 21  3 (14%)   16 (76%)  
Coverall Yes Booth type Cross/Semi 20  12 (60%) 0.0022  15 (75%) 0.3267 
   Downdraft 57  14 (25%)   38 (67%)  
Glove type None/Latex Booth type Cross/Semi 22  13 (59%) 0.0061  17 (77%) 0.3791 
   Downdraft 42  11 (26%)   30 (71%)  
Glove type Nitrile/Neoprene Booth type Cross/Semi 15  7 (47%) 0.0227  11 (73%) 0.5494 
   Downdraft 31  5 (16%)   21 (68%)  
N = number of samples; MDL = method detection limit; aSignificance was determined by Tukey-Kramer multiple comparisons tests at α-level 




Table C.3.  Summary of linear mixed models for predicting post-shift urine TAHI and HDA levels (µg/L). 
TAHI level Explanatory Estimate 
Standard 
Error 
p value AIC R2  HDA level Explanatory Estimate 
Standard 
Error 
p value AIC R2 
Base Intercept -5.99 3.93 0.1347 604.8 0.03  Base Intercept -15.30 2.34 <0.0001 569.4 0.29 
Model 3-A ISO PBZ 0.33 0.34 0.3330    Model 3-D HDI PBZ 0.21 0.19 0.2615   
 ISO Skin 0.18 0.13 0.1826     HDI Skin 0.09 0.05 0.0923   
 Creatinine -0.65 0.55 0.2360     Creatinine 2.48 0.44 <0.0001   
 Worker var 5.14 1.95 0.0085     Worker var 1.78 1.09 0.1038   
 Residual var 7.91 1.39 <0.0001     Residual var 6.70 1.16 <0.0001   
               
Base Intercept -2.33 3.07 0.4522 606.3 0.05  Base Intercept -15.31 2.25 <0.0001 566.9 0.30 
Model 3-B ISO PBZ-APF -0.16 0.18 0.3928    Model 3-E HDI PBZ-APF 0.28 0.13 0.0355   
 ISO Skin 0.25 0.13 0.0546     HDI Skin 0.08 0.05 0.1400   
 Creatinine -0.83 0.55 0.1407     Creatinine 2.63 0.45 <0.0001   
 Worker var 4.98 1.95 0.0107     Worker var 1.83 1.08 0.0909   
 Residual var 8.02 1.41 <0.0001     Residual var 6.44 1.12 <0.0001   
               
Final Intercept -10.39 2.64 0.0003 595.4 0.25  Final Intercept -14.92 2.27 <0.0001 566.3 0.29 
Model 3-C ISO PBZ 0.49 0.30 0.1068    Model 3-F HDI Skin 0.11 0.05 0.0273   
 Paint time 0.96 0.40 0.0188     Creatinine 2.54 0.45 <0.0001   
 Booth type -2.49 0.77 0.0024     Respirator type -0.95 0.74 0.2012   
 Worker var 2.60 1.48 0.0802     Worker var 1.94 1.13 0.0870   
 Residual var 8.30 1.45 <0.0001     Residual var 6.57 1.14 <0.0001   
AIC = Akaike’s Information Criterion; R2 = marginal R2 statistic calculated with the PROC GLM procedure in SAS; ISO = HDI isocyanurate; 
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